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Abstract. 
Wilms' tumour is a paediatric kidney neoplasia accounting for about 8% of all 
childhood cancers. The tumour arises by uncontrolled proliferation of the 
metanephric blastemal stem cells and is a clear example of a cancer caused by 
disrupted developmental mechanisms. Investigation of a locus, at lip 13, 
predisposing to Wilms' tumour led to the identification of the Wilms' tumour 
suppressor gene, (WTI). In situ analysis of WTI mRNA expression revealed a 
complex developmentally regulated pattern. Mutations in the WTI gene have also 
been linked to gonadal dysgenesis, mesothelial defects and leukaemia. Homozygous 
Wt] 'knockout' mice die at E13.5 with no development of kidneys or gonads and 
disruption of the thoracic organs. 
I used a transgenic approach to examine aspects of both WTI expression and 
regulation. A 5 kb region (USWT1) of the putative WTI promoter was linked to a 
lacZ reporter and used to generate several transgenic embryos. The expression pattern 
driven by this reporter construct was similar to that of the endogenous locus but very 
weak and susceptible to position effects. To overcome this problem a YAC spanning 
the human WT1 locus was used to drive expression of a lacZ reporter in transgenic 
mouse embryos. The reporter gene expression driven by this construct mirrors that of 
the endogenous Wtl locus except in the sex specific Sertoli and granulosa cells. I 
used the YAC driven reporter gene expression in these transgenic embryos to 
carefully study the expression pattern of Wtl. The transgene is expressed in both 
mesodermal and neuro-ectodermal lineages. It is expressed in mesenchymal cells 
produced by the proliferating coelomic epithelium; hence Wtl is a marker for this 
specific cell type. It is also expressed in the interdigtal mesenchyme during limb 
morphogenesis. This newly identified site of Wt] expression was confirmed by Wtl 
mRNA in situ analysis and raises a potential role for Wt] in the control of apoptosis. 
Cells expressing the transgene are present in all the differentiating epaxial 
musculature of the embryo implying that Wtl may play a role in myogenesis. In the 
iv 
neuro-ectodermal lineage, transgene expression implies that Wtl may play a role in 
neural patterning. 
The YAC transgene expression studies presented in this thesis complement further 
YAC transgenic work we have undertaken. Transgenic animals were made with an 
unmodified YAC spanning the WTI locus. This transgene was able to partially rescue 
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Oranizati g 	on of Thesis. 
This thesis describes an experimental study undertaken to investigate the 
developmental expression, function and regulation of the Wilms' tumour suppressor 
gene WT]. The introductory chapter reviews the present state of knowledge regarding 
the developmental role and regulation of the WTI gene. In this chapter I also briefly 
describe the reasoning which underlies the experimental approaches used in this 
study. In chapter two I describe the cloning of a small region of the proximal 5' WTI 
promoter. This region of the WTI promoter is then used to drive expression of a 
reporter gene in cell lines and transgenic mice. Chapter three deals with the 
construction and molecular analysis of transgenic mice containing a YAC spanning 
the WTI locus. Chapter four contains a detailed description of the developmental 
expression pattern of these YAC transgenes. In chapter five I describe work carried 
out in response to the data provided by studying this transgene expression. This work 
includes mRNA in situ hydridization analysis and study of the Wtl knockout mouse 
phenotype. Within chapters two to five I briefly discuss the significance of the results 
presented. Such discussion is contained within the text of the chapter rather than 
inserted at its end. This discussion material is reviewed in chapter six which attempts 
to put findings into a broader context. Chapter six also contains proposals for further 
studies which may be undertaken on the basis of the data described within this thesis. 
Chapter seven details the materials and methods used during this study. 
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1. Introduction. 
Wilms' tumour is a childhood kidney neoplasia accounting for around 8% of all 
childhood cancers. It has a incidence of 1 in 10,000 children normally presenting by 
the seventh year (Breslow et al., .1988). The great majority of Wilms' tumours are 
sporadic, <1% of cases being familial. The tumour arises by uncontrolled 
proliferation of the metanephric blastemal stem cells involved in normal kidney 
development. It hence represents a clear example of a cancer being caused by 
disrupted developmental mechanisms, reviewed by Pritchard Jones and Hastie, 1990. 
Around 10% of all sporadic Wilms' tumours are caused by a mutation or deletion in 
the Wilms' tumour 1 gene (WTI) (Coppes et al., 1993a). This gene gives rise to a 
zinc finger protein with at least 16 different isoforms (Haber et al., 1991; Hewitt and 
Saunders, 1996b). In addition to acting as a tumour suppressor WTI has multiple 
roles in development. Loss or reduction in the expression of this gene in humans may 
cause developmental defects in the urogenital system (Hastie, 1992). Mice 
homozygous for a Wtl null allele completely fail to develop gonads or kidneys 
indicating that the gene is a key player in the development of the urogenital system 
(Kreidberg et al., 1993). Wt] knockout mice also have defects in the development of 
the organs of the thoracic cavity; they die at midgestation perhaps due to defects in 
heart development. The expression pattern of WTI has been studied by mRNA in situ 
and immunohistochemical analysis (Pritchard Jones et al., 1990; Armstrong et al., 
1992; Pelletier et al., 1991c; Mundlos et al., 1993; Rackley et al., 1993). It is 
expressed in a large number of sites including the developing urogenital system and 
the mesothelium. However a better understanding WTI expression is still required to 
aid understanding the biology of the gene. 
1.1 Isolation of the WTI gene. 
Wilms' tumour is one of an associated congenital set of abnormalities which are 
present in patients with WAGR. Deletions of the chromosomal region 1 lpi3 were 
identified in several cases of WAGR (Francke et al., 1979). Lewis et al. then 
demonstrated a homozygous deletion of an lip 13 marker in a sporadic Wilms' 
tumour. The smallest region of overlap between the two deletions present in this 
tumour defined a region of 345 kb in which the Wilms' tumour predisposition gene 
(named WTI) could lie. Two single copy probes isolated from a human chromosome 
lip library mapped to this region and were used to isolate a partial cDNA from a pre-
B cell library (WT33) (Call et al., 1990). The same gene was also concurrently, 
independently isolated by chromosome jumping between CpG islands (Gessler et al., 
1990). 
WTI is deleted or mutated in only approximately 10% of sporadic Wilms' tumours 
(Coppes et al., 1993a). Additional genes associated with sporadic Wilms' tumours 
have been located to chromosome lipls (designated W12) (Koufos et al., 1989), 16q 
(Maw et al., 1992) and by comparative genomic hybridization to 3q, 4q 9p and 20p 
(Altura et al., 1996). Very few cases of inherited WTI mutation have been reported 
(Pelletier et al., 1991b). However linkage analysis in several large families have 
excluded WTI as the major familial Wilms' tumour predisposition gene (Huff et al., 
1988; Grundy et al., 1988; Schwartz et al., 1991). Recently a familial predisposition 
gene (FWTJ) was localized to 17q12-q21 (Rahman et al., 1996). 
1.2 Structure of the WTI gene. 
The WTI gene consists of 10 exons covering 50 kb of genomic sequence (Haber et 
al., 1991; Hewitt and Saunders, 1996b) (Fig. 1). Northern analysis detected a 
transcript of around 3.2 kb in foetal kidney, spleen, testis and ovary with an 
additional 2.7 kb transcript detected in foetal testis (Pritchard Jones et al., 1990). 
Alternative initiation and splice sites in addition to RNA editing means that at least 
sixteen different WT 1 isoforms are produced from the locus. Failure to produce 
isoforms in the correct ratio may lead to severe clinical effects (Bruening et al., 1992; 
Konig et al., 1993). Furthermore different isoforms may have different molecular 
functions. WTI utilizes two different translation initiation sites (Fig. 9). Initiation at 
an AUG codon directs synthesis of protein isoforms in the range of 47-49 kDa whilst 
a CUG codon 204 bases 5' of this directs synthesis of protein isoforms in the range of 
54-56 kDa (Bruening and Pelletier, 1996). The protein encoded by WTI contains an 
N terminal proline/glutamine rich domain (exons 1-4) and a putative leucine zipper 
(exon 4). The C terminal of WT  contains four zinc fingers (exons 7-10) of the Cys2 
His2 type first identified in Xenopus Transcription Factor ifiA (TFIIIA) (Miller et al., 
1985) (Fig. 1). 
The WTI transcript shows RNA editing, U 839 may be converted to C (Sharma et al., 
1994a). It also has two alternative splice sites (Haber et al., 1991) (Fig. 1). 
Alternative splicing of exon 5 inserts 17 amino acids into the N terminal domain of 
the protein. Utilization of an alternative splice at the end of exon 9 inserts an extra 
three amino acids lysine, threonine and serine (KTS) between zinc fingers three and 
four of the protein. Throughout this thesis different WTI isoforms utilizing 
alternative splice sites will be referred to as WTI (+ or -17aa / + or-KTS). WT1 (+1+) 
refers to a WTI protein carrying both the 17 amino acid insert and the KTS insert. 
WTI(-/+) refers to a WT  protein lacking the 17 amino acid insert and carrying the 
KTS insert. WTI (+1-) carries only the 17 amino acid insert and WT1 (-I-) lacks both 
inserts. In those tissues which have been analysed the ratio of different splice form 
remains the same 1(-/-):2.5(+I-):4(-/+):8(+/+) (Haber et al., 1991). 
WY] has been cloned from a number organisms: human, mouse, rat, chick, alligator, 
axolotl, Xenopus and zebrafish (Buckler et al., 1991; Sharma et al., 1992; Kent et al., 
1995; Carroll and Vize, 1996; Del Rio-Tsonis et al., 1996). It is very highly 
conserved between mouse, rat and human with an amino acid sequence identity of 
over 96% rising to 100% in the zinc fingers (Buckler et al., 1991). All isolated WTI 
3 
genes show conservation of the +KTS alternative splice form implying that it has 
strong functional importance. On the other hand, the +17aa splice site is not 
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Fig 1: Schematic structure of the WT1 gene, mRNA and protein products. 
After Menke 1996 
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1.3 Molecular function of the WT1 protein. 
1.3.1 Transcription factor activity of WTI. 
The W71 protein shows nuclear localisation (Mundlos et al., 1993; Larsson et al., 
1995). It has an N-terminal proline/glutamine rich domain which may act as 
transcription regulatory domain and four zinc fingers capable of DNA binding 
activity. Given this information it was originally proposed that WT1 acts as a 
transcription factor. 
The proline /glutamine rich amino terminus of the WTI protein is similar to 
transcription transregulatory domains identified in proteins such as CTFINF- 1 
(proline rich) and Spi (glutamine rich) (Mitchell and Tjian, 1989). Domain swap 
experiments between WTI and Early Growth Response 1 (EGR1) or GAL4 
demonstrated the N terminal domain of WTI to be capable of repressing 
transcription (Madden et al., 1991; Madden et al., 1993). Insertion of the l7aa 
alternative splice into the transregulatory domain may accentuate its suppressor 
function. In transient transfection assays the WT1(-i-/+) protein isoform represses 
around 25 times better than the WT1(-/+) isoform (Rupprecht et al., 1994). Moreover 
it has been shown that the WT I (-/+) protein activates transcription from a modified 
Platelet Derived Growth Factor A (PDGFA) promoter-reporter construct whereas 
isoform WT1(+/-i-) isoform represses it (Wang et al., 1995b). 
The first of the WTI zinc fingers (ZF1) is highly similar to those of the Spi 
transcription factor family, in particular Sp3. The final three (ZF2-4) are almost 
identical to those of the Early Growth Response (EGR) protein family(Ca!l et al., 
1990). The WT  zinc fingers confer sequence specific DNA binding activity. The - 
KTS, but not the +KTS, isoform of the WTI protein, binds the same GC rich 
sequence as EGR1 (5' GCG GGG GCG 3') (Rauscher, 3d et al., 1990). Bickrnore et 
al. have identified non GC rich sequences to which both + and -KTS WTI isoforms 
can bind, albeit with differing specificity (-KTS > +KTS) (Bickmore et al., 1992). 
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Additional studies have identified other potential WT  binding sites (Wang et al., 
1995b; Hofmann et al., 1993; Drummond et al., 1994; Nakagama et al., 1995). 
The binding of the WTI - KTS to the EGR1 consensus site implies that this WT  
isoform could compete with EGR1 for specific targets. To date it remains unclear 
what DNA sequences may represent a true in vivo target for WT  binding. A number 
of potential target genes for regulation by WTI have been hypothesised on the 
presence of putative WT  binding sites in their promoters (Table 1). In transient 
transfection experiments, WT  activated/repressed the activity of these promoters. 
The physiological relevance of these promoter regulation experiments, however, is 
unclear. The GC rich target sequences to which WT1 binds, are found in the 
promoters of thousands of genes which have CpG islands. Many of these genes are 
housekeeping genes and it is unlikely that WT  regulates them all (Hastie, 1994). 
Furthermore the choice of cell system, expression vector and topology of the reporter 
construct can influence the transcriptional regulation mediated by WTI. In Nll-13T3 
cells WTI -KTS represses transcription from the Egri promoter. However, it 
activates transcription from the same promoter in Saos-2 and U20S cells 
(Maheswaran et al., 1993). WT I(-/+) suppresses transcription from one version of 
the PDGFA promoter (-153/+388) yet activates transcription from a shorter one (-
601+388) (Wang et al., 1995b). Expression of WT(-/-) driven by the RSV LTR 
stimulates the activity of the Egri promoter, whereas expression of the same isoform 
driven by the CMV (cytomegalovirus) promoter activates it (Reddy et al., 1995). 
The transcription factor activity of WTI is mediated by expression of other cellular 
components. Interaction with a nuclear component in NIH3T3 cells is required for 
transcription suppressor function (Wang et al., 1995a). p53 interacts physically and 
functionally with WTI. Immunoprecipitation studies demonstrate that these two 
proteins may be part of the same complex. In transient transfection assays WTI (-
KTS), in the p53 negative Saos-2 cells, acts as a transcriptional activator. When co-
transfected with p53, however, WT1(-KTS) acts as a repressor (Maheswaran et al., 
1993). Cellular factors other than p53 must mediate WTI activity given that 
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WT 1 (-I-) activates transcription from the Egri promoter in both the p53 negative 
Saos-2 and p53 positive U20S cells (Maheswaran et al., 1993; Englert et al., 1995a). 
One such protein may be prostate apoptosis response 4 (Par4) which binds WTI in 
the yeast two hybrid system. Transient transfection studies have demonstrated that 
Par4 inhibits the ability of WT1 to activate, and enhances its ability repress, 
transcription from target promoters (Johnstone et al., 1996). 
Table 1 Putative target promoters for regulation by WTI. 
Gene promoter Reference 
Bc12 (Hewitt et al., 1995b) 
C-myb (McCann et al., 1995) 
C-myc (Hewitt et al., 1995b; Wang et al., 1993b) 
CSF1 (Harrington et al., 1993) 
EGFR (Englert et al., 1995a; Wang et al., 1993b) 
Egri 
____________________ 
(Rauscher, 3d et al., 1990; Madden et al., 1991; Reddy et al., 
1995; Gashler and Sukhatme, 1995) 
G-protein ai 2 (Kinane et al., 1996) 
IGFJR (Werner et al., 1993; Werner et al., 1995; Werner et al., 
1996) 
IGF2 (Drummond et al., 1992; Nichols et al., 1995) 
Insulin receptor (Wang et al., 1993b) 
Inhibin a (Hsu et al., 1995) 
Ki-ras (Wang et al., 1993b) 
Midkine (Adachi et al., 1996) 
nov (Martinerie et al., 1996) 
ODC (Moshier et al., 1996) 
PAX2 (Ryan et al., 1995) 
PDGFA (Wang et al., 1992; Wang et al., 1993a; Wang et al., 1995b; 
Gashler et al., 1992) 
RARa (Goodyer et al., 1995) 
TGF16 (Dey et al., 1994) 
WTI (Rupprecht et al., 1994; Hewitt et al., 1996a; Malik et al., 
1994) 
1.3.2 WT1 may act as a post transcriptional regulator 
WTI may have a post transcriptional role in gene regulation. Larsson et al. 
discovered that the WT1(+KTS) and the WTI(-KTS) isoforms, on balance, localize 
to different compartments of the nucleus. WT1(-KTS) isoforms localized to areas 
containing transcription factors. WT1(+KTS) forms, on the other hand, localized 
with the speckled/coiled body domains which contain snrps and other components of 
the cellular splicing machinery. They also demonstrated co-immunoprecipitation of 
WTI and components of the splicing machinery (Larsson et al., 1995). Other studies 
have indicated that WTI -mediated repression of the Insulin-like Growth Factor 2 
gene (1g/2) reporter constructs is a result of post transcriptional events (Ward et al., 
1995). The W71 zinc fingers, in particular ZF1, were required for this activity. The 
+KTS WTI isoform binds the 1g/2 RNA much better than the -KTS (Caricasole et 
al., 1996). Perhaps WTI regulates both transcription and post transcriptional 
processes through zinc finger binding. Such activity has been demonstrated for the 
TFTIIA transcription factor (Pieler and Theunissen, 1993). Structural modelling has 
demonstrated the presence of an RNA recognition motif within the amino terminal 
domain of the protein in addition to RNA binding by the zinc fingers (Kennedy et al., 
1996). Englert et al propose that speckled domains within the nucleus simply 
represent a storage site for WT  isoforms and mutants with reduced DNA binding 
affinity (Englert et al., 1995b). They demonstrated that no WTI protein isoforms co-
localize with the nuclear splicing factor SC35. They also showed that truncated WTI 
proteins or those with disrupted zinc fingers localize to speckles along with WTI 
+KTS isoforms. 
1.4 Expression of the WTI gene. 
WTI expression during mouse and human embryonic development has been 
investigated by a number of authors using the techniques of in situ hybridisation and 
immunohistochemical analysis (Pritchard Jones et al., 1990; Armstrong et al., 1992; 
Pelletier et al., 1991c; Mundlos et al., 1993; Rackley et al., 1993). The WTI gene 
shows a complex and developmentally regulated expression pattern. It is first 
expressed in the embryonic intermediate mesoderm, then subsequently in the organs 
of the urogenital system which derive from this structure. The WT1 gene is also 
expressed in the mesothelium, an epithelial tissue which surrounds the internal 
organs of the body. It shows additional sites of expression within the developing 
nervous system (Armstrong et al., 1992). 
Expression of WTI is evolutionarily conserved. WTI expression in rat, chick and 
alligator embryos parallels the pattern seen in mouse and human (Sharma et al., 
1992; Kent et al., 1995). In Xenopus xWTJ expression is observed in the dorsal 
portion of the splanchnic lateral plate in tailbud embryos, the glomus of early 
tadpoles and in the adult mesonephros (Carroll and Vize, 1996). 
1.4.1 WTI expression during kidney formation. 
WTI is expressed during the development of the foetal kidneys. Three different 
kidneys are sequentially formed during embryogenesis. These are the pronephros, 
mesonephros and metanephros. The following account deals with the formation of 
the murine kidneys, but those of humans follow a very similar developmental 
pathway. For a review of kidney development see Saxen 1987, 'Gray's Anatomy' 
(Bannister et al., 1995) and Lechner and Dressler 1997. A schematic representation 
of the development of the mouse nephric system is shown in Fig. 2. 
The pronephros, mesonephros and metanephros all arise from the nephrogenic 
mesenchyme of the intermediate mesoderm. From E8.5, a wave nephrogenic 
differentiation proceeds caudally from the region of about the fifth somite. The 
pronephric (Wolffian) duct invaginates into the nephrogenic mesenchyme 
simultaneous with forming the pronephros. As the duct extends in a rostro-caudal 
direction along the embryo (becoming the mesonephric duct) a series of epithelial 
tubules form in the nephrogenic mesenchyme which lay adjacent to it. At the level of 
the pronephros, these tubules remain as rudimentary clusters of cells. However those 
of the mesonephros form more complex structures. The first 6-8 tubules of the 
mesonephros (the cranial tubules) develop by budding directly from the mesonephric 
duct. At more caudal levels the tubules form within the mesonephric mesenchyme. 
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They lie close to the duct but are still separated from it by a basement membrane. The 
two different populations of mesonephric tubules have different modes of formation. 
The cranial tubules form by extension of the mesonephric duct. The caudal ones form 
by a mesenchyme to epithelial cell type transition within the nephrogenic 
mesenchyme (Sainio et al., 1997). 
Wtl is expressed in the nephrogenic mesenchyme prior to tubule formation but it is 
not expressed in the epithelial mesonephric duct. The state of gene expression in the 
pronephric and cranial mesonephric tubules is not clear. However it is expressed in 
the glomeruli of the caudal mesonephric tubules after they have formed (Armstrong 
et al., 1992; Pritchard Jones et al., 1990; Rackley et al., 1993). Expression in the 
mesonephric tubules is in structures analogous to those of the metanephros. 
Expression of the gene has been studied in more detail in the process of metanephric 
nephrogenesis (Fig. 3). 
At around E10.5 the ureteric bud evaginates from the mesonephric duct just above 
the level of the cloaca. This bud, as with the rest of the mesonephric duct, does not 
express Wtl. The bud invades the mesenchymal metanephric blastema, a spatially 
distinct population of cells lying at the caudal end of the nephrogenic mesenchyme. 
Cells of the metanephric mesenchyme express Wri at low levels. Invasion of the 
ureteric bud induces cells of the metanephric blastema to condense at its tip. An 
upregulation of the level of Wt] expression occurs in those blastemal cells 
condensing around the ureter tip. Interestingly the spectrum of nephric structures 
found within a Wilms' tumour implies that it is at this stage of development where 
loss of WT1 function can lead to tumourigenesis (Pritchard Jones and Fleming, 1991; 
Hastie, 1994). Following invasion, the ureteric bud proceeds to divide forming many 
branches within the metanephric blastema. The blastema is induced to condense at 
the tip of each branch. Continued branching of the ureter is responsible for the radial 
wave of nephrogenesis which occurs throughout the developing kidney. 
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The condensed mesenchyme undergoes a burst of proliferation and then differentiates 
into an epithelial cyst known as the renal vesicle. The renal vesicle continues to 
express Wtl. It now undergoes a series of morphological changes. It first forms a 
comma shaped body; cells furthest from the collecting duct (the proximal part of the 
vesicle) become elongated and a slit forms within the vesicle. Next a second slit 
forms at the opposite distal pole, resulting in the comma shaped body becoming S-
shaped. Wtl expression becomes localized during the transition from comma to S-
shaped body in the proximal part of the body. The distal part of the S-shaped body 
extends and joins the collecting duct which then undergoes extension to form the 
proximal and distal convoluted tubules and the loop of Henle. The Wtl expressing 
cells at the proximal part of the S-shaped body become flattened and are destined to 
form the Bowman's capsule. The inner cells of the Bowman's capsule undergo 
differentiation into the glomerular podocyte cells. Wtl expression is restricted to the 
podocytes where it remains expressed postnatally and continues in adult life. 
Angiogenic cells, possibly derived from the lateral mesenchyme, invade the proximal 
slit to form the capillaries and mesangial cells of the glomerulus. The podocytes 
overlay the capillaries of the glomerular tuft. 
Cells of the metanephric mesenchyme which are not induced or do not undergo 
nephrogenesis form either the supporting stroma of the kidney or undergo apoptosis 
(Koseki et al., 1992). Wtl is not expressed in the kidney stroma and hence is lost 
from the metnephric blastemal cells as they undergo this transition. 
Within the nephrogenic cord a wave of regression follows that of differentiation. This 
removes the pronephros and subsequently the mesonephros. By around E13.5 only 









Fig. 2 Schematic representation of the nephric system of the developing mouse embryo. 
Adapted from Lechner and Dressler 1997. A composite is depicted so that the pronephros 
(P) and mesonephros (cranial (Cr-M)and caudal tubules(Ca-M)) are seen together, 
although by the time the ureteric bud (UB) has formed the presumptive pronephros has 
begun degenerating. The mesonephric or Wolifian duct (W) is first observed about the 
level of the fifth somite in the pronephric region and develops caudally toward the cloaca 
(Cl). The metanephric mesencyme (MM, not drawn to scale) is found at the caudal end 
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Fig. 3 Schematic representation of the different stages of nephrogenesis showing the 
localization of WTI expression. 
After Hastie 1994. Light shading low levels of WTI mRNA. Heavy shading high levels 
of W17 mRNA. 
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1.4.2 WTI expression during the development of the gonads. 
In addition to the pronephros, mesonephros and metanephros the gonads are also 
formed from the intermediate mesoderm. They develop in close proximity to the 
mesonephros and also express Wtl. For a review of human gonad development see 
'Gray's Anatomy' 1995 (Bannister et al., 1995). A schematic representation of WTI 
expression during gonad development is shown in Fig. 4. 
In the mouse, gonad development begins at around El1.5 (Kaufman, 1992). At this 
stage all of the coelomic epithelium surrounding the internal organs of the body 
including the developing kidneys and gonads is expressing the Wt] gene (Armstrong 
et al., 1992; Rackley et al., 1993; Pritchard Jones et al., 1990). Formation of the 
gonads begins as a thickening of the coelomic epithelium on ventromedial aspect of 
the mesonephric ridge. This thickening is known as the primary sex cords. The gonad 
rapidly grows out from the urogenital ridge into the coelomic cavity forming the 
genital ridge which continues to express Wtl. The genital ridge runs the full length of 
mesonephros. It is longer at this stage than the final gonad which is formed. 
Concurrent with the formation of the genital ridge, a second duct, the 
paramesonephric (Mullerian) duct, appears in the mesonephric ridge. It invaginates 
into the lateral mesonephric ridge and runs parallel to the mesonephric duct. Similar 
to the mesonephric duct the paramesonephric duct does not express Wtl. 
At around El 3 the male and female gonads begin to follow different developmental 
pathways (Kaufman, 1992). In the male gonad (testis), 'secondary' sex cords, also 
known as seminiferous cords, form within the gonadal mesenchyme. These cords 
enclose the germ cells which have migrated into the gonad primordium from near the 
allantois. The walls of the seminiferous cords consist of epithelial Sertoli cells. 
Formation of Sertoli cells is required to switch the developing gonad to a male 
specific developmental pathway rather than a default female one (Ramkissoon and 
Goodfellow, 1996). Expression of WT] is lost from the mesenchymal cells of the 
testis but is retained in the Sertoli cells and the coelomic epithelium surrounding it 
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(Armstrong et al., 1992; Pritchard Jones et al., 1990). As the seminiferous cords form 
within the gonad a second set of tubules, the rete testis, differentiate within the 
gonadal mesenchyme. These also express Wtl (Mundlos et al., 1993). By the stage of 
gonadal sex determination the mesonephric tubules have regressed. In male embryos 
the most cranial tubules do not regress. The rete testis provides a bridge between the 
seminiferous cords and the remaining cranial mesonephric tubules which 
differentiate into the efferent ducts of the testis. 
The non-WTI expressing mesenchymal cells of the testis differentiate into Leydig 
cells. These cells produce the sex hormone testosterone. The Sertoli cells produce 
anti-Mullerjan hormone (AMH) also known as Mullerian inhibiting substance (MIS). 
Under the influence of MIS the paramesonephric duct degenerates. Under the 
influence of testosterone the mesonephric duct differentiates into the vas deferens 
and becomes convoluted at the level of the gonad to form the epididymis (Fig. 5). 
In the female gonad (ovary) no sex cords form. The gonadal mesenchyme maintains a 
grainy appearance. Individual germ cells within the gonad become surrounded by 
follicular/granulosa cells. During gonad maturation, Wtl expression is lost from the 
mesenchyme but continues to be expressed in the granulosa cells and the 
mesothelium overlaying the ovary (Mundlos et al., 1993; Hsu et al., 1995). The rete 
ovarii form within the developing ovary but do not connect to other structures. The 
follicular cells of the ovary produce the steroid hormone oestrogen which causes the 
regression of the entire mesonephric duct and the rete ovarii. Under the influence of 
this hormone the paramesonephric ducts differentiates into the oviducts and the 
cranial ends of these ducts open to form the ostia. The caudal ends of the oviducts 
fuse at the cloaca and extend to produce the uterus and contribute to the vagina (Fig. 
5). The myometrial and the endometrial stroma of the uterus express Wtl (Pelletier et 
al., 1991c; Zhou et al., 1993). This expression remains into adult life staying constant 
during normal hormonal cycling. In pregnant rats expression of WTI was highly 
upregulated in endometrium undergoing decidualization in response to embryo 
implantation (Zhou et al., 1993). 
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Expression of WTI in Sertoli and granulosa cells continues into adult life. Expression 
of the gene within these cells is related to the state of maturation of their associated 
germ cells. In the adult rat ovary WTI is expressed and in the granulosa cells of 
primordial, primary and secondary follicles. WTI levels decrease with follicular 
development (Hsu et al., 1995). WTI expression in Sertoli cells has been studied in 
the Mexican axolotl Amblystoma mexicanum. The testis of the axolotl contain zones 
containing germ cells at different stages of maturation. WTI expression was only 
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Fig. 4 Schematic representation of the development of the gonads and associated 
ducts as seen in transverse Section showing localization of WTI expression. 
Adapted from 'Grays Anatomy' 1995 eds. Bannister et. at. Light green low levels of 
WTI mRNA. Dark green high levels of WTI mRNA. 
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Fig. 5 Schematic representation of secondary sexual determination 
After Gilbert 1991. (A) The indifferent gonad differentiates on the medial side of the 
mesonephric ridge. The Mullerian (paramesonephric) duct differentiates alongside 
the Woiffian (mesonephric) duct and both join the cloaca. (B) In the male the testis 
produces testosterone and MIS which induces the retention and differentiation of the 
mesonephric dut into the epididymis and the regression of the paramesonephric duct. 
(C) In the female the mesonephric duct and tubules degenerate. The paramesonephric 
duct forms the oviducts and uterus under the influence of oestrogen. 
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1.4.3 Expression of WTI in the mesothelium and underlying 
mesenchyme. 
In addition to expression in the mesothelium surrounding the developing urogenital 
system, WTI is expressed in the mesothelial coat of all organs in the coelomic cavity 
(Armstrong et al., 1992; Rackley et al., 1993). It is expressed in the pericardium, on 
the surface of the diaphragm, gut mesenteries and on the inner surface of the 
coelomic cavity. 
In the wall of the thoracic cavity WTI is not just expressed on the inner surface but is 
found in deeper layer of cells adjacent to differentiating muscle in the intercostal 
region (Kent et al., 1995) and within the developing musculature of the body wall 
(Armstrong et al., 1992). In stage 13-14 alligator whole mount in situ studies, WT] 
expression was seen in the developing body wall muscle and also in a novel site in 
the presumptive wrist and armpit regions of the forelimb (Kent et al., 1995). WTI is 
also expressed at high levels in the spleen which develops from the surface of the 
splanchnopleuric mesenchyme (Armstrong et al., 1992). Further expression of the 
gene has been detected by RT-PCR in the extra-embryonic mesoderm of the placenta 
(Jinno et al., 1994). 
1.4.4 WTI expression in haematopoietic cells. 
WTJ expression has been detected in foetal yolk sac by RT-PCR (Fraizer et al., 
1995). The yolk sac contains the blood islands which are a site of embryonic 
haematopoiesis. WTI is likely to be expressed during formation of some 
haematopoietic cell types (King Underwood et al., 1996) and the original WTI cDNA 
was isolated from a pre B-cell library (Call et al., 1990). WTI expression has also 
been detected in adult thymus (in situ and northern analysis) (Park et al., 1993b) and 
at low levels in bone marrow and peripheral blood (RT-PCR) (Inoue et al., 1994; 
Fraizer et al., 1995; King Underwood et al., 1996). 
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1.4.5 Expression of WTI in ectodermally derived tissues. 
WTI is expressed in ectodermally derived tissues of the nervous system. In the 
developing mouse embryo Wtl is expressed in the neural tube from E10.5. This 
expression becomes localized to the ventral horns of the cord by E15.5. Similar 
domains have also been detected in human and rat (Armstrong et al., 1992; Sharma et 
al., 1992; Rackley et al., 1993). WTI is also expressed in the eye (RT-PCR on E12.5 
mouse embryo) and the developing and adult brain. It is detected by in situ 
hybridisation analysis in the roof of the fourth ventricle of the brain at E15 in mouse 
(Armstrong et al., 1992) and the area postrema of the adult rat brain (Sharma et al., 
1992). 
1.5 Involvement of WTI (mutations) in disrupted 
development. 
The first insights into the biological role of WTI came from the clinical study of 
humans. Approximately 8% of all Wilms' tumours are associated with other 
developmental abnormalities. The WAGR (Wilms' tumour, Aniridia, Genital 
abnormalities, mental Retardation) syndrome (Miller et al., 1964) is cause by 
deletion of a region of lip 13 containing the WTI gene. The more severe Denys-
Drash syndrome (DDS) (Denys et al., 1967; Drash et al., 1970) is due to the effects 
of a WTI dominant negative allele. 
1.5.1 WAGR syndrome. 
WAGR patients have a constitutional heterozygous deletion of chr. lip 13 (Francke 
et al., 1979). Virtually all cases are sporadic with only very few cases of an inherited 
lip 13 deletion reported (Fantes et al., 1992; Henry et al. 1993). WAGR patients have 
a 100% incidence of aniridia - congenital absence of the iris. Aniridia is due the loss 
of one copy of the PAX6 gene also lying at lipl3 (Ton et al., 1991). Around 30% of 
WAGR patients present Wilms' tumours (Coppes and Williams, 1994). There is a 
marked excess of male WAGR patients (almost 2:1). Over 50% of these develop 
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genital abnormalities ranging from cryptorchidism (undescended testes) and 
hypospadias (misplaced urethral opening on the penis) to more severe forms of 
sexual ambiguity. Loss of one copy of the WTJ gene (haploinsuficiency) is likely to 
be responsible for these genital abnormalities (van Heyningen et al., 1990). 
Monoallelic WTI expression has been detected in the brains of two human foetuses 
by RT-PCR (Jinno et al., 1994). However loss of WTI activity does not appear to be 
responsible for the mental retardation seen in WAGR patients. Retardation in patients 
is independent of the parental origin of a deleted chromosome. Loss of a gene or 
genes other than WTJ lying in lip 13 may be responsible for WAGR associated 
mental retardation. Retardation appears to be more prevalent in patients with larger 
deletions in the lip13  region (Huff, 1994). 
1.5.2 Denys-Drash syndrome. 
Denys-Drash patients are characterized a triad of partial gonadal dysgenesis (POD), 
diffuse mesangial sclerosis (DMS) and Wilms' tumour (Denys et al., 1967; Drash et 
al., 1970). Both Wilms' tumour (90%) and the DMS (100%) are highly penetrant 
(Coppes and Williams, 1994). The DMS seen in DDS patients is potentially lethal 
unless these patients are offered a renal transplant. They suffer from hypertension 
caused by collapse of the glomerular capillary. This in turn is caused by the 
production of fibrotic material by frequently hypercellular mesangial cells (Jadresic 
et al., 1990). Genital abnormalities seen in DDS patients are more severe than those 
in WAGR. As in WAGR they are more frequent in XY individuals, who often have 
psuedohermaphroditism (look phenotypically female). Internal abnormalities range 
from streak gonad, in which the gonadal ridge does not fully form, to the 
development of ovo-testes. 
The spectra of WTI mutations associated with DDS are different to those associated 
with sporadic Wilms' tumours. A representative sample of reported WTI mutations is 
shown in Fig. 6. Nearly all mutations described in sporadic tumours are nonsense or 
frame shift mutations which are localized anywhere throughout the gene (Coppes et 
al., 1993a). The majority of DDS patients however show missense mutations in WTI 
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zinc fingers 2 and 3. These mutations specifically affect residues which either chelate 
a zinc ion or have been shown to interact with DNA in the co-crystal structure of 
EGR1 (Pavietich and Pabo, 1991). 60% of these mutations affect either arginine 394 or 
aspartate 396  of ZF3. By analogy to EGR1, R394  probably binds a guanidine base in the 
target DNA molecule and D396  interacts with the arginine stabilizing this interaction. 
Fig. 7 illustrates the position of residues in the WTI protein predicted to be altered 
by a representative sample of mutations detected in DDS. 
Haploinsufficiency at the V/Ti locus may be responsible for the genital defects 
associated with WAGR syndrome. However the more severe dominant genital and 
renal phenotype associated DDS implies that a different molecular mechanism is at 
work. A neomorphic dominant effect of DDS associated WTI mutations is unlikely 
given that a number truncate the protein at the level of the zinc fingers and hence 
abolish any DNA binding (Baird et al., 1992; Schneider et al., 1993; Little et al., 
1993). In addition several mutations in the zinc fingers of WTI associated with DDS 
have been demonstrated to destroy WTI binding to the EGR1 consensus site 
(Pelletier et al., 1991a). A more likely mechanism of action is a dominant negative 
one (Hastie, 1992). The WTI protein can self associate and the self-association 
domain maps to the N-terminus of the molecule (Moffett et al., 1995). In fact 
oligomers of full length protein form less stable complexes than oligomers between 
full length and truncated proteins, a mechanism which may serve to amplify the 
dominant negative effects of DDS associated WTI mutations. In two cases a separate 
class of mutation causes DDS; mutation in the splice donor site at the end of exon 9 
prevents the inclusion of the +KTS alternative splice (Bruening et al., 1992; Konig et 
al., 1993). This illustrates the importance of the correct ratio of splice forms for the 
cellular function of WTI. 
The differences between WAGR and DDS and are not always distinct. For example 
one report (Baird et al., 1992) describes a case with a 1 lpl2-13 deletion with DMS 
normally characteristic of DDS. In another case the same deletion of lip 13 was 
inherited by two cousins the XX individual developed aniridia whilst the XY case 
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also had PGD (Henry et al., 1993). It seem likely that the balance between 
developing WAGR like and DDS phenotypes is due to a combination of the type of 
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1.5.3 The Wtl knockout mouse. 
The phenotype of human patients with a mutation in WTJ gives an indication of the 
possible biological roles of the gene. However for further information direct 
experimental analysis is required. To that end Kreidberg et al. disrupted the Wtl gene 
in mice. Deletion of the Wtl gene by demonstrated it to be necessary for both normal 
kidney and gonad development (Kreidberg et al., 1993). 
Mice heterozygous for a Wt] null allele are phenotypically normal and do not 
develop Wilms' tumours. This is also the case for SeyDeY  mice which contain a large 
deletion in the Wtl-Pax6 region similar to that which occurs in WAGR patients 
(Glaser et al., 1990). 
Mice homozygous for the WTI null allele however die in utero between E13 and 15. 
Development of both the mesonephros and metanephros was severely affected in the 
Wtl null embryos. Cranial tubules but no caudal tubules form in the mesonephros 
(Sainio et al., 1997). At the level of the metanephros the ureteric bud does not branch 
from the mesonephric duct. The metanephric blastema forms but undergoes apoptosis 
and regresses. Whilst spinal cord is a strong inducer of nephrogenesis in cultures of 
wild type metanephric blastemal explants, it was unable to promote nephrogenic 
induction in mutant metanephric blastemal explants (Kreidberg et al., 1993). These 
data imply that Wtl is playing two roles in metanephric development. It is required 
for both the branching of the ureteric bud and for the cell autonomous differentiation 
of the metanephric blastema during nephrogenesis. 
The gonads of homozygous null Wtl mice also fail develop. A reduced thickening of 
the coelomic epithelium overlying the presumptive gondal ridge occurs at Eli. 
Further development was aborted. Germ cells were still present in the region of the 
presumptive gonad at E12 so Wtl activity is not required for their migration. 
Wt] homozygous null mutants show defects in heart development and occasional 
pericardial bleeding; mutants older than E12 have massive edema. It is these defects 
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in the circulatory system which probably lead to foetal death, however this is by no 
means clear. In addition to a malformed heart, mutants have small, malformed lungs 
which often herniate through an incomplete diaphragm (Kreidberg et al., 1993). Wt] 
is not expressed in the heart or the lungs but is expressed in the mesothelium 
surrounding them. Defects in the development of this tissue may therefore seriously 
affect the organ which it surrounds. Cases of diaphragmatic hernia in DDS patients 
also provides evidence that WT] activity in the developing diaphragm is of functional 
consequence in humans (Devriendt et al., 1995). Wt] is also expressed in the 
mesenchymal cell of the urogenital ridge and cloaca which give rise to the uterus 
(Armstrong et al., 1992). This structure does not develop in the Wt] homozygous null 
embryos (Kreidberg et al., 1993). Similarly the uterus is also malformed in some 
human Wilms' tumour survivors (Nicholson et al., 1996). 
1.5.4 Involvement of WTI in Wilms'tumourigenesis. 
Mutations in the WTI gene have been found in approximately 10% of sporadic 
Wilms' tumours. The tumour is a malignant embryonal tumour of the kidney. The 
majority of Wilms' tumours have a 'triphasic' histology comprising of blastemal, 
epithelial and stromal elements (Beckwith et al., 1990). Although this tumour 
develops postnatally it contains immature blastema and epithelial structures which 
are normally present during embryonic kidney organogenesis. Wilms' tumour is a 
clear example of a cancer caused by loss of developmental control (Pritchard Jones 
and Hastie, 1990). Tumours may contain renal vesicles, comma, S-shaped and 
'glomeruloid' bodies, but the formation of more mature structures such as glomeruli 
and proximal and distal tubules does not occur. In addition Wilms' tumours may 
contain foci of heterotropic elements such as striated and smooth muscle, 
chondrocytes, and adipocytes. These elements are believed to derive from the 
aberrant differentiation of blastemal stem cells. The blastema cells must therefore 
have a degree of pluripotency to form these tissues types which is restricted during 
normal kidney development. 
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Wilms tumours are found in association with kidney lesions known as nephrogenic 
rests. Nephrogenic rests are normally found in approximately 1% of infant post-
mortems. This level increases to approximately 40% in patients with unilateral and 
100% with bilateral Wilms' tumours (Beckwith et al., 1990). Nephrogenic rests may 
represent premalignant lesions which serve to immortalize stem cells within the 
kidney. Nephrogenic rests can be categorized into two types. Intralobular 
nephrogenic rests (ILNR) consist of islands of stromal and epithelial components and 
appear to be generated from a defect in early nephrogenesis. INLRs are associated 
with tumours of 'triphasic type' which often have mutations at the WTI locus. Two 
cases have been reported where specific mutations in the WTI gene are present in a 
Wilms' tumour and its associated rest but not in the normal surrounding kidney 
tissue (Park et al., 1993a). Perilobular nephrogenic rests (PLNRs) on the other hand 
consist of mainly epithelial structures and appear to have arisen late in the process of 
nephrogenesis. They are associated with tumours which are not triphasic but consist 
of more uniform epithelial tubular and glomeruloid structures. PLNRs are more 
associated with Wilms' tumours caused by disruptions of loci in lip 15 and 
Beckwith-Wiedemann syndrome (BWS). 
Several growth factor gene represent potential targets for transcriptional regulation by 
WT 1, e.g. Platelet Derived Growth Factor A (PGDFA), Epidermal Growth Factor 
Receptor (EGFR), Colony Stimulating Factor (CSF), Transforming growth factor J3 
(TGF-/3), Insulin-like growth factor 1 receptor (IGFJR) and Insulin-like growth 
factor 2 (IGF2) (see Table 1). Deregulation of WTI mediated regulation of these 
growth factor genes could potentially lead to increased cell proliferation and 
neoplasia. IGF2 is a very strong candidate for interaction with WTI during 
tumourigenesis. It is a potent mitogen for mesenchymal cells and is required for 
correct kidney development in vitro (Gansler et al., 1989). IGF2 is expressed at high 
levels in undifferentiated metanephric blastema. IGF2 levels decline during 
nephrogenesis as those of WTI increase. Furthermore IGF2 is overexpressed in 95% 
of Wilms' tumours and its expression may persist in epithelial structures where it is 
normally down regulated (Yun et al., 1993). 
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Widespread programmed cell death occurs during normal nephrogenesis (Koseki et 
al., 1992). Growth factors such as EGF and bFGF (fibroblast growth factor) can 
prevent cell death when added to cultured metanephric blastema (Weller et al., 1991; 
Perantonj et al., 1995). The relationship between WT  activity and the process of 
apoptosis is not clear. The protein has been shown to either inhibit or induce 
apoptosis. Interaction between WTI and p53 stabilizes the p53 protein and inhibits 
p53 mediated cell death (Maheswaran et al., 1995). In contrast expression of high 
levels of WTI in p53 negative Saos-2 cells induces apoptosis which may be caused 
by the transcriptional repression of the endogenous EGFR gene (Englert et al., 
1995a). PAX2 represents another target for potential regulation by WTI (Ryan et al., 
1995), it downregulates expression of p53 (Stuart et al., 1995) and is often 
overexpressed in Wilms' tumours (Eccies et al., 1995). 
WT  may also interact with the cell cycle machinery. WT1(+/-) and (+1+) can block 
cell cycle progression. This block may be relieved by expression of endogenous 
cyclinE/CDK2 and cyclinDl/CDK4 (Kudoh et al., 1995). WTI has been shown to 
physically interact with human ubiquitin-conjugating enzyme 9 (UBC9). In yeast 
UBC9 has been shown to be involved in cell cycle progression and is required for the 
proteolytic degradation of S and M phase cyclins (Wang et al., 1996). 
An alternative mechanism by which tumours may arise is by disruption of the ratio 
between WTI splice variants. Simms et al.(Simms et al., 1995) reported that 7 out of 
10 Wilms' tumours have an increase in the ratio between WT1(-l7aa) and 
WT1(+l7aa). Expression of the WT1(-/-) isoform in adenovirus transformed baby rat 
kidney (BRK) cells increased the tumourigenic potential of those cells whilst WTI (-
1+) strongly suppressed their tumourigenicity (Menke et al., 1996). 
Heterozygous Sey Dey and Wt] knockout mice fail to develop Wilms' tumours 
(Kreidberg et al., 1993). A Wilms' tumour has been observed, however, in a single 
mouse chimeric for wild type ES cells and cells in which the endogenous Wtl gene 
has been has been truncated in the zinc fingers similar to some DDS mutations 
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(C. Patek pers. comm.). A potential experimental model for Wilms' tumour exists in 
rats. Kidney neoplasia in rats can be induced by N-nitroso-N'-methylurea chemical 
mutagenesis. At least 40% of rat nephroblastomas induced in this way have 
mutations in the WTI gene (Sharma et al., 1994b). 
1.5.5 Involvement of WTI in tumours other than Wilms' tumours. 
Disruption of the WTI gene plays a role in the development of a significant 
proportion of Wilms' tumours. Given the expression pattern of WTI in a range of 
different tissues it seems likely that the gene may also be involved in the 
development of a range of tumour types. In rare cases, tumours histologically 
identical to Wilms' tumours arise outside the metanephric kidney and in the adult. 
These extra-renal nephroblastomas are mainly found in the retroperitoneal space and 
gonads. Aterman argues these tumours may be formed by misplaced metanephric 
tissue. However these tumours could arise from mesonephric or the gonadal 
mesenchyme which has failed to regress (Aterman, 1989). 
WTI may also play a role in the development of gondal tumours. Pelletier et al. have 
described one case where bilateral juvenile granulosa cell tumours co-developed with 
Wilms' tumour in a DDS patient (Pelletier et al., 1991a). However no WTI mutation 
have been described in Frasier's syndrome (nephrotic syndrome and 
gonadoblastoma) (Poulat et al., 1993), ovarian tumours (Bruening et al., 1993), sex 
cord-stroma tumours (Coppes et al., 1993b) or other urogenital tumours (Quek et al., 
1993). 
The mesothelium is another tissue in which the WTI gene is expressed. Park et al. 
examined 32 cases of malignant mesothelioma (Park et al., 1993b). This study 
identified one mutation in a mesothelial lesion, which was not malignant, and likely 
to represent a mesothelial developmental defect. Similarly Langerak et. al. identified 
no WTJ disruption in a panel of 12 malignant mesothelioma cell lines (Langerak et 
al., 1995). 
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V/Ti is strongly implicated to be involved in the genesis of leukaemias. WT] 
mutations have been found in 4/36 of cases of sporadic acute adult myeloid 
leukaemia (King Underwood et al., 1996). All of these resulted in a truncated protein 
and 3/4 were present in a heterozygous state implying that a dominant or dominant 
negative mechanism may be operating. In another study of 33 cases of childhood 
acute lymphatic leukaemia and 15 cases of childhood acute myeloid leukaemia no 
mutations in the WTI gene were found (Algar et al., 1997). In fact all of these 
leukaemic cell lines which were tested expressed WTI. Other studies have reported 
high levels of WTI expression in leukaemia cell lines and patient leukaemias (Miwa 
et al., 1992; Miyagi et al., 1993). In leukaemia patients elevated expression of the 
gene is correlated with both poor prognosis and treatment outcomes (Inoue et al., 
1994). In leukaemia cell lines, induced to differentiate, down regulation of the WTI 
gene is specifically associated with differentiation along myeloid and erythroid 
pathways (Sekiya et al., 1994; Phelan et al., 1994). However blocking the expression 
of WTI with antisense oligonucleotides, inhibited proliferation and induced apoptosis 
in 2 out of 3 myeloid leukaemia lines (Algar et al., 1996). WTI may be playing 
multiple roles in the process of haematopoiesis. It may act to repress genes in 
immature haematopoietic cells which are required to allow cells to proceed along 
specific differentiation pathways. In support of this hypothesis, WD is expressed in 
immature leukaemic cells with high rates of proliferation and in immature normal 
haematopoietic cells (King Underwood et al., 1996; Inoue et al., 1994). However the 
identification of WTI mutations in adult acute myeloid leukaemias implies that the 
gene may play a separate later role in myeloid differentiation. 
Fusion of the N terminal domain of the Ewing's sarcoma gene EWS and the C 
terminal end of WTI leads a chimeric transcript implicated in the genesis of 
desmoplastic small round-cell tumour (Gerald etal., 1995; Ladanyi and Gerald, 
1994). These cancers are found closely associated in the main with the mesothelial 
membranes of the abdominal cavity, three cases have been reported in the pleura and 
one in the brain (Tison et al., 1996). 
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1.6 Possible developmental roles of WTI. 
WTI seems to have several roles during development. The gene is expressed in the 
developing nephron, mesothelium and secondary sex cords (Pritchard Jones et al., 
1990; Armstrong et al., 1992; Rackley et al., 1993; Mundlos et al., 1993). The 
phenotypes of the Wt] knockout mouse and WAGR and DDS patients demonstrate 
that proper WTJ function is required for the normal development of all these tissues. 
The developing nephron, mesothelium and secondary sex cords all undergo a 
mesenchymal to epithelial cell type transition during development. On the basis of 
WTJ expression in these tissues it was proposed that the gene may play a role in 
mediating this transition (Pritchard Jones et al., 1990). 
In fact WTJ may play several alternative roles at different stages of development, this 
is most clearly demonstrated in metanephric nephrogenesis reviewed by Hastie 1994 
(Fig. 3). The expression pattern of WTI is very dynamic during the process of 
nephrogenesis. It is expressed in very low levels in the uninduced metanephric 
blastemal stem cells. The level of expression is upregulated in the cells condensing at 
the ureter tip. WTI is then localized during nephrogenesis to the podocyte layer of the 
glomerulus where it remains being expressed during adult life. Examination of 
kidneys from the knockout mouse, WAGR, DDS and sporadic Wilms' tumour 
patients indicates that the gene may have different roles at these different stages of 
nephrogenesis. 
In a Wtl homozygous null knockout mouse only cranial mesonephric tubules are 
formed and no branching of the ureteric bud occurs (Kreidberg et al., 1993). A 
number of other genes involved in different stages of kidney development have 
recently been identified, for a review see Lechner and Dressier 1997. The Ret-k gene 
is expressed in the ureteric bud as it emerges, and later in the growing tips of its 
branches. Ret-k knockout mice also show a reduction in the number of mesonephric 
tubules and failure of ureteric bud formation. Ret is co expressed with Glial cell 
derived neurotrophic factor receptor-a (Gdnfr-a) and in tandem, these molecules act 
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as a receptor for the TGF-0 related molecule Glial cell derived neurotrophic factor 
Gdnf to induce the branching of the ureteric bud. In Gdnf knockout animals, the 
ureteric bud also does not branch from the mesonephric duct and the metanephric 
blastema subsequently undergoes apoptosis. Gdnf is expressed in the metanephric 
mesenchyme simultaneously with Wtl. Potentially Wt] expression may precede and 
permit Gdnf expression. To date however, the state of Gdnf expression in Wt] 
knockout mice has not been investigated. 
In addition to being required for branching of the ureteric bud Wt] is required cell 
autonomously to mediate the response of the metanephric mesenchyme to signals 
inducing nephrogenesis (Kreidberg et al., 1993). Wnt molecules are prime candidates 
for this signal. Wntll is expressed at the growing ureter tips. Other signals may be 
required within the blastema to promote nephrogenesis. Wnt4 is switched on in the 
condensing mesenchyme around the tips of the ureteric buds and required for 
nephrogenesis (Stark et al., 1994). Bmp7, a member of the TGFI3 family, is expressed 
in the ureteric bud and is upregulated in the condensing mesenchyme. It is also 
involved in the control of nephrogenesis (Dudley et al., 1995; Luo et al., 1995; 
Vukicevic et al., 1996). Perhaps Wtl activity within the metanephric blastema is 
required for the subsequent upregulation of Wnt4 and Bmp7 expression in this tissue. 
Wt] is upregulated in those cells of the metanephric blastema which undergo a 
mesenchymal to epithelial cell type transition during nephrogenesis and may play a 
role in this process (Pritchard Jones et al., 1990). It may do this by regulating other 
genes involved in this transition e.g. Pax2 and Pax8. Pax2 is a putative target gene 
for control by Wtl. It is overexpressed in many Wilms' tumours and has an 
expression pattern complementary to that of Wtl (Eccles et al., 1995). Pax2 is 
essential for the mesenchyme to epithelial transition during metanephric 
development. In homozygous Pax2 null mice, no epithelial tissues are formed within 
the intermediate mesoderm (Torres et al., 1995). Anti Pax2 oligonucleotides prevent 
any epithelium formation in metanephric blastemal explant cultures (Charite et al., 
1994). 
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WTI may not only be involved in the onset and control of nephrogenesis but it may 
play a role in the maintenance of the nephron. In the adult nephron, WTI continues to 
be expressed in the podocytes. The podocytes can synthesise a complete glomerular 
basement membrane and may play a role in its degradation since they show endocytic 
activity (Mundel and Kriz, 1995). The DMS seen in DDS patients demonstrates the 
requirement for WTI in the proper functioning of the podocyte cells in the adult 
nephron. 
1.7 Regulation of the WTI gene. 
Expression of the WTI gene is tightly controlled during embryonic development. 
Abberant expression of the gene can have severe clinical effects. Study of the 
transcription regulation of the gene is therefore essential. Firstly mutations of the 
regulatory elements of the gene may be of clinical importance. Secondly analysis of 
the regulatory elements will lead to the identification of factors interacting with the 
WTI promoter and help unravel the regulatory cascade of which the WTI gene is part. 
To date however WTI transcriptional regulation has proven to be very difficult to 
unravel. The putative WTI/Wt] promoter region is highly conserved between mice 
and humans (-73% identical) (Gessler and Bruns, 1993) (Fig. 8). There are long 
stretches of complete homology between the two promoters. The promoters are 
—70% GC rich and lack TATA or CCAAT boxes (Gessler and Bruns, 1993; 
Hofmann et al., 1993). The overall structure of the promoter is more similar to 
housekeeping and other ubiquitous tumour suppressor genes e.g. Retinoblastoma 
(RB) and P53 than tissue specific or developmentally regulated genes. In keeping 
with the similarity to ubiquitously expressed genes a putative promoter lying in the 5' 
region of the WTJ gene displays promiscuous activity when tested in a large number 
of cell lines (Table 2). In a 24 kb stretch of the 5' promoter a 9 bp (CTC) 3 repeat is 
responsible for around 80% of promoter activity (Cohen et al., 1997) (Fig. 8). The 
Sp 1 transcription factor binds to this repeat in extracts of cell lines and murine 
tissues. Versions of the WTI promoter in which this repeat is mutated have a greatly 
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reduced ability to be bound by Spi and to drive transcription. Spi regulates the 
promoter of other TATA less genes, e.g. TgfJ3, Egfr and c-Ha-ras, by binding to GC 
boxes within the promoter (Blake et al., 1990). Interestingly, although the WTI 
promoter contains several GC boxes, it is through the CTC repeat that Spi mediated 
transcriptional activation is modulated. 
Table 2 Cells lines in which WTJ promoter activity has been demonstrated. 
Cell line Cell type Reference 
293 human embryonic kidney (Nornes et al., 1990; Fraizer et 
al., 1994; Rupprecht et al., 1994; 
Campbell et al., 1994; 
Wu et al., 1995) 
JMN human mesothelioma (Nornes et al., 1990) 
HeLa human cervical carcinoma (Nornes et al., 1990; 
Wu et al., 1995) 
Hep3B human hepatocelluar (Fraizer et al., 1994; 
carcinoma Wu et al., 1995) 
G401 human rhabdoid tumour of the (Fraizer et al., 1994) 
kidney  
K652 human chronic myelogenous (Fraizer et al., 1994; 
leukemia in blast crisis Wu et al., 1995) 
HEL human erythroleukemia (Wu et al., 1995) 
CEM human acute lymphoblastic T (Wu et al., 1995) 
cell leukaemia 
[
TM3 mouse leydig (Campbell et al., 1994) 
COS7 African green monkey kidney (Hofmann et al., 1993) 
The TA/Ti promoter contains several WT1/EGR1 binding sites raising the possibility 
that WT 1 may bind and regulate its own promoter. Footprinting studies identified 
seven putative regions of WTI binding with the 5' region (Fig. 8). Transient 
transfection assays have demonstrated that high levels of the WTI protein repress the 
activity of the WTI promoter by 50% (Rupprecht et al., 1994). One of the WT1 
footprints identified in the WTI promoter overlaps with the Spi binding CTC repeat. 
This raises the possibility that that competition between Spi and WT1 for the CTC 
repeat is involved in the regulation of the WTI gene. WTI has been shown to 
negatively regulate expression of the Egfr promoter and this repression is mediated 
by binding a CTC repeat region in this promoter (Englert et al., 1995a). 
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In transient transfection experiments the WTI promoter appears to be constitutively 
active. However, Cohen et al. have reported differential DNAseI hypersensitivity in 
the endogenous WTJ locus between W71 expressing and non expressing cells 
(Cohen et al., 1997). Therefore there must be regulatory elements which are involved 
in 'opening up' the WT] promoter in specific cell types. A number of such potential 
tissue specific regulatory elements have been identified in cell culture experiments. 
Lying immediately 3' to the WTI gene is a haematopoietic enhancer. This enhancer 
can activate gene expression in erthyroid cell lines through the binding of GATA1 
(Wu et al., 1995). Lying within intron 3 of the WT] gene is a repressor element 
containing an alu repeat. This repressor is capable of repressing transcription from 
the WT] locus in all cell lines in which it has been tested except those of kidney 
origin (Hewitt et al., 1995a). Around 250 bp 5' of the CTC repeats in both the mouse 
and human promoters is an element (CR) which contains two paired box binding 
sites (Fig. 8). High levels of PAX8 and PAX2, but not PAX5, transfected into cell 
lines, upregulate reporter gene expression via this CR element. PAX8 binding to the 
CR element has been demonstrated in transfected cells; PAX2 binding to the element 
has not been detected (Dehbi et al., 1996; Dehbi and Pelletier, 1996). 
The WTI gene may be post transcriptionally regulated. The WIT] gene lies around 
800 bp 5' of the WT] gene; it is transcribed in a centromeric direction, as opposed to 
the telomeric direction of WT] (Gessler and Bruns, 1993) (Fig. 9). The WIT] gene 
does not appear to encode a protein and may exert its activity as an RNA. WT] and 
WIT] are transcriptionally co-regulated. They are expressed in the same spatio-
temporal pattern during development and at an invariable ratio of 5-1OWT]:1WIT] 
transcripts (Yeger et al., 1992). Uncoupling of WTI WIT] regulation occurs only in a 
few Wilms' tumours where deregulation of WT] expression is likely(Huang et al., 
1990). Eccles et al. 1994 and Campbell et al. 1994 both identified a number of 
cDNAs, running antisense to WT], spanning part of WT] intron 1, the upstream 
sequences between WT] and WIT] and part of the WIT] gene. Malik et al. 1995 
showed that DNA sequences within the first intron of WT] can act as a promoter 
producing an antisense transcript of exon 1. The putative WIT] promoter as with the 
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putative WTI promoter has no TATA or CCAAT boxes but several consensus Sp I, 
WTI and PAX2 binding sites. Unlike the WTI promoter, that of WIT] is not CG rich 
and is positively activated by WT1 protein. Stable transfection with a construct 
encoding the message from the putative WIT] promoter significantly reduced (to 
50%) the level of WTI protein in cell lines with high endogenous WTI activity. WTI 
gene expression therefore may be regulated by antisense transcripts. This method of 
regulation has been proposed for other genes than WT] e.g. N and c-myc, and c-Ha-
ras. Similarly to WT]/WIT], N-myc and its antisense transcript N-cym are 
transcriptionally co regulated (Armstrong and Krystal, 1992). To date a mouse 
homologue of WIT] has not been isolated. The mouse as well as human however 
exhibits bi-directional transcription through the first exon of WT] implying that 
antisense control may also occur at the Wt] locus (Campbell et al., 1994). 
Analysis of putative WTI promoter activity in cell lines gives some indication as to 
the localization of regions required for promoter activity and the factors which bind 
to them. For a true in vivo analysis of WTI promoter function transgenic analysis is 
required. Cohen et al. created four transgenic mouse lines containing a WTI 
promoter-IacZ reporter construct (Cohen et al., 1997). The promoter region they used 
ran from 1.9 kb upstream of the main transcription initiation site to 0.2 kb 
downstream (see Fig. 9). These transgenic mice showed no reporter gene expression. 
Hewitt et al. isolated a further 6 mice containing a 2.5 kb WTI promoter-lacZ 
reporter constructs and 15 with shorter versions of this construct (Hewitt et al., 
1996). None of these mice expressed the reporter gene in transgenic embryos. It is 
difficult to explain why the same region of the WTI promoter activates transcription 
in cell lines but is inactive in transgenic animals. As the putative WT1 promoter 
region contains CpG islands WTI may potentially be regulated by tissue specific 
DNA methylation. If this is the case the lack of methylation in transfected DNA may 
lead promiscuous promoter activity in cell lines. A larger 42 kb cosmid containing 
the WTI gene was also introduced into transgenic lines by Hewitt et al. Transcription 
is activated from the WT] locus of this transgene but it is unclear whether it has any 
tissue specific activity (Hewitt, J. et al., 1996). 
M. 
Fig. 8 Sequence of the DNA 5' of WTI. 
uppercase - human, lowercase - mouse. The (CTC) 3 repeat and CR element are 
highlighted along with a putative Sry binding site. Arrows represent transcription 
start sites and the two alternative translation initiation sites are indicated (TLSS 1, 
TLSS2). Lines above the sequence represent WTI footprints. 
GOA 
Sry 
Mouse 	acacttcataattatctatcccgaacaatttca. ccttgaatctcaacct 
	
I 	III 	1111111 	I 	III 	11 	1 	1111 
Han 3801 AGGGACGTTCGC7TTCAGTCCCGACCTCTGGA.ACCCACAAAGGGCCACCT 3850 
gcgaacccagagggactaatctcctaaagtgaccccgcagctagcctcta 
111111 	III 	III 	liii 	II 	I 
3851 C'rTrCCCCAGTGAcCCCAAGTCATGGCcAC'rCCCcTACCCGACAGTTCT 3900 
gaattctggacatgggaggagataagccccaaagttaggctatctgcctc 
I 	II 	I 	I 	II 	I 	II 	I 	I 
3901 AGAAGCAAGAGCCAGACTCAAGGGTGCAAAI3CAAGGGNATACGCrrCTFT 3950 
agaacccaggagagttctctgqgctctct .....ttc4gccctctt 








4051 TCTCTACTtECAC$GC.ATTCGACCCTGCccGr.AcTcACTrCTTACCTGA 4099 
acgcct.tgcctcaaqgcgcctacactcgggaaqgcca gctaggg 
11111 	II 	IIIIIIIIIIIIIIIIIIIII 	1111 
4100 ACGACTCTCCAGTGAGACGAGGCTCCCACACTGGCGAAGGCCAAGAAG 4149 
tagcagggg 
111111 	II 	III 	II 	IllIlIllIllIll 	111111 
4150 GAGGTGGGGGGAGGGTIGTGCCACACCGGCCAGCTAGAGCGCGTGTG 4199 
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Fig.9 Schematic representation of WTJ and WIT1 transcription start sites. 
1.8 Analysis of gene regulation - methodology. 
In the study reported in this thesis we wished to analyse the mechanism of WTI gene 
regulation and also to create a good marker for WTI expression during development. 
In this section I discuss why the transgenic method and in particular the YAC 
transgenic method was chosen for this study. We made transgenic lines using three 
different reporter constructs. The first contains a region of the 5' WTI promoter 
linked to a lacZ reporter gene. The region of WTI promoter used in this construct is 
slightly bigger than that used by Cohen et al. and Hewitt et al. in recent reports (Fig. 
9). The second and third constructs were both made by integrating a lacZ reporter 
gene into exon 1 of the WTI gene locus on a YAC. By using these YAC constructs 
we hoped that the inserted transgenic locus would carry all WTI regulatory sequences 
in the correct chromatin environment. LacZ expression from this locus therefore, 
would mirror exactly that of the endogenous Wt] gene. We could then use such a 
transgene exactly mimicking the expression pattern of Wt] as a marker to examine 
the expression of the gene on both wildtype and mutant genetic backgrounds. 
Cell lines are useful for biochemical studies of promoter activity such as 
identification of DNaseI hypersensitive sites and protein footprints. These sites may 
indicate regions of the promoter which may be bound by transcription factor 
molecules. The relative importance of different elements within a promoter in 
controlling gene expression from a locus can be assessed by introducing mutations 
into the putative promoter. The ability of these 'mutant' promoters to activate 
transcription of a reporter gene 'hooked up' to the promoter can then be assayed by 
introducing these constructs into cell lines. The tissue specific activity of the 
promoter can be tested, to some degree, by assaying activity in a range of cell types. 
Although such techniques are relatively quick and easy to carry out, putative 
enhancers revealed by such analysis may often not be utilized in vivo. 
To assess the in vivo developmental control, mediated by elements within a gene 
promoter, a transgenic assay is required. A short transgene containing enhancers 
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lying immediately proximal to a gene is often enough to drive proper tissue specific 
activity of a reporter gene in a transgenic animal, e.g. Msxl (MacKenzie et al., 1997). 
On the other hand the activity of many promoters is often weak and the expression 
pattern subject to 'position effects', e.g. genes of the 0 globin cluster (Martin et al., 
1996). Position effects are caused by the chromatin at the site of transgene integration 
affecting the expression of that transgene. Elements lying at the site of integration 
can act as enhancers driving expression of the transgene in incorrect cell types, this is 
know as regulation position effects (RPE) (Milot et al., 1996). Alternatively, 
transgenes can take up an 'inactive' chromatin configuration. This may be caused by 
spreading of inactive chromatin present at the site of transgene integration, similar to 
the effect of position effect variegation (PEV) first described in Drosophila 
melanogaster (Martin and Whitelaw, 1996). 
Enhancer elements may lie a great distance from the region of gene initiation. 
Transgenic constructs carrying only a short region of a gene may therefore not 
contain all elements required to drive transgene expression in the correct cell types. 
For example, lying 6-22 kb 5' of the human 8 globin gene are five DNaseI 
hypersensitive sites. These sites contain multiple binding sites for tissue specific 
transcription factors. Mutations in humans in this region disrupt correct expression of 
the genes of the 0 globin cluster and cause haemaglobinopathies (Townes and 
Behringer, 1990). This region of hypersensitive sites plays a very important role in 
the control of the genes of the 3 globin cluster and has been termed the 0 globin 
locus control region (LCR). Inclusion of the LCR on a transgenic construct which 
also carries the genes of the 3 globin cluster increases the level of tissue specific 
transcription form each of these genes. It further prevents transgenes from being 
subject to both RPEs and PEV. In many cases the spatial arrangement of elements 
within a locus may also be essential for its proper expression. For example the 
correct order of the genes within the globin cluster and their relationship with the 
LCR is essential for correct gene switching during development (Hanscombe et al., 
1991). 
43 
In order to attempt to recreate the endogenous locus and include potential long range 
regulatory elements in a transgenic animal it is often advantageous to use a very large 
transgenic construct. Yeast artificial chromosomes have a number of advantages for 
use in transgenic experiments. They are capable of maintaining DNA inserts in 
excess of 1 Mb in size and have been successfully utilised for the generation of 
transgenic animals. For example, YAC constructs encoding PAX6 (420 kb) (Schedi 
et al., 1996b), f3-amyloid precursor protein (APP) (650 kb) and human chromosome 
region 2lp22.2 (430-1100 kb) have all been successfully used to generate transgenic 
animals. An added advantage for YAC constructs is that they can be quickly and 
easily altered, for example to introduce reporter genes or promoter mutations, by 
homologous recombination in yeast. For a review of the uses of YACs in transgenic 
studies consult Peterson etal., 1997. 
To get a faithful study of gene expression, however, the endogenous locus is 
obviously the best promoter to study. An endogenous gene locus can be targeted and 
manipulated in ES (embryonic stem) cells. These cell can then be used to generate 
transgenic lines. Deletion individually of each of the 5 DNaseI hypersensitive sites 
contained with the 0 globin LCR has been undertaken at the endogenous locus. 
These deletions have no effect on expression or mildly reduce expression of linked 
globin genes. Using YAC transgenic analysis however deletion of individual 
hypersensitive site significantly reduced the level of transcription from linked J3 
globin genes (Martin et al., 1996). The discrepancies between these different 
experiments indicate that YAC transgenic constructs may still, to a degree, be 
influenced by position effects in the same way as much smaller constructs. On 
balance however using YAC transgenes is often advantageous over targeting the 
endogenous locus. As carrying out homologous recombination and manipulation of 
sequences in ES cell is a very much more difficult and time consuming process than 
in YACs. 
2. Analysis of WTI regulation by a 5kb 
promoter sequence. 
The putative WTI promoter in the region between WTI and WIT] and spanning the 
WTI transcription start sites has promiscuous promoter activity in transfected cell 
lines (Table 2). In order to analyze the ability of this putative WTI promoter to 
regulate gene expression in vivo, we isolated 5kb of proximal WTI promoter. This 
5kb promoter sequence (hereafter referred to as USWT1) consisted of around 3 kb 5' 
of the WTI transcription initiation site, WTI exon 1 and 1 kb of intron 1. USWT 1 
spans sequences identified as a minimal promiscuous WTI promoter (Hofmann et al., 
1993; Fraizer et al., 1994). It includes WTI, Spi and PAX binding sites proposed to 
have a role in the regulation of the WTI gene (Dehbi et al., 1996; Dehbi and Pelletier, 
1996; Cohen et al., 1997; Rupprecht et al., 1994) (Figs. 8 and 9). 
2.1 Cloning of USWT1, a 5kb WT1 promoter sequence. 
The bacteriophage construct XWT4, contains around 15 kb of human genomic 
sequence upstream of WTI, WTI exon 1 and about the first kilobase of WTI intron 1. 
A 5 kb BamBi/SalI fragment (USWT1) was isolated from ?WT4 and cloned into 
pUC18 to give plasmid pUS WT1. One of two different lacZ cassettes was 
subsequently cloned into the SacII site of pUSWT 1 by blunt end ligation. Inserting a 
3.7 kb XbaJ!BamHI lacZ fragment, isolated from RB8Z (Charite et al., 1994), into 
pUS WT1 gave rise to pNLS. The XbaIIBamHI lacZ fragment inserted into pNLS 
contains, in addition to the lacZ gene, a nuclear localization sequence. A second 
plasmid pNOR was constructed by ligating the 3.7 kb HindffllBamHl IacZ fragment 
isolated from pCH 110 (Pharmacia) into the pUSWT1 SacII site. The lacZ cassette in 
pNOR unlike that of pNLS carries no nuclear localization signal. In both pNLS and 
pNOR the lacZ cassette inserted is under the control of its own translation initiation 
site. 
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2.2 Transient transfection of cell lines. 
To investigate whether the pNOR and pNLS constructs were able to drive lacZ 
expression, a series of cell line transfection experiments was undertaken. A range of 
different cell lines was used in an attempt to estimate any potential tissue specificity 
residing in the USWT1 promoter fragment. The results of this investigation are 
summarized in table 3. Transfection of cells was carried out as described in materials 
and methods using pNOR, pNLS or pCMV. pCMV contains the lacZ gene driven by 
the highly active ubiquitous CMV promoter (MacGregor and Caskey, 1989). 
Efficiency of transfection is highly divergent between different cell lines; hence using 
pCMV as a positive control gives an indication of the transfection efficiency of each 
line. The level of -galactosidase activity of each promoter (CMV, NOR and NLS) 
was assessed by estimating the percentage of cells per transfected plate which stain 
blue following incubation with X gal. Such a technique is crude, but is believed to be 
a reliable method of estimating f3-galactosidase activity (MacGregor et al., 1989). 
The 5kb of putative WTI promoter (USWT1) in pNOR and pNLS has promoter 
activity. It is highly active in mouse mesothelioma (AC29) cells and also to a lesser 
extent in human granulosa cell tumour (C0V343) cell lines. Both of these cell lines 
express WTI endogenously. pNOR and pNLS show equivalent activity in each cell 
line. 3-galactosidase expression in cells transfected with pNLS is localized to the 
nucleus (Fig. 11). Cell lines which do not express endogenous WT  (1OT1/2 and C2 
cells) do not show pNOR or pNLS promoter activity. However both the lOT 1/2 and 
C2 cells were only transfected once and showed a low level of transfection 


















Fig. 11 f-ga1actosidase expression in AC29 cells transfected with pNOR, pNLS or 
pCMV. 
-ga1actosidase transcribed from pCMV and pNOR is present throughout the cell or 
mainly in the cytoplasm. -galactosidase transcribed from pNLS in located mainly in 
the cell nucleus. 
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Surprisingly the USWT1 promoter sequence does not drive -galactosidase 
expression in mouse mesonephric cells (M1 5) and Sertoli cells (PyT45) indicating 
that it is not a promiscuous promoter. These cell lines are both easily transfectable 
and express endogenous Wtl in high levels. The inability of USWT1 sequences to 
drive reporter gene expression in M15, PyT45, C2 and 10T I/2 cells is in 
contradiction to findings of other investigators. Several groups have demonstrated 
that the region of WTI promoter spanning the transcription start site acts as a 
promiscuous promoter (Table 2). In particular both Frazier et al. 1994 and Cohen et 
al. 1997 have demonstrated that constructs very similar to USWT1 are active in 293 
foetal kidney cells, K562 leukaemia cells, JMN mesothelioma cells and HeLa 
cervical carcinoma cells. It is difficult to explain the difference between the findings 
of this study and those of other groups. Potentially with a more careful and sensitive 
analysis we could identify a low level of USWT 1 promoter activity in those cell lines 
in which we have so far failed to do so. However the purpose of this experiment was 
in the main to determine if the pNOR and pNLS constructs were able to drive 
reporter gene expression. This is the case. 
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Table 3 Estimation of pNOR and pNLS activity in transiently transfected cell lines. 
cell line cell type & reference WT1 CMV NLS No. of 
name activity and experimenta 
NOR 1 repeats. 
AC29 mouse mesothelioma ++ 10-30 1-2 2 
(Langerak et al., 1995)  
C0V434 human granulosa cell + 3-10 0.1 6 
tumour (van den Berg 
Bakker et al., 1993)  
M15 polyoma large T ++ 10-30 0 3 
immortalized mouse 
mesonephric 
(Larsson et al., 1995)  
PyT45 polyoma large T ++ 10 0 1 
immortalized Sertoli cells 
from adult mouse testicular 
tumours (Rassoulzadegan et 
al., 1993)  
lOT 1/2 mouse fibroblastic 2 0 1 
(Larsson_et_al.,_1995)  
C2 mouse myoblastic - 5 0 1 
(Larsson et al., 1995) 
A schematic indication of the level of endogenous WTI activity is given in the 
column headed (WTI expression) along with the relevant references for cell type and 
WTI activity, (++ = high, + = medium, - = none). Promoter activity of pCMV, 
pNOR and pNLS is given as an estimate of the percentage of cells per transfected 
plate which stain blue following incubation with X-Gal. 
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2.3 Establishment of transgenic lines containing NOR and 
NLS transgenes. 
Transient transfection of cell lines demonstrated that USWT 1 has a promoter 
activity. Potentially this activity was not promiscuous in contradiction to the findings 
of other groups. In order to investigate the true tissue specificity of this promoter in 
vivo, transgenic lines were made using pNOR and pNLS as transgenes. 
pNOR and pNLS were digested with BamHT and SphI. This digestion released an 8 
kb fragment containing the USWT1 sequence with integrated lacZ cassette. The 8 kb 
fragment was then used to microinject oocytes isolated from superovulated (C57BL/6 
x CBA)F1 mice. 167 of the oocytes injected survived overnight culture to the 2 cell 
stage. These were transferred into pseudopregnant host mothers. 54 mice were born 
of which 3 were transgenic, NOR21 (male), NLS52 (female) and NLS53 (female). 
Founder NLS53 did not transmit the transgene (around 50 offspring were analyzed). 
NOR21 and NLS52 transmitted the transgene founding lines NORp21 and NLSp52 
respectively. A genomic Southern blot of offspring from founders NOR21 and 
NLS52 indicates that the transgenes have inserted intact (Fig. 12). Embryos isolated 
from NORp2 1 and NLSp52 showed developmentally regulated -galactosidase 
expression. There was little similarity however, in the expression pattern seen in 
these two lines. For a detailed description of the expression pattern of NORp2 1 and 
NLSp53 refer to section 2.6. 
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Fig. 12 Genomic Southern blot of lines NLSp52 and NORp2 1. 
Genomic DNA of offspring from breeding lines NLSp52 (lanes 1-11) and NORp2 I 
(lanes 12-22) was digested with EcoRI and XhoI and Southern blotted. Control lanes 
are EcoRI/XhoI digested plasmid (pNLS or pNOR) DNA. The blot was probed with 
TRPLZ (see section 7.14). TPLZ highlights the lacZ EcoRI fragment in NLSp52 (2.5 
kb) and NORp2 1 (5.5 kb). In lanes pNLS and pNOR another band of around 700bp 
indicates the EcoRI/XhoI fragment spanning the 3' end of lacZ and the 3'end of WTI 
exon I. TPLZ also hybridizes to the murine Trp/ gene giving a strong band at 2.6kb 
and weak bands at 5.5 and 5 kb. A further band in lanes pNLS and pNOR, slightly 
bigger than the TrpI 2.6 kb band, represents hybridization to pUCI8 plasmid 
sequences (2.66kb). The NLS transgene is present intact in lanes 3, 4, 5, 8 and 10. 
The NOR transgene is intact in lane 19 but has undergone a rearrangement in lane 15. 
This was the only example of rearrangement-recorded in all offspring analyzed. 
52 
MW  C  




2.3 - 	 . 
2.4 Isolation of 'transient' transgenic embryos. 
The developmental expression pattern of the transgene was very different between 
NORp2 1 and NLSp52. To allow quicker analysis of several different transgenic 
embryos a 'transient' approach was used. Mouse oocytes were microinjected, the 
resulting embryos isolated at E12.5 and examined for transgene expression. E12.5 
was chosen on the basis of the reported Wt] expression pattern. It is a stage where the 
gene is expressed in a number of different developing structures. Analysis of 
NORp2 1 and NLSp52 embryos had further highlighted transgene expression in the 
interdigital areas of the developing handplate which would not be seen earlier than 
E12.5. Finally £12.5 is the most developed stage at which there is full penetration of 
the X-gal stain allowing embryos to be stained whole. With microinjection help from 
Dr. Andreas Schedi and Ms Lesley McInnes 8 transgene expressing embryos (T1-8) 
were isolated, stained and vibrotome sectioned. These embryos were examined for 
any conserved expression domains. The conservation of any such domains between a 
number of the embryos may indicate that elements responsible this expression are 
present on USWT I. 
2.5 Comparison of expression between NORp21, NLSp52 
and T1-8. 
Comparison of the expression pattern between each of the NOR or NLS transgenic 
embryos allows any potential tissue specific activity of USWT1 to be assessed. There 
is a large degree of variation between the -ga1actosidase expression pattern in each 
of the embryos. This variation indicates that the USWT1 promoter is weak and 
susceptible to position effects. (For a detailed description of the expression pattern in 
each of these embryos refer to section 2.6). Between the 10 embryos analysed it was 
possible to identify domains of transgene expression which are similar to the 
endogenous expression of Wtl and/or reoccur in more than one embryo. These 
domains are summarized in table 4. Fig. 13 illustrates the 3-galactosidase expression 
pattern in two of these transient transgenic embryos. 
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A main site of expression for Wtl is within the developing urogenital system in 
particular in the mesonephros, metanephros and gonads (Pritchard Jones et al., 1990; 
Armstrong et al., 1992; Rackley et al., 1993; Pelletier et al., 1991c). No expression of 
the transgenes could be detected in any of these tissues which was distinguishable 
from background endogenous 13-galactosidase activity. Wt] is expressed in the 
pericardium, diaphragm and mesenteries of the gut. 4/10 of the embryos examined 
showed transgene expression in some of these tissues and 3/10 had expression on the 
surface of the umbilical hernia which is an extension of gut mesentery. 2/10 of 
embryos show NOR and NLS promoter activity in the body wall muscle, another 
previously reported domain of gene expression. Whilst all of the embryos examined 
showed expression in the brain, the domains of expression appeared to differ between 
each. However expression in the ventral part of the spinal chord was seen in 3/10 of 
the lines and appears to be a similar region to that in which Wt] is active. 
A number of other sites of transgene expression, not similar to domains of Wtl 
activity, are common between several of these transgenic embryos. In particular 6/10 
of the embryos show varying degrees of expression in limb mesenchyme In the main 
this appears to be in differentiating limb musculature which is perhaps analogous to 
transgene expression in differentiating body wall muscle. 3/10 of the embryos show 
transgene expression in intercostal mesenchyme which again could potentially be in 
developing muscle. Another domain of transgene expression in 5110 of these 
transgenic embryos is the hand plate in particular the interdigital regions and/or the 
marginal zones. These regions of loose mesenchyme undergo apoptosis raising the 
possibility that the transgenes may be marking domains of apoptosis in these 
embryos (Konig et al., 1993). 
NORp21, T8 and to some degree T4 have a general expression pattern of 0-
galactosidase similar to that of Wtl. Hence the 5kb of WTI promoter sequence 
(USWT1) present in pNOR and pNLS has tissue specific promoter activity. It is able 
to drive reporter gene expression in a tissue specific manner similar to endogenous 
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Wt] expression. It is not however, able to drive reporter gene expression within the 
developing urogenital system. USWT1 does drive reporter gene activity in a 
potentially novel site for Wt] activity. Half the embryos isolated in this study show 
expression of lacZ within the interdigital regions of the developing handplate. In fact 
this domain does represent an previously unidentified domain of Wt] activity as has 
later been confirmed by in situ hybridization analysis (see Chapter 5). 
One must be careful interpreting the NOR/NLS transgenic experiments. Whatever 
activity USWT1 has is weak and is easily subject to alteration by its site of 
integration into the host genome (position effects). It may be that transgenes in 
general, and NORINLS in particular, have increased susceptibility to position effects 
driving expression in certain organs or tissues, e.g. the limb and parts of the nervous 
system. Therefore preponderance of 3-galactosidase expression in tissues is not a 
definitive indication of the ability of the USWT1 promoter fragment to drive reporter 
gene expression within them. 
Since this study was completed Cohen et al. 1997 and Hewitt et al. 1996 have 
reported using about a 2 kb a region of the WTI promoter linked to lacZ to generate 
10 transgenic lines. They were unable to get transgene expression in any of these 
lines. The constructs they used contain only around 1 kb less 5' sequence than 
USWT 1 (Fig. 9). The integrated transgenes in their studies appear to have adopted an 
'inactive' configuration within the host genome. pNORJpNLS in this study did not. 
Reasons as to why this has happened are not at all clear. These constructs and 
USWT1 span similar regions of the putative 5' proximal WTI promoter; therefore 
they must contain similar elements for the binding of basal and tissue specific 
transcription factors. Increase copies of an inserted transgene may lead to increased 
transgene expression, e.g. (Schedl et al., 1996b). Neither Cohen et al., Hewitt et al. 
nor myself have determined the numbers of copies integrated in any of these WTI 
promoter-reporter transgenic lines. It seems unlikely however that I will have 
consistently got insertion of many copies of transgene leading to higher levels of 
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expression whilst they did not. Perhaps the extra chromatin inserted in the NORINLS 
transgenics as opposed to Cohen's and Hewitt's has helped to 'open up' a promoter 
which is weak in activity. The promoter is then activated to an extent where 
transcription from the locus is now detectable. This opening may simply be due the 
extra volume of DNA inserted in NLSINOR animals; alternatively it could be due to 
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Fig. 13 3-gaIactosidase expression driven by USWT1 in E12.5 transient transgenic 
embryos. 
T4 (a) and T5 (b) show transgene activity in regions of endogenous Wtl activity. 
Abbreviations: (NT) neural tube, (IC) intercostal mesenchyme, (Liv) liver, (P1) pleura, 
(Pe) peritonea, (UH) umbilicus. (Vb) vertebrae. 
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Table 4 13-galactosidase expression in NORJNLS transgenic embryos. 
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interdigital 1 





II notochord 0 H 
Lines NORp21 and NLSp52 are stable transgenic lines 
Embryos T1-8 are transient transgenic analyses 
3-Whilst organs such as the mesonephros metanephros and gonads strongly 
express WtJ the NOR and NLS transgenes are not expressed in them in any of the 10 
transgenic lines analysed. 
4- Wt  expression detected by RT-PCR (Armstrong et al. 1992) 
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2.6 LacZ expression pattern in NOR and NLS transgenics. 
2.6.1 Transgene expression in NORp21. 
Expression of the NOR transgene in NORp2 1 transgenic embryos shows several 
similarities to that of endogenous Wtl. At E12.5 there is transgene activity in the 
pericardium, diaphragm, lateral body wall, body wall adjacent to the vertebrae and 
the tongue. Interestingly the visceral layer of the umbilical hernia expresses 3-
galactosidase, this tissue is continuous with the peritoneal mesentery of the gut which 
is a site of endogenous Wt] activity. NOR transgene activity is evident in many other 
domains where endogenous Wtl activity has not been reported. In the head, it is 
expressed in the mesenchyme behind the eyes, adjacent to the palate, at the back of 
the head, in the lower jaw and also in the nasal epithelium. NOR is expressed in parts 
of the third ventricle and forebrain. It is also expressed strongly in the notochord but 
interestingly not at the very tip of the tail. NOR is expressed in the apoptotic 
interdigital mesenchyme and in the developing musculature of the limb at the points 
where the limbs abut the body. 
In the adult Wt] activity is localized to the podocyte cells of the metanephros and the 
mesothelium. NOR is not expressed in the adult metanephros but is in the 
mesothelium overlaying the gonad. 
2.6.2 Transgene expression in NLSp52. 
At E12.5 NLS is expressed solely in the developing limb. It is confined to the dorsal 
side of the hand plate in both the posterior marginal zone and between digits 4 and 5. 
In the adult animal transgene expression has only been identified in the mesothelial 
coating of the gonad. 
2.6.3 Transgene (NOR) expression in Ti. 
Transgene expression in Ti is solely in parts of the cerebral cortex and midbrain. 
2.6.4 Transgene (NOR) expression in T2. 
In T2 the NOR transgene is expressed on the surface of the umbilical hernia, 
intercostal mesenchyme, tongue and part of the lower jaw. There is transgene 
expression in all limb mesenchyme except that which is condensing to form the 
chondrogenic bone precursors. Part of the cerebellum, the mesenchyme of the tail 
and maxilla also show transgene activity. 
2.6.5 Transgene (NOR) expression in T3. 
In contrast to the transgene expression in T2, NOR in T3 is expressed in the 
condensing chondrogenic mesenchyme of the limbs and ribs, also in the notochord 
and part of the forebrain. The mesenchyme/peritoneum overlying the surface of the 
liver expresses NOR. This is a domain of high endogenous Wt] activity. 
2.6.6 Transgene (NOR) expression in T4. 
T4 has transgene expression in the peritoneum/mesenchyme overlying the liver, 
pleura/mesenchyme surrounding the lungs, the interdigital mesenchyme and limb and 
body wall musculature. All of these tissues express Wtl endogenously. Further 
transgene expression surrounds the thymus, tip of the tail and mesenchyme adjacent 
to the palatal shelves and pharyngo-tympanic tube. 
The transgene is expressed in the ventral interneurons of the spinal chord, similar to 
the reported Wtl expression domain. However at cervical regions it is also expressed 
in the motor neurones of the ventral horns where WTI is not. In the rest of the 
nervous system transgene expression occurs in the hindbrain, a stripe across the 
midbrain, the optic nerve and the trigeminal ganglion. 
Expression of the NOR transgene in T4 is illustrated in Fig. 13. 
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2.6.7 Transgene (NOR) expression in T5. 
As with T4, T5 has NOR expression in the ventral spinal chord. There is further 
expression in what appears to be the developing musculature of the fore and hind 
limbs and the marginal zones of the handplate. The corpus striatum, pons/midbrain 
junction and in cells scattered throughout the tail also express NOR. 
Expression of the NOR transgene in T5 is illustrated in Fig. 13. 
2.6.8 Transgene (NOR) expression in T6. 
T6 shows transgene expression in the mesenchyme around the eye, around the aorta 
and a hint of expression in the pelvic musculature. 
2.6.9 Transgene (NLS) expression in T7. 
There is transgene expression in the shoulder muscle and tongue of T7. Further 
expression occurs in the mesenchyme of the nose and palate and in part of the 
developing hypothalamus. 
2.6.10 Transgene (NLS) expression in T8. 
The transgene expression in T8 is very similar to that in some of the other embryos. 
There is expression of NLS in the interdigital mesenchyme, limb and shoulder 
muscles, intercostal mesenchyme, pericardium, pleura and the mesenchyme 
surrounding the paramesonephric duct as it approaches the urogenital sinus. All of 
these are domains of endogenous Wtl expression. Like T4 and T5 there is - 
galactosidase activity in the ventral spinal chord, and also the midbrain, medulla 
oblongata and dorsal root ganglia. 
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3. Creation of YAC transgenic lines. 
3.1 Lines A, C and D. 
Three of the transgenic lines, A, C and D, used in this study were donated by Dr 
Andreas Schedi (MRC HGU, Edinburgh, U.K.),. Line A contains the construct 
WT470LZi and lines C and D WT280LZ. In all these lines a WTI exon 1/n-
galactosidase fusion protein is expressed from the WTI promoter of the transgene. 
The constructs used to create these lines were made as demonstarted in Fig. 14. A 
YAC (yIE5) was isolated spanning the human WTI locus (Fantes et al., 1995). yIE5 
was introduced in yeast strain CGY25 16. It was then retrofitted with an amplification 
vector (Schedl et al., 1993; Smith et al., 1993) to give rise to WT470. Alternatively 
yIE5 was truncated by homologous recombination with a fragmentation vector 
consisting of a 4.5 kb EcoRI-SalI fragment from 10 kb 3' of the WTI termination site 
cloned into pCGS990Hyglox (Smith et al., 1993). Truncation of yIE5 gave rise to a 
280kb YAC, WT280. A lacZ gene was introduced into WT470 and WT280, by 
homologous recombination with the insert of pWT-lac. The recombination of pWT-
lac with a WTI carrying YAC is shown in Fig. 15, (in this case the YAC is 800/4). 
This recombination gave rise to WT470LZi and W1'280LZ respectively. 
pWT-lac was constructed by cloning a 1.5 kb PstI-SalI fragment, spanning WTI exon 
1, from A.WT4 into a modified pUC18 vector (pUC18MCS). A lacZ gene was then 
inserted, in frame, into the XhoI site at the end of exon 1. 
Lines A, C and D are all male sterile. The amplification vector used to retrofit yIE5 
contains the Thymidine kinase (TK) gene which has been implicated in transgenic 
male sterility. In order to generate a construct which would allow male transmission, 
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yIE5 was retrofitted a second time, using a modified amplification vector in which 
the TK gene has been deleted (gift of Dr. S. Shen, MRC HGU, Edinburgh, U.K.), to 
give YAC construct 800/4. 
3.2 Lines E, F, G and H. 
To confirm the expression pattern seen in line A, further transgenic lines expressing 
3-galactosidase under the control of the WTI promoter were required. To avoid the 
problems of male transgenic sterility I constructed a new YAC construct, 
WT470LZii. This construct was created by homologous recombination between 
pWT-lac and 800/4 (Fig. 15). As with WT4701,Zi, a WT1 exon1/3-galactosidase 
fusion protein under the control of the WT1 promoter will be produced from 
WT470LZii. I then isolated WT470LZii DNA and used it to produce four more 
transgenic founders E, F, G and H. 
3.2.1 Construction of WT470LZii. 
The replacement vector pWT-lac, digested with NotI, was used for transformation of 
yeast containing 800/4. Recombination between the WTI locus of 800/4 and pWT-lac 
inserts lacZ and Leu2 into the end of WTI exon 1. Transformed cells were selected 
by plating on -URA (Ura3 is present on the YAC short vector arm) -LEU media and 
10 colonies picked. Pulse field gel (PFGE) analysis of plugs made from these 
colonies detected 9 containing a yeast artificial chromosome of the correct size (470 
kb) (Fig. 16). 
To detect if the lacZ gene has homologously recombined into WT470 (800/4) a 
Southern blot of EcoRI digested plugs was undertaken. This blot was hybridized with 
a WT1 exon 1 specific probe (WTX). Insertion of the lacZ gene into the end of WTI 
exon 1 reduces the size of the exon 1 containing fragment from 15 kb to 8 kb (Fig. 
15). Such a blot indicated the majority of colonies obtained from the transformation 
carry a mixture of recombined and non-recombined YACs (Fig. 17). This is an 
expected result, as due to the presence of the amplification vector on 800/4 each 
yeast cell carries several YACs. Only some of these may have undergone 
homologous recombination. One colony (number 8) contains solely products of 
homologous recombination. For technical reasons this colony was not used for 
making yeast plugs to isolate YAC DNA for microinjection. Instead colony 10 was 
picked and then streaked out again under -LEU selection. All colonies picked from 
this plate contained only WT47OLZii and no 800/4. One of these colonies was then 
used to as a source of YAC DNA for microinjection. 
3.2.2 Isolation and microinjection of WT470LZii. 
WT470LZjj YAC DNA was isolated as described in the materials and methods 
chapter. Transgenic lines were derived by microinjection of this DNA into (C57BL/6 
x CBA)Fl oocyte pronuclei. Some injections were carried out by myself, the majority 
by Ms Lesley McInnes. Four founder mice were obtained, E (female), F (male), G 
(male) and H (male). Only E and H were fertile and transmitted the transgene 
(through both male and female germlines). 
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Fig. 15 Homologous recombination between 800/4 and pWT-lac introduces lacZ and leu2 into the YAC WT1 locus. 
The YAC 800/4 carries the human WT1 locus. Recombination between this locus and the two regions of pWT-lac homologous 
to WTI exon 1 and to intron 1 inserts lacZ and leu2. The resulting YAC containing the fusion gene between WTI exon 1, 
lacZ and leu2 is named WT470LZii. 
Fig. 16 Pulse field gel analysis of plugs made from colonies following transformation 
of 800/4 with pWT-lac. 
(a) A pulse field gel of plugs made from colonies obtained after transformation of 
800/4 with pWT-lac. The yeast chromosomes can be clearly seen including one of 
the correct size for WT470LZii (470kb). A Southern blot made from this gel is 
probed with (b) a WTI cDNA (probe-WT33) and then stripped and probed with (c) a 
lacZ probe (ILZ),In (b) and (c) all lanes contain a chromosome of the correct size 
(470kb) which hybridizes with both WT33 and ILZ. The colony represented in lane 9 
also carries chromosomes of the wrong size which hybridize both WTI and lacZ. The 
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Fig. 17 Southern blot of EcoRI digested 800/4 plugs following transformation with 
pWT-lac. 
Yeast plugs, made from colonies resulting from the transformation of 800/4 with pWT-
lac are digested with EcoRI. This digest is Southern blotted and probed with WTI exon 
1 (probe-WTX). Insertion of lacZ into WT1 exon 1 reduces the size of the band detected 
with this probe from 15kb to 8kb. Only colony 8 contains solely the products of insertion 
of lacZ into WTI exon 1. 
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3.3 Molecular analysis of YAC transgenic lines. 
The extent of YAC transgene integration in each transgenic line was determined by 
hybridizing EcoRI digested genomic Southern blots with a range of probes. The 
probes used were SVA and LVA (YAC short and long vector arms respectively), 
WT33 (WTI cDNA)and L800 (a 800 bp fragment isolated from around 100kb 3' of 
the WTJ termination site). For a description of these molecular probes see materials 
and methods. The results of this genomic Southern analysis are shown in Fig. 18 and 
schematized in Fig. 19. 
Lines A, C and D, all of which contain the TK gene in the LVA, are male sterile. All 
of these lines have the LVA integrated into the genome. The modified amplification 
vector used to make WT470LZii has TK deleted from the LVA. Two of the lines 
containing this transgene transmit it through both the male and female germline; 
neither of them have the LVA integrated. Two male founder mice, containing 
WT470LZii, F and G were sterile. Founder G had testes less than one quarter the size 
of wild type. It would be interesting to ascertain whether founders F and G have 
integrated a modified amplification vector. It seems likely that these mice will have 
an integrated WT470LZii LVA. If this is the case, the part of the TK gene responsible 
for male sterility is still present on the vector used to make 800/4. 
A PCR based approach was used to estimate the number of copies of transgene 
integrated in each line. Primers J422 and J423 (materials and methods) amplify 
human and mouse WTI exon 10 with identical efficiency to give rise to a 107 bp 
product. The region which they amplify spans a sequence difference between the 
human and mouse genes. A BstUI restriction site is present in the mouse, but not 
human, sequence. PCR products derived from the mouse genomic template will carry 
this site, those from the human YAC transgene template will not. Digestion of the 
mouse product with BstUI cuts it into 59 and 49bp fragments. PCR using J422 and 
J423 was carried out on genomic DNA from each transgenic line. Aliquots of 
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reaction product were removed during the exponential stage of sequence 
amplification (20- 30 cycles). These products were then BstUI digested, run on a gel 
and Southern blotted. The blot was then hybridized with the oligonucleotide J420 
(materials and methods). J420 hybridizes with equal efficiency to mouse template (59 
bp) and human template (107 bp) derived PCR products. The ratio of human derived 
to mouse derived PCR products gives an indication of the number of human WT1 
loci carried in the line (Fig. 20). 
In order to answer questions raised elsewhere in this thesis (Chapter 5) the 
chromosomal location of transgene integration in lines A and H was determined via 
fluorescent in situ hybridisation (FISH) (Fantes et al., 1992) (Fig. 21). The FISH 
analysis was carried out by Muriel Lee, on chromosome spreads of splenic 
haemopoietic cells. The probe used was cosmid B2.1 (Fantes et al., 1995). 
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Fig. 18 Southern blot of EcoRI digested genomic DNA from transgenic lines A , 
H, C and D. 
Lanes A-D refer to their respective transgenic lines, (human) a wildtype human and 
(mouse) a Swiss strain mouse. The YAC DNA used in this blot came from 
WT28OLZ. 
Southern blot probed with the WT] cDNA. The lane containing human DNA 
represents the normal pattern of hybridization for the WTI gene probed with its own 
cDNA. The numbers alongside the blot refer to the exons represented by each of 
these bands. Insertion of the lacZ gene into exon 1 of WTI as has occurred in 
WT47OLZ(i and ii) and WT280LZ adds an EcoRI site between exons 1 and 2. Due 
to this the exon I and 2 band is split into two( * = exon 1, ** = exon 2). The human 
WTI cDNA also hybridizes, less well, to the mouse Wi'] gene. This hybridization 
gives bands A-F, which can be seen in the mouse control lane, and also more clearly 
in lanes E and H. Lines A, H, C and D show fully intact WTI loci integrated into the 
transgenic line. In line E however only bands from WTI exon 1-3 are present, the rest 
of the gene has been lost. 
Southern blot probed with the YAC short vector arm (SVA). The short vector 
arm is integrated in lines A, E and H. The presence of multiple copies of SVA 
sequences in line H and their range of sizes implies the transgene has integrated in a 
tandem array of YAC with differing breakpoints 3' of the SVA. 
Southern blot probed with the YAC long vector arm (LVA). Transgenic lines C 
and D contain at least one copy of the LVA whilst line A shows bands of two 
differing sizes. A band in the human DNA lane must be due to contamination. 
(d)Southern blot probed with L800. The L800 probe is a 800 bp fragment isolated 
from around 100kb 3' of the WTI termination site. This region is not present on 
WT280LZ hence no band is seen in lines C and D. Lines A, E and H all contain at 
least one copy of this region. The band present in the human DNA lane must be 
sample contamination. 
The contaminating band seen in the human control lane is of a similar size to that 
produced by hybridization of the L800 probe to WT470LZ. This raises the possibility 
that in the band in lanes A,E and H is also contamination. This is particularly a 
possibility in the analysis of line E. In line E the transgene is truncated 3' of WTI 
exon3 and has no LVA. If the L800 probe is hybridizing to line E then a YAC 
intergration/rearrangement event similar to that postulated in fig. 19 must have 
occurred. Alternatively if the L800 probe is hybridizing to contamination in this lane 
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Fig. 19 Schematic representation of the extent of transgene integration in transgenic 
lines. 
Genomic Southern blots of each transgenic line were hybridized with a selection of 
probes: SVA and LVA (YAC short and long vector arms respectively), WT33 (WTI 
cDNA)and L800 (a 800 bp fragment isolated from around 100kb 3' of the V/Ti 
termination site). 
A- Transgenic line A shows full integration of the transgene. 
E- Transgenic line E is deleted from WTI intron 3 until a point 5' of L800, it is 
further truncated 3' of L800. Alternatively the transgene may simply be truncated 3' 
of WTI intron 3. 
H- Transgenic line H shows full integration of the transgenes 5' of L800 they are 
then truncated 3' of this point. 
C&D Transgenic lines C&D are both truncated at a point 5' of WTI but contain full 
integration of transgene sequences 3' of the gene. 
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Fig. 20 Estimation of the transgene copy number in each transgenic line. 
The ratio of human derived to mouse derived PCR products gives an indication of the 
number of human Wi'] loci carried in the line. Samples were removed from a PCR reaction 
at 25 (lane 1) 28 (lane 2) and 30 (lane 3) cycles. The figure shows the relative amount 
of human and mouse derived product at each of these stages. PCR was carried out on 
lines heterozygous for the transgene and homozygous for mouse Wtl. Hence the number 
of copies of transgene is equivalent to the ratio of human to mouse product multiplied by 
2. Line A contains 1 copy of a transgenic WT1 locus, line H 9, line C 1 and line D 2. It 
is not possible to carry out this copy number analysis for line E as the transgene is deleted 
for WTI exon 10. A control shown represents PCR carried out on DNA from a non 
transgenic Swiss mouse. The ratio and percentages quoted in this figure are both calculated 
directly from the intensity of the bands shown using the 'ImageQuant' programme 
(Molecular Dynamics). 
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Fig. 21 Fluorescent in sitt hybridisation (FISH) mapping of transgene integration 
sites. 
Computer enhanced chromosome spreads from lines A(a) and H(b). Spreads were 
probed with cosmid B2. 1. In line A the transgene (green signal) has integrated into 
chromosome 4 in the region of (A3-B). Line H shows transgene (green signal) 
integration in the telomere of chromosome 4(E). 
77 
Line A 





















3.4 Summary of the state of transgene integration in each 
line. 
3.4.1 Line A. 
Line A contains one copy of what appears to be a complete WT470LZi transgene. A 
Southern blot of genomic DNA from line A probed with WT33, indicates the WTI 
locus to be fully intact. Similarly both vector arms and L800 are integrated. There 
appear to be two copies of the LVA indicating a second partial integration of the 3' 
end of WT470LZi. FISH analysis maps the transgene to chromosome 4, in the region 
from A3 through B. 
3.4.2 Line E. 
It was not possible to determine the WT470LZii transgene copy number in line E 
using the PCR based approach as the WTI locus has only partially integrated. It is 
only possible to make out bands corresponding to exons 1, 2 and 3 when a Southern 
blot of line E genomic DNA is probed with WT33. The SVA and L800 are present 
but not the LVA. This indicates that WT470LZii is deleted from WTI intron 3 until a 
point 3' of WTI and 5' of L800. It is then truncated further 3' of L800. Potentially 
this transgene locus may not contain one deleted YAC but the cointegration of two 
truncated YAC fragments. 
Alternatively it is possible that the L800 signal in the line E genomic blot is 
contamination. If indeed this is the case then the YAC transgene may simply be 
truncated 3' of WTI exon3. Further analysis will be required to distinguish between 
these two possibilities. 
3.4.3 Line H. 
FISH analysis shows integration of many copies of WT470LZii. All of these are 
integrated in the vicinty of the telomere of chromosome 4 (band E). PCR analysis 
indicates 9 copies of the WTI locus are integrated in line H. A line H genomic 
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Southern blot hybridized with WT33 indicates that at least some of these are intact. 
There are many more than 9 copies of the SVA integrated, but none of the LVA. The 
EcoRI fragments which hybridize to SVA in the line H blot show a range of differing 
sizes. All these data imply that WT470LZii has integrated in a tandem array 
containing differing YAC breakpoints 3' of the SVA. This type of YAC transgene 
integration has been previously reported (Schedl et al., 1996b). It may be the result of 
a particular mechanism of assimilation into the host genome. By FISH analysis the 
transgene maps to the telomere of chromosome 4. Perhaps integration into a telomere 
could be a contributing factor in this mechanism, possibly due to the highly repetitive 
nature of this structure. 
3.4.4 Line C. 
Line C contains one copy of integrated transgene with an intact WTI locus and LVA. 
It however contains no SVA implying truncation of WT280LZ 5' of WTI. 
3.4.5 Line D. 
Two copies of the WTJ locus are present in line D. These appear to be intact although 
due to low levels of DNA loaded on a genomic Southern blot it is difficult to make 
out the hybridization signal. The hybridization signal is weak but a long exposure 
suggests that line D contains two copies of the LVA. It contains no SVA sequences 
indicating the region downstream of the WTI locus is intact but that upstream it is 
truncated. 
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4. Analysis of the expression pattern of the 
YAC transgenes. 
Three lines generated by microinjection with WT47OLZ transmit the transgene. Lines 
A and H have identical embryological expression patterns which closely mirror that 
of endogenous WtI and highlight some potential unreported domains of expression. 
Line E has expression which is generally a subset of that of lines A and H but has 
some differences. Transgene expression in those adult tissues examined from the non 
transmitting lines F and G was the same as lines A and H. I will first describe the 
expression pattern seen in lines A and H then describe the differences between this 
and that of line E. 
Following a description of the expression pattern of WT470LZ I will detail the less 
extensive analysis carried out on lines containing the WT280LZ transgene. Three 
lines, C, D and I, have been generated using the WT280LZ transgene. All transmit. 
However WT280LZ expression has been investigated in depth only in lines C and D. 
Finally Dr. Andreas Schedi has used the WT280 YAC to generate three transgenic 
lines. I will briefly review the results of experiments he has conducted using these 
transgenic animals. 
4.1 Early WT470LZ expression in E8.5-9.5 embryos (stage 
12-15). 
4.1.1 Expression in the pronephros and mesonephros. 
The first expression of WT470LZ is detected in a six somite stage embryo (Fig. 22a). 
It occurs in single cells in the region of the forming intermediate mesoderm. The 
intermediate mesoderm forms from the proliferating coelomic epithelium at the 
junction between the splanchnopleuric and somatopleuric mesoderm (Bannister et al., 
1995). In the chick the first formation of intermediate mesoderm has been observed 
at the eight somite stage, lateral to the sixth somite (Saxen, 1987). In the WT470LZ 
transgenic mouse, the first cells to show expression of WT470LZ are immediately 
caudal to somite six of a six somite embryo. This expression domain potentially 
marks the first delamination of intermediate mesoderm cells from the coelomic 
epithelium. As the next somites form these -galactosidase expressing cells become 
clustered (Fig. 22b). The first structure to be formed by the intermediate mesenchyme 
is the pronephros, which in the mouse consists of clusters of cells (Saxen, 1987). 
Hence these clusters of WT470LZ cells are likely to mark the pronephros. 
Subsequently to pronephros formation, the pronephric duct forms caudally and 
independently of the pronephros and does not express the transgene. By 15-18 
somites (stage 14) the intermediate mesenchyme has given rise to a mesonephric 
condensation of cells; these cells express WT470LZ and extend caudally as the tail 
elongates concurrent with somitogenesis (Fig. 22c). In different embryos it is 
possible to see transgene expression either more caudal than the last somite which 
has been formed or up to two somites rostral to this. Therefore the differentiation of 
mesonephric tissue is to some degree independent of somitogenesis. Futhermore 
although the mesonephros is a segmental organ it does not show the segmentation 
seen in the paraxial mesenchyme. At the 22 somite stage mesonephric tubules begin 
to form and can be seen as a thickening in the caudal part of the -galactosidase 
positive mesonephric ridge (fig. 22d). At the rostral end of the 22 somite embryo 
mesonephric ridge transgene expression has spread into the proliferating coelomic 
epithelium overlying the mesonephric tissue (Fig. 22f). 
Using this reporter gene it has now been possible to deduce the exact timing of initial 
Wtl expression. The gene is first active in the pronephric cell clusters. In contrast 
previous in situ analyses have been unable to detect Wt] activity earlier than the 13 
somite stage. In these studies WtI mRNA expression detected was in the more 
substantial mesonephric tissues (Armstrong et al., 1992; Rackley et al., 1993). 
4.1.2 Expression in the septum transversum. 
Simultaneous to the switching on of WT470LZ expression in the pronephros a 
second domain of -galactosidase positive cells appears caudal to the embryonic 
heart. This domain of expression is the septum transversum (Fig 22b). The septum 
transversum is a second tissue which forms by proliferation of the (caudal 
pericardial) coelomic epithelium (Bannister et al., 1995). It is originally a single 
block of cells but at the 16 somite stage becomes split by invasion of the endodermal 
hepatic bud. This split into two parts, the pars diagrammatica/pars pericardialis and 
the pars mesenterica, can clearly be seen in transgenic embryos (Fig. 22c,d and e). By 
the 22 somite stage a third domain of -galactosidase expression appears, in the 
mesenchyme adjacent to the cardinal vein as it passes the developing forelimb buds. 
In situ studies have not previously reported expression of Wtl in the septum 
transversum. Chick and alligator WTJ whole mount in situ hybridizations indicate 
WTI expression in 'vitelline veins' caudal to the heart (Kent, 1994; Kent et al., 
1995). These domains could well refer to expression in the septum transversum. The 
septum transversum forms tissues which express Wt] at later stages of development, 
e.g. parts of the pericardium, diaphragm, and gut mesenteries (Armstrong et al., 
1992; Rackley et al., 1993). Hence it is very likely that lacZ expression in the septum 
transversum represents a bonafide region of Wt] expression. 
The intermediate mesoderm and the septum transversum are spatially distinct. There 
is no evidence that developmental signals regulating the timing of their formation are 
shared. We have observed E8.5 embryos in which either the septum transversum, or 
the- nterrnediate mesoderm, but not both is expressing the transgene. However we 
have yet to quantify these observations. 
The proliferating coelomic epithelium gives rise to two types of progeny, 
mesenchymal and epithelial cells (Bannister et al., 1995). Both the intermediate 
mesoderm and the septum transversum are localized mesenchymal cell populations 
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produced by the proliferating ceolomic epithelium. At a later stage of development 
another mesenchymal organ, the spleen, derives from the splanchnopleuric coelomic 
epithelium dorsal to the stomach and expresses Wt] (Armstrong et al., 1992; Rackley 
et al., 1993). Hence, Wtl appears to be expressed in mesenchymal derivatives of the 
proliferating coelomic epithelium. Mesenchymal cells derived from the coelomic 
epithelium may stay mesenchymal or undergo a mesenchymal to epithelial transition. 
The pronephric/mesonephric duct is an example of an epithelial tissue which arises 
directly from the coelomic epithelium without going through a mesenchymal stage 
(Bannister et al., 1995; Saxen, 1987), it does not express Wi'] (Pritchard Jones et al., 
1990; Armstrong et al., 1992; Rackley et al., 1993) nor the WT470LZ transgene (Fig. 
220. 
Fig. 22 Early expression pattern of the WT470LZ transgene. 
(a) 6 somite mouse embryo (line A). Expression of WT470LZ can be seen in the 
intermediate mesoderm forming at just caudal to the sixth somite. (b) 10 somite 
mouse embryo (line A). Expression of the transgene can be seen in clusters of cells 
representing the forming pronephros and in the septum transversum. (c) In the 17 
somite mouse embryo (line A) the mesonephric cordlmesonephros is forming which 
expresses WT470LZ. WT470LZ continues to be expressed in the pronephros and the 
septum transversum. (d) 22 somite mouse embryo (line A), the septum transversum 
has been split by invasion of the hepatic bud into the pars pericardialis and pars 
mesenterica, (* plane of section for panel f). (e) saggital section (x50) of E9.5 mouse 
embryo (line A). (0 transverse section of E9.5 mouse embryo (x 100) (line A). 
Abbreviations: (H) heart, (TM) intermediate mesoderm, (ST) septum transversum, (P) 
pronephros, (Ms) mesonephros, (PP) pars pericardialis, (PM) pars mesenterica, (HP) 
hepatic primordium, (CIm) ceolom, (NT) neural tube, (C) caudal, (Rs) rostral, (A) 
aorta, (S) somite, (CE) coelomic epithelium, (GT) gut tube, (SpM) splanchnopleuric 
mesoderm, (SmM) somatopleuric mesoderm, (MsD) mesonephric duct, (D) dorsal, 
(V) ventral. 
Note: In fig 22f the arrow labelled CE is not pointing to the coelomic epithelium but 
to the mesonephric cord (mesonephric mesenchyme - Ms). The coelomic epithelium 
is the single epithelial cell layer laying ventral to the mesonephric cord. 
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4.2 WT470LZ expression in E 9.5-11.5 embryos (stages 16-
18). 
4.2.1 Transgene expression in the mesonephros. 
By E9.5 the mesonephric ridge has expanded rostrally as far as the septum 
transversum and caudally to the cloaca. Formation of the mesonephros is beginning 
(Saxen, 1987; Kaufman, 1992). Since the completion of this study Sainio etal. have 
reported that the mesonephros contains two different types of nephron which form 
via different mechanisms (Sainio et al., 1997). This study did not investigate the 
difference in transgene expression between the two different nephron types. In the 
mature mesonephric nephron WT470LZ is not expressed in the tubule, but is 
expressed in the glomerulus (Fig. 23a). This expression pattern exactly mirrors that 
reported for the endogenous Wt] (Pritchard Jones et al., 1990; Armstrong et al., 
1992; Rackley et al., 1993). The pronephric/mesonephric duct continues not to 
express the transgene. 
At stages 15-16 transgene expression encompasses the whole mesonephric ridge and 
hence includes the region of the adrenogenital primordia (Hatano et al., 1996). As 
development proceeds (stages 18-19) (Fig 23) the adrenal and genital primordia split. 
The genital primordia becomes localized to the ventrosagittal part of the ridge where 
the level of transgene expression remains strong. In contrast, dorsomedially where 
the adrenal primordia localizes the transgene expression begins to weaken and is lost 
by stage 18. 
4.2.2 transgene expression in other mesoderm derived tissues. 
Between E9.5 (stage 15) and E10.5 (stage 16) there is rapid expansion of transgene 
expression. The somatopleuric and splanchnopleuric proliferating coelomic 
epithelium as well as a thin layer of mesenchyme beneath the epithelium begin to 
express the transgene (Fig. 23). This layer is new mesenchymal tissue produced by 
the coelomic epithelium (Bannister et al., 1995). It has a more fibrous appearance 
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than the mesenchyme which it overlays and will go on to form a number of tissues 
including the pleura, pericardium and peritoneum. All these tissues are continuous 
with each other, the septum transversum and mesonephric mesenchyme. Wt] is 
expressed in all of the mesenchyme derived from coelomic epithelia throughout the 
embryo in addition to specific localized regions. Much of the reported expression 
pattern of Wtl can be explained by following the development of tissues formed from 
this mesenchyme using transgene expression as a marker. 
By E1O.5 the common sinuatrial chamber of the heart which was embedded in the 
septum transversum has risen up into the pericardial cavity. As it does this it carries 
with it the transgene expressing pars pericardialis which forms the epicardium. Later 
between ElO.5 and El 1.5 sclerotomal rib precursors migrate into and split the 
somatopleuric mesenchyme of the pericardium (Bannister et al., 1995). Transgene 
expression continues in the mesenchyme of the parietal pericardium on the proximal 
side of the ribs and partially surrounds them (Fig. 23b). 
The forming gut derived from the splanchnopleuric endoderm is covered in a layer of 
J3-galactosidase expressing peritoneal tissue derived from the proliferating 
splanchnopleuric coelomic epithelium and the pars mesenterica of the septum 
transversum (Bannister et al., 1995). 
The endodermal hepatic diverticulum continues to grow into the J3-galactosidase 
positive septum transversum. Soon after the formation of the endodermal bud the 
endodermal cells begin to proliferate. The basement membrane which separates the 
mesenchyme of septum transversum from its overlying (coelomic) epithelium breaks 
down. The epithelial cells migrate into the mesenchyme guiding the endodermal 
tissue of the hepatic diverticulum. This endodermal tissue forms columns into the 
mesenchyme. The migration of these epithelial and endodermal cells gives rise to the 
hepatic sinusoids (Bannister et al., 1995). These sinusoids are a site of 
haematopoiesis from ElO, containing extra vascular haematopoietic foci. The 
epithelial tissue lining the sinusoids is derived from the epithelium overlaying the 
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septum transversum (Le Douarin, 1975). WT470LZ is expressed on those cells lining 
the sinusoids (Fig. 24). Later, as the liver increases in size the lateral plate mesoderm 
and its overlying epithelium are also incorporated into the liver (Bannister et al., 
1995; LeDouarin, 1975). 
Blood formation takes place in the blood islands of the extra embryonic yolk sac de 
novo from E8. Transgene expression has not yet been investigated in this tissue. The 
AGM region (aorta, gonads and mesonephros), i.e. the region of the urogenital ridge, 
has de novo haematopoietic activity from E9. It is not clear where the site of 
haematopoiesis is in the AGM, however haematopoietic foci have been observed 
within the dorsal aorta. For a review of haematopoiesis in the mouse embryo see 
Dzierzak and Medvinsky, 1995. The mesonephric ridge expresses the transgene, but 
WT47OLZ does not appear to be expressed within the dorsal aorta (Fig. 23). 
The hepatic sinusoids are a site of haematopoiesis from ElO. It is not clear what 
tissue within the liver these haematopoietic stem cells derive from. One proposal is 
that the stem cells do not originate de novo within the liver but migrate into it. This 
migration is potentially in two waves, first from the yolk sac and subsequently the 
AGM (Dzierzak and Medvinsky, 1995). 
WT470LZ is expressed in both the AGM and the hepatic sinusoids. WTI has been 
implicated in the process of haematopoiesis and has been detected in adult bone 
marrow by RT-PCR (Inoue et al., 1994; Fraizer et al., 1995; King Underwood et al., 
1996). However the transgene is not clearly expressed in any haematopoietic foci in 
either the AGM or the hepatic sinusoids. It remains to be ascertained if the transgene 





















Fig. 23 Expression of WT470LZ in urogenital development (E 11.5 mouse embryo). 
(a) transverse section at level of the forelimbs (x50). WT470LZ is expressed in the 
mesenchyme of the intermediate mesoderm including the genital ridge. It is also expressed 
in the mesemchyme underlying the coelomic epithelium in the region of the somites. 
It is not expressed in the mesonephric tubules or the mesonephric duct but is expressed 
in the mesonephric glomerulus. The germ cells within the genital ridge do not express 
the transgene. (b) transverse section at the level of the hind limbs (00). WT47OLZ is 
expressed in the mesenchyme produce lying below the proliferating coelomic epithelium 
and the metanephric blastema. WT47OLZ is not expressed in the ureteric bud and the 
rib primordia. Abbreviations: (A) aorta. (Rb) rib precursors, (SpM) splanchnopleuric 
mesoderm. (SmM) somatopleuric mesoderm. (IJB) ureteric bud. (MtB) metanephric 
blastema. (DM) dermomyotome, (SCV) subcardinal vein. (MnD) rnesonephric duct, 
(MnT) mesonephric tubule, (G) mesonephric glomerulus, (GR) genital ridge, (GC) germ 
cells, (HL) hind limb, (NT) neural tube. 






Fig. 24 WT47OLZ expression in hepatic sinusoids of a El 2.5 mouse embryo. 
(x200). The transgene is expressed in the epithelial lining on the sinusoid and the 
mesothelial coat of the liver both of which are derived from the septum transversum. 
Abbreviations: (BC) blood cells, (M) mesothelium, (Sin) sinusoid, (SinE) epithelium 
lining the sinusoid. Line H 
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4.3 WT470LZ transgene expression between E12.5 and 15.5 
and in the adult. 
4.3.1 Transgene expression in mesonephric ridge and gonads. 
By E12.5 the mesonephros is regressing. WT470LZ is still expressed in a gradient, 
high in the genital ridge (ventrolateral) and very low in the mesonephric mesentery 
(dorsomedial). The epithelial paramesonephric duct invaginates from the coelomic 
epithelium at the lateral margins of the mesonephros between E12.5 and E13.5 
(Kaufman, 1992). Similar to the mesonephric duct the paramesonephric duct does not 
express WT470LZ (Fig. 25b). 
From El 1.5 to E13.5 whilst the growing gonad is still indifferent WT470LZ is 
expressed in the somatic interstitial cells of the gonad but not the germ cells (Figs. 
23a and 25). Following sex cord formation in the developing testes (E13.5) transgene 
expression becomes localized in the interstitial cells surrounding the cords (Fig. 25). 
Surprisingly it is not expressed in the Sertoli cells constituting the wall of the cords; 
this is in contradiction to the expression pattern of Wt]. Wt] is expressed in Sertoli 
cells from foetal into adult life (Pritchard Jones et al., 1990; Armstrong et al., 1992; 
Mundlos et al., 1993). 
In both testis and ovaries transgene expression is lost from the interstitial cells at the 
centre of the developing gonad after E13.5, but remains longer at the periphery. 
There is strong transgene expression however in the rete testis (and female rete 
ovari) (Fig. 25c and d). Wt] expression has previously been reported in these 
structures (Mundlos et al., 1993). The origin of these structure is not known, they are 
a relatively new evolutionary addition to the gonad and are only found in tetrapod 
vertebrates (Hildebrand, 1988). The rete testis links the cranial mesonephric tubules 
which will form the lobules at the head of the epididymis with the seminiferous 
tubules of the gonad. It is epithelial and formed within the mesenchymal stroma of 
the gonad. It may form by extension of mesonephric tubules adjacent to the 
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developing gonad, or could differentiate de novo within the gonadal mesenchyme. 
Satoh describes the formation of primordial sex cords which extend out from the 
mesonephric tubules before the rapid expansion of the gonadal mesenchyme out into 
the coelomic cavity (Satoh, 1985; Satoh, 1991). He proposes that these cords will 
give rise to both the rete testis/ovarii and the secondary folligulogenous and 
seminiferous sex cords. If the rete testis does form by extension of the mesonephnc 
tubules, it may be formed by recruitment of mesenchymal cells lying distal to the 
mesonephric tubules to undergo a mesenchymal to epithelial transition. This process 
would be similar to that seen during nephrogenesis. Alternatively migration of 
epithelial cells from with the mesonephric tubule may give rise to the rete 
testis/ovarii. WT470LZ is highly expressed in the rete testis however, whilst the 
mesonephric tubules do not express the transgene. As this is the case it seems 
unlikely that the rete testis/ovarii form by clonal expansion of the mesonephric 
tubules. The glomerular cells of the mesonephros do show a high level of WT470LZ 
expression. Extension of these glomerular cells to give the rete testis however also 
seems unlikely as Satoh describes primordial sex cord formation by bifurcation of the 
mesonephric tubule and not extension of the glornerulus. 
There is a large degree of contention as to the origin of the secondary sex cords. 
Satoh argues that it is extension of the primordial (mesonephric derived) sex cords 
which gives rise to the secondary sex cords (Satoh, 1985; Satoh, 1991). The 
thickening of the coelomic epithelium over the gonad to form primary sex cords 
merely facilitates the rapid extension of the gonad into the coelomic cavity. A 
number of investigators believe that the secondary sex cords arise from the coelomic 
epithelium of the gonad and not from the mesonephros (Bannister et al., 1995). The 
coelomic epithelium thickens prior to the expansion of the gonad into the coelomic 
cavity forming primary sex cords. These are proposed to extend to subsequently form 
the secondary sex cords and hence differentiate into the Sertoli cells of the testis and 
granulosa cells of the ovary. A previous Wt] expression study lends strength to this 
hypothesis. Mundlos et al., 1993 show cords of Wt  positive cells running from the 
epithelium surrounding the developing ovary into its centre. These cords may well 
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represent the forming granulosa cells, however the authors do not discuss this data. 
Buehr et al., 1993 showed that mesonephric cells were required for testis 
development. They did not appear to contribute to the testicular Sertoli cell or 
ovarian granulosa cell populations only to the peritubular myoid cells. Interestingly, 
although WT470LZ is not expressed in the testicular Sertoli cells, it is in the 
testicular rete and the peritubular cells both of which are of potential mesonephric 
origin (Fig. 25 c and e). 
Given the high level of Wt] expression in the coelomic epithelium and 
Sertolilgranulosa cells but not the interstitial cells of the gonad Wtl may represent a 
very informative marker for following the development of different gonadal cell 
populations. Careful immunohistochemical analysis of the dynamics of Wtl 
expression in the developing gonad may lead to further information about the origin 
of granulosa and Sertoli cells. Such analysis may be able to demonstrate whether 
these cells and the rete testis/ovarii are derived from the mesonephros, coelomic 
epithelium, or a mixture of both. 
WT470LZ is expressed in both the capsule (of the epididymis) which envelops the 
testis, and the ovarian capsule. In the male, transgene expression becomes 
concentrated around the mesonephric duct and the remnants of the mesonephric 
tubules, which become the lobules at the head of the epididymis (Fig. 25a). In the 
female expression similarly becomes concentrated around the paramesonephric duct 
(future oviduct) (Fig. 25 b and d). In the adult female the stroma of the endometrium 
and myometrium both express the transgene. These tissues develop from the 
mesenchyme surrounding the genital cord. The genital cord is formed by the caudal 
fusion of the paramesonephric ducts. Therefore the mesenchyme forming the 
endometrium and myometrium is originally derived from the coelomic epithelium of 
the urogenital ridge. Wt] is expressed endogenously in the endometrium and 
myometrium (Armstrong et al., 1992; Rackley et al., 1993; Zhou et al., 1993). 
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In adult testes expression of WT470LZ is in the peritubular but not the Sertoli cells 
(Fig. 25e). In the adult ovary transgene expression occurs in the interstitial cells. 
WT470LZ is not clearly expressed in the follicular granulosa cells. A hint of 
expression in these cells may be artefactual (Fig. 25f). Further examination of 
WT470LZ in ovarian tissue is required. This study should use ovaries from young 
animals as Wt] is not expressed in mature follicles but only in primordial, primary 
and secondary follicles (Hsu et al., 1995). 
The WT470LZ transgene is expressed throughout embryogenesis in a pattern 
mirroring that of MI. However it is not expressed in either the testicular Sertoli cells 
and probably not in the ovarian granulosa cells. Both the Sertoli and granulosa cells 
are sites of endogenous Wz'1 expression. A possible expiation for the inability of 
WT470LZ to drive reporter gene expression in Sertoli and granulosa cells is because 
it is derived from genomic DNA surrounding the human WTI locus rather than from 
the murine Wt] locus. DNA sequences which play a role in sexual differentiation are 
often highly divergent between species, for example the Sry gene (sex determining 
region Y) is evolving rapidly and may even be subject to adaptive selection 
(Whitfield et al., 1993). Sry is expressed in the pre Sertoli cells of the genital ridge 
switching them to a Sertoli fate from a default female granulosa cell state 
(Ramkissoon and Goodfellow, 1996). Perhaps those regulatory DNA sequences 
required to drive Wt] expression in the sex specific Sertoli and granulosa cells have 
undergone species specific divergence. 
Fig. 25 Expression of WT470LZ in the developing gonad. 
(a) El 3.5 testis (x50) (line H). Expression of WT470LZ mimics that of endogenous 
Wri except there is no expression in the Sertoli cells. (b) E13.5 ovary (x 100) (line 
H). Wt/ WT470LZ is expressed in the gonadal mesenchyme but not the primordial 
germ cells.(c) E15.5 testis (x 100) (line H). WT470LZ expression is upregulated in 
the rete testis. (d) E15.5 ovary (x200) (line H). WT470LZ expression is upregulated 
in the rete ovarii. (e) Adult testis (x200) (line F). Expression is only in the 
peritubular cells. (f) Adult ovary (line A) (x200). There is WT470LZ expression in 
the interstitial cells surrounding the follicles but not the granulosa cells. 
Wt/ is expressed endogenously in both the Sertoli and granulosa cells however there 
is no X-gal staining in these cells in both line A and line H. It is likely that this means 
there is no WT470LZ expression in these cells. However it is possible that the reason 
that there is no staining in these cells is because there is a failure of X-gal 
penetration. In particular in panels e and f the tissue was stained whole and then fixed 
and sectioned afterward. To test this possibility adult gonads should be cryosectioned 
and then stained as were the embryonic organs (panels a-d). One way to test if the 
lack of staining is due the failure of transgene expression rather than X-gal 
penetration is to stain organs such those from the mouse strain ROSA26 with a 
constitutively active transgene. 
Abbreviations: (TA) tunica albuginea (which is formed by condensation of 
mesenchyme beneath the peritoneal epithelium), (SmT) seminiferous tubules, (M5D) 
mesonephric duct, (IC) interstitial cells, (M5T) mesonephric tubules, (CptE) caput 
epididymis, (CpsE) corpus epididymis, (CaE) cauda epididymis, (PGC) primordial 
germ cell (Note: this is mislabelled (PcG) in 25b), (PMsD) para-mesonephric duct, 
(SC) Sertoli cell, (rt) rete testis, (ro) rete ova ri (PTC) peritubular cell, (Sz) 





















4.3.2 Transgene expression in the adrenal glands. 
There is no transgene expression in the cortex or medulla of the foetal adrenal gland 
following its split from the genital primorida (Fig 23a). The developing foetal adrenal 
gland is quickly enveloped ventrally and later dorsally by a mesenchymal capsule 
derived from the mesonephros. This capsule expresses the WT470LZ transgene 
which again mirroring the reported Wri expression pattern (Rackley et al., 1993)(Fig. 
26 a and b). 
The gonad and adrenal cortex both derive from the proliferating coelomic epithelium 
of the urogenital ridge. However whilst the cells of the gonad continue to express 
Wtl/WT470LZ, those of the adrenal cortex do not. The interstitial cells of the gonad 
stay mesenchymal in nature whilst the gonad expands rapidly into the coelomic 
cavity. In contrast the cells constituting the foetal adrenal cortex are highly 
differentiated. The forming adrenal is invaded by neural crest cells which form the 
adrenal medulla. Subsequently capillaries arise from the adjacent mesonephric 
arteries and invade the cortex radially. The foetal adrenal cortical cells remain in 
small subcapsular nests. These nests proliferate forming cords which penetrate deep 
between the sinusoids and capillaries. These cells which make up the foetal adrenal 
cortex degenerate as they move toward the medulla (Bannister et al., 1995). 
The fetal cortex undergoes a rapid degeneration in neonates and is replaced by the 
adult cortex. The adult cortex consists of three zones the thin outer zona glomerulosa, 
inside this is the thick zona fasciculata and between the zona fasciculata and the 
medulla lies the thinner zona reticularis. Cells of the adult adrenal cortex unlike those 
of the foetal cortex have high metabolic activity. They secrete hormones such as 
mineralocorticoids (zona glomerulosa), glucocorticoids (zona fasciculatalreticularis) 
and, in many mammals including humans, but not rodents, sex hormones (zona 
reticularis). The zona glomerulosa is derived from the small nest of cortical cells 
which lie just beneath the adrenal capsule in the foetal gland. The zona fasciculata 
and zona reticularis both form from cords which emenate from the zona glomerulosa 
as the foetal cortex is replaced by that of the adult (Bannister et al., 1995). 
Varigated WT470LZ expression is seen in the adult adrenal gland in columns 
running through the cortex (Fig. 26e). Lines transgenic for a lacZ reporter under the 
control of the mouse steroid 21-hydroxylase gene promoter show the same varigated 
columnar expression pattern in the adult adrenal cortex (Morley et al., 1996). This 
pattern is a reflection of a variagated distribution of steroid 21-hydroxylase/lacZ 
transgene rnRNA. Cryptic repression of steroid 21-hydroxylase/lacZ transgene is 
occurring in a subset of the cells of the zona glomerulosa. The cells of zona 
glomerulosa then proliferate centripetally giving rise to clonal columns in the adrenal 
cortex in which the transgene is either expressed or repressed. The same mechanism 
is likely to be responsible for the columnar expression of WT47OLZ. 
Wt] expression has not been reported in the adult adrenal cortex, WT470LZ activity 
within this tissue indicates that it may be. There are a number of similarities between 
the adrenal gland and other organs which express the Wt] gene. The adrenal cortex is 
derived from the mesenchyme of the intermediate mesoderm and shares its 
primordium with the gonad. This primordium is identifiable by its expression of the 
product of the Ftz-F1 gene- steroidogenic factor 1 (SF I) (also known as adrenal 4-
binding protein (Ad4BP)) (Hatano et al., 1996). SF1 is an orphan nuclear receptor 
implicated in the regulation of genes encoding the steroid hydroxylases. Knockout of 
the Ftz-F1 gene in transgenic mice leads to lack of gonads and adrenal glands (Luo et 
al., 1994; Sadovsky et al., 1995). 
The adrenal cortex furthermore has the rare ability to regenerate after damage. The 
subcapsular cortical cells continue to produce cortical tissue throughout adult life 
(Bannister et al., 1995). The adrenal cortex shares this ability to regenerate with other 
tissues which are known to express Wri, such as the endometrium of the uterus and 
the metanephros. If one metanephros is damaged the other is able to undergo a new 
programme of growth and differentiation to take on the function of the damaged 
organ. WTI has been demonstrated to be upregulated during this process in the pig 
(Kushner et al., 1992). In the axolotl (Amblystoma mexicanum) it is believed that 
Sertoli cells have a bipotentiality and may differentiate into duct cells which upon 
encountering a germ cell engulf it and redifferentiate into Sertoli cells. WTI is 
expressed during this process of redifferentiation into Sertoli cells (Del Rio-Tsonis et 
al., 1996). It is interesting to speculate that WTI may be involved in retaining the 
ability of a cell to dedifferentiate and undergo a new programme of proliferation and 
redifferentiation. 
To attempt to detect Wtl activity in the adult adrenal cortex I carried 
immunohistochemical staining of the murine adult adrenal cortex. This staining only 
detected protein within the mesothelial coat of the organ, not the cortex. Therefore 
Wtl may not be expressed at all in the adult adrenal cortex or may be expressed at 
levels too low to be detected by immunohistochemical techniques. On the other hand 
perhaps WTI is expressed in the human adult adrenal cortex and sequences on the 
human WT470LZ YAC drive transgene expression in the murine tissue. However the 
equivalent expression of Wtl in the murine adult adrenal cortex may not occur. 
4.3.3 Transgene expression in the developing metanephros. 
3-galactosidase expression in the developing metanephros of WT470LZ transgenic 
lines exactly mirrors that reported for Wtl (Pritchard Jones et al., 1990; Armstrong et 
al., 1992; Rackley et al., 1993; Mundlos et al., 1993; Phelan et al., 1994) (Fig. 26). At 
E1 1. 5  the ureteric bud branches from the caudal portion of the mesonephric duct. It 
grows into the tissue of the metanephric blastemal stems cells (Fig. 23b). There is no 
transgene expression in the ureteric bud but there is expression in the metanephric 
blastemal stem cells. The ureteric bud grows and branches within these cells and 
transgene expression is increased in those cells which condense around the tip of 
these branches. Expression is further upregulated in the proximal part of the S shaped 
body which form the podocyte cells of the mature glomerulus. As nephrogenesis 
proceeds radially in the developing kidney -galactosidase expression is lost in the 
more proximal blastemal cells of the kidney which differentiate into stroma. 
Transgene activity is also present in the peritoneal tissue which envelopes the organ. 
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In the adult metanephros WT470LZ is expressed in the podocyte cells of the 
glomerulus (Fig. 26d). This expression pattern is consistent with published Wtl in 
situ data. However -galactosidase activity can also sometimes be seen in the renal 
pelvis and collecting ducts. These structures do not express the endogenous Wtl 
gene. Furthermore these structures do not express the transgene in the developing 
foetal metanephros. Perhaps lacZ activity driven by the WT470LZ YAC is being 
upregulated in the adult collecting ducts and renal pelvis. This seems unlikely and 
does not reflect the very close similarity between the WT470LZ activity and Wtl 
expression. The podocyte cells of the glomerulus are involved in the filtration of the 
blood in the glomerulus and the deposition of solutes into the nephron. Hence a 
second explanation for the ft-galactosidase activity in the renal pelvis and collecting 
ducts is that the podocytes are secreting some of the high levels of WT 1/ 3-
galactosidase fusion protein contained within them into the metanephric nephrons. 
The presence of this protein then gives rise to the -galactosidase activity seen in the 
ducts; either because it is trapped in the ducts during staining or because some of it is 
reabsorbed back into the walls of the ducts and pelvis. 
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Fig. 26 Expression of WT470LZ in the metanephros and adrenal gland. 
Refer also to Fig. 3. (a) E15.5 metanephros and adrenal gland (x50) (line H). 
WT470LZ is expressed in the mesothelial tissue surrounding the organs, it is 
expressed at a higher level in the blastema and is upregulated in the comma shaped 
bodies and glomeruli. (b) E17.5 metanephros and adrenal gland (00) (line H). 
WT470LZ is lost from the kidney stroma but continues to be expressed at the 
periphery of the kidney where nephrogenesis is proceeding. (c) Close up of comma 
shaped body from plate b (x 100) (line H). WT470LZ expression can be seen in a 
band of metanephric blastemal cells alongside the bifurcating ureteric bud. (d) Adult 
glomerulus (x IOU) showing expression of WT47OLZ in the glomerular podocyte cells 
but not those of the capillary (line H). (e) Vibratome section through an adult adrenal 
gland (x30) (line A). 
Abbreviations: (Ad) adrenal gland, (CB) comma shaped body, (IG) immature 
glomerulus, (G) glomerulus, (St) stroma, (CD) collecting duct - bifurcation of the 
ureteric bud, (M) mesothelium, (P) podocyte, (Cap) capillary, (GT) glomerular tuft, 
(AdM) adrenal medulla, (AdC) adrenal cortex, (MtB) metanephric blastema. 
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4.3.4 transgene expression in the pleura, pericardium and 
peritoneum. 
The internal organs of the embryo undergo a large degree of transformation and 
expansion from El 2.5 onwards. Throughout this period of development WT470LZ 
continues to be expressed in the pleural, peritoneal and pericardial tissues of the 
embryo which surround these internal organs (Fig. 27). By following the processes of 
organ development the significance of the later expression pattern of the transgene 
becomes clearer. 
Expansion of the lungbuds in the pericardial/peritoneal canals causes displacement of 
the pleura causing it to invade, and split, areas of the body wall. This invasion splits 
away the (WT470LZ expressing) coelomic epithelium derived mesenchyme from the 
underlying mesoderm (Bannister et al., 1995); this process is illustrated in Fig. 27c. 
Structures formed by this process continue to express the transgene. Pleural tissue 
invades the region dorsal to the lungs and heart coming to lie over the surface of the 
scierotome derived vertebrae and ribs (Fig. 27c 1 and 2). At E13.5 when the 
intercostal muscles are beginning to form WT47OLZ is still expressed intercostally. 
Rostral expansion of the apical part of the lung forces pleural tissue rostrally (Fig. 
27c 1)so that it comes to rest on the lateral aspect of the common cardinal vein (Fig. 
27a and b). Further expansion of the lateral parts of the pleural cavity splits the 
somatopleuric mesenchyme bordering the pericardial cavity. The tissue peeled away 
from this mesenchyme now lies between the pleural and pericardial cavities forming 
the dorsal visceral pericardia; it continues to express WT470LZ (Fig. 27c 3). The 
dorsal part of the lungs expand caudally. This dorsocaudal expansion peels away part 
of the (somatopleuric) mesenchyme dorsal to the mesonephric ridge such that this 
mesenchyme contributes to part of the diaphragm (Fig. 27c 2). In addition to 
contribution from the somatopleuric mesenchyme the diaphragm also derives from 
the WT470LZ positive tissue of the pars diagrammatica and dorsal mesentery of the 
oesophagus. 
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The development of the peritoneal cavity is extremely complex. WT470LZ 
expression is found on the serosal visceral surfaces of the gut and other abdominal 
organs. This is similar to that described for Wtl.(Armstrong et al., 1992; Rackley et 
al., 1993) The serosal visceral surface of the gut is derived from pars mesenterica of 
the septum transversum and the splanchnopleuric coelomic epithelium (Bannister et 
al., 1995) both of which continue to express WT470LZ. 
As foetal development proceeds the thickness of the pleural, peritoneal and 
pericardial tissues becomes greatly reduced. In neonates and adults a single layer of 
visceral epithelia (the mesothelium) is left on the surface of the body organs. In adult 
WT470LZ transgenic animals transgene expression is evident in the mesothelial 
tissue surrounding organs such as the heart, testes, ovaries and adrenal glands. Fig. 
28 shows WT470LZ expression in the pericardial mesothelium of the adult heart. 
The diaphragm, parietal and visceral pericardia, mesenchyme adjacent to the 
developing sclerotome, mesenchyme of the abdominal wall, gut mesentery and the 
visceral coating of other foetal organs have all previously been shown to express Wtl 
(Armstrong et al., 1992; Rackley et al., 1993; Phelan et al., 1994; Mundlos et al., 
1993). Similarly the adult mesothelium is a postulated site of Wtl activity and it 
expresses WT470LZ. All these tissues share a common embryological origin, they 
are derived from the coelomic epithelium or mesenchyme produced from it 
(Bannister et al., 1995). As Wt] is also expressed in organs formed from the 
intermediate mesoderm, derivatives of the coelomic epithelium comprise a major site 
of Wt] expression. 
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Fi2 	ression of WT470LZ in the developing pleura, pericardium. peritoneum 
and diaphranL 
(a) Transverse section ElO.5 mouse embryo (x25) (line A). There is transgene 
expression in a layer below the cardinal vein, and a thin layer of expression in the 
pleura, visceral and parietal pericardia. (b) Transverse section El2.5 mouse embryo 
(x25) (line A). The volume of the pleura, pericardia and peritonea has increased from 
ElO.5. The parietal pericardium is histologically distinct from the overlaying fibrous 
pericardium. The pleura has invaded the dorsal mesenchyme and lays adjacent to the 
vertebrae. (c) Sagittal section E13.5 mouse embryo (x25) (line H). WT470LZ is 
expressed in the pleura, pericardium, peritoneum and diaphragm. The metanephros 
has not stained in this section due to the presence of an intact capsule through which 
X-Gal cannot penetrate. I) the pleura expands apically. 2) the pleura expands 
caudally splitting away part of the somatopleuric mesoderm to form part of the 
diaphragm. 3) expansion in lateral part of the pleural cavity. (d) Transverse section 
E12.5 Wi'] homozygous null mouse embryo (x25). The heart and lungs are 
malformed. There may be a reduction in the volume of pleura and visceral and 
parietal pericardium. Abbreviations: (P1) pleura, (At) atrium, (Ve) ventricle, (NT) 
neural tube, (CV) cardinal vein, (L) lungs, (VP) visceral pericardium (PP) parietal 
pericardium, (FP) fibrous pericardium (Mu) muscle, (Vb) or (V) vertebrae, (D) 
diaphragm, (Mt) metanephroS, (Li) liver, (Fe) peritoneum, (CS) corpus striatum, 
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Fig. 28 Expression of WT47OLZ in adult heart, 




4.3.5 Transgene expression in differentiating musculature. 
In situ analysis of Wt] expression previously identified expression in differentiating 
body wall musculature (musculature of the trunk) between El 2 and El 3 (Armstrong 
et al., 1992). The WT470LZ transgene is similarly expressed in differentiating body 
wall musculature. However expression of the transgene occurs in all developing 
epaxial muscles. All epaxial muscle are formed by premitotic myoblast cells which 
migrate from the ventrolateral edge of the somitic myotome differentiating into 
muscle at their destination (Bannister et al., 1995). The regions where epaxial muscle 
formation occurs by migration of somitic myoblasts are the limbs, trunk and 
diaphragmatic muscles. The muscles of the tongue are formed in the same way; 
single myoblasts migrate from the ventrolateral part of the occipital somites into the 
base of the tongue. However the formation of other muscles in the head is more 
complex (Bannister et al., 1995). The extrinsic ocular muscles, i.e. those muscles 
involved in movement of the eye, develop from prechordal mesenchyme at the rostral 
tip of the notochord process. The great majority of striated musculature of the head 
derives from the somitomeres (Bannister et al., 1995). Somitomeres contain the 
paraxial mesenchyme but do not undergo a process of segmentation similar to that of 
somitogenesis. Mesenchyme from the somitomeres migrates into the branchial arches 
early in foetal development. Subsequently premitotic myoblasts derived from this 
mesenchyme migrate back out of the arches to form the striated musculature of the 
head. 
In E10.5 embryos 3-galactosidase expressing cells surround the ventrolateral edge of 
the somitic myotome (Fig. 29a). The picture is clearer in E12.5 embryos, strong 
domains of transgene expression being present both rostra!, (in the developing 
deltoids) and caudal to the base of the forelimb (Fig. 29b). These rostral and caudal 
domains of expression are continuous with 3-galactosidase expression in the dorsal 
and ventral myogenic zones of the forelimbs (Fig. 29c and d). A similar pattern is 
repeated in the hindlimbs which develop about half a day behind the forelimbs. 
Further transgene expression is seen in all differentiating trunk muscles. Between 
E13.5 and E15.5 a low level of transgene expression can be seen in the tongue (Fig. 
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30b), in which Wt] expression has previously been reported by RT-PCR (Armstrong 
et al., 1992). Further WT470LZ expression is seen in other developing striated 
muscle of the head. 
The cell type expressing WT470LZ is unclear. WT470LZ is not expressed in the 
somitic myotome. It is however expressed in sparsley separated cells within the 
developing epaxial muscles. Where these developing muscles pass through a field of 
mesenchyme which is expressing the transgene the number of cells expressing the 
transgene in the muscle is much higher (Fig. 29b and c). Possibly this indicates that it 
it not myoblasts themselves which are expressing the transgene but other 
mesenchymal cells caught up within the developing myotubes. Transgene expression 
is not seen in fully formed myotubes. As WT47OLZ is expressed in the mesenchyme 
into which epaxial muscle can migrate e.g. the limbs and intercostal regions, WTI 
may somehow be involved in the process of myoblast migration. 
The significance of WT470LZ expression within the developing epaxail muscle of 
the body remains unclear. The role if any of Wt] in the process of myogenesis 
requires a great deal of clarification. However studies carried out by Dr Kiyoshi 
Miyagawa have implicated Wtl in the process of myogenesis. He demonstrated a 
correlation between the state of the W7'l gene in Wilms' tumours and the histology of 
the tumour (Hastie, 1994). Tumours with a mutation in the V/Ti gene contained a 
large amounts of muscular tissue whereas this tissue was not seen in tumours 
containing no WTI mutation. Furthermore when WTI protein was added to a culture 
of myoblastic (C2P9) cells it inhibited myotube formation by those cells. 
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4.3.6 Transgene expression within the limb. 
Further to the expression of WT470LZ within the developing limb musculature 
expression of the transgene is also seen in regions of limb mesenchyme undergoing 
apoptosis. 
WT470LZ expression is switched on at E12.5 in the anterior and posterior marginal 
zones and the base of the mesenchyme web between the third and fourth digits. Over 
the next twenty four hours -ga1actosidase expression is very dynamic first appearing 
between the second and third digit and then spreading in stripes either side of the 
condensing digits. Simultaneously expression begins in the webs between the first 
and second digit and the fourth and fifth digits, and, by E13.5 zones of WT470LZ 
expression run alongside each developing digit (Fig. 29c). At E15.5 thin domains of 
expression sit in the remnants of the interdigital web and run alongside each digit. 
Further transgene expression occurs around the developing metatarsals and between 
the condensing radius and ulna (Fig. 29e). 
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Fig. 29 Expression of WT470LZ in the developing limb and body wall musculature. 
Transverse section of region of mesonephros and somite in El 0.5 mouse embryo 
(x 100) (line A). WT470LZ is expressed in the mesonephros and in a layer of tissue 
below the coelomic epithelium. This domain of expression wraps around the ventral 
end of the myotome. There is no expression of WT470LZ within the myotome itself. 
Expression of WT470LZ in the deltoid muscle of a El2.5 mouse embryo - 
transverse section (x 100) (line A). WT470LZ is expressed within the somatopleuric 
rnesenchyme in which the muscle is forming and within the muscle itself. (c) Thick 
saggital section E13.5 mouse embryo (line A). WT470LZ is expressed in the 
deltoids, intercostal regions, interdigitally and between the radius and ulna (* plane 
of section for plate d). (d) Coronal section of E1 3.5 mouse forelimb (x50) (line H). 
(e) Sagittal section of E15.5 mouse hind limb (x50) (line H). WT470LZ is localized 
along side and between the developing digits and bones. 
Abbreviations: (NT) neural tube, (Myt) myotome, (SmM) somatopleuric 
mesenchyme, (CE) coelomic epithelium, (Cim) coelom, (Ms) mesonephros, (Del) 
deltoid, (IC) intercostal mesenchyme, (BW) body wall, (ID) interdigital, (OZ) opaque 
zone, (VMZ) ventral myogenic zone, (DMZ) dorsal myogenic zone, (Rd) radius, (UI) 
ulna, (D) digit, (Li) liver, (Pe) peritoneum. 
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4.3.7 Transgene expression in the head. 
At E12.5 the transgene is expressed in the mesenchyme adjacent to the pharyngo-
tympanic (Eustachian) tube. It is not however, expressed in the ectodermal epithelial 
lining of the tube. This domain of expression occurs surrounding the whole length of 
the tube but is particularly pronounced at the distal end where the tubo-tympanic 
recess will form. A further domain of WT470LZ expression occurs distal to this, 
laying beneath the acoustic meatus. By E15.5 expression below the external acoustic 
meatus is less pronounced, however strong transgene expression occurs in the 
mesenchyme surrounding the tubo-tympanic recess. A similar expression in the head 
mesenchyme occurs at the lateral margin of the vertically directed palatal shelves and 
weak expression occurs at the base of the forming eyelids (data not shown). 
Throughout development the pharyngo-tympanic tube and the palatal shelves 
undergo extensive morphological changes. The expression WT470LZ in the 
mesenchyme surrounding these tubes may be associated with this remodelling. At the 
distal end of the pharyngo-tympanic tube the tubo-tympanic recess will form by 
hollowing out a region of this mesenchyme, a similar process will occur at the 
acoustic meatus. Given that WT47OLZ is expressed in regions of apoptosis in the 
limb the tissue expressing the transgene is these domains may also be involved in 
apoptosis. 
In the adult animal the acinar cells of the submandibular glands express the 
transgene. The submandibular glands arise from an ectoderm mesenchyme 
interaction however no transgene activity is seen during foetal development. 
4.3.8 Transgene expression in ectoderm derived tissues. 
4.3.8.1 Transgene expression in the forebrain and midbrain. 
At E1O.5 theWT470LZ is switched on in a non mesodermal lineage. It is expressed in 
part of the ectodermally derived forebrain. This is potentially a new site of Wt] 
expression. By E12.5 transgene expression in the forebrain of the developing embryo 
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has become localized to several cell layers on the medial aspect of the rapidly 
expanding corpus striatum (Fig. 30a and b). Expression continues in this domain 
between E12.5 and E15.5 by which time it has waned. The transgene is also 
expressed at E13.5 in very few cells scattered throughout the roof of the neopallial 
cortex. As WT470LZ expression extends right into the forebrain (corpus striatum) 
the gene does not appear to be involved in delineating brain segmental boundaries. 
At E12.5 WT470LZ expression appears in individual cells in the intermediate zone 
of the dorsal part of the roof of the midbrain. The number of these cells increases 
over the next 24 hours. The cells are large and round in shape. By virtue of the shape 
and position of these cells they are potentially trigeminal mesencephalic cells (T. 
Jessel pers. comm.). These cells are neural crest in origin but fail to migrate out of 
the brain; they express the neuronal marker Lim]. To confirm that these - 
ga!actosidase expressing cells are trigeminal mesencephalic cells they will be 
checked for Lim] immunoreacti vity. 
A preliminary investigation of WT470LZ expression in the adult has localized 
transgene expression to two domains in the midbrain. The first domain constitutes a 
group of cells in the region of the thalamus which may represent cells derived from 
the medial ganglionic eminence (corpus striatum mediale) (Bannister et al., 1995). 
The second group is found in a region of the deep white layer of the superior 
co!liculus. Trigeminal mesencephalic cells contribute to the cells of the superior 
colliculus (Bannister et al., 1995). Hence both these WT470LZ expressing domains 
may be linearly derived from WT470LZ neurons generated during early brain 
formation. 
4.3.8.2 Transgene expression in the cerebellum. 
Wtl activity has previously been detected in the roof of the fourth ventricle of the 
foetal brain (Armstrong et al., 1992). Cells in the roof of the fourth ventricle begin to 
strongly express WT470LZ at E12.5. They continue to do so at E13.5 (Fig. 3!) and 
E15.5. AtE13.5 and El5.5 cells in the intraventricular portion of the cerebellar 
115 
primordium are also expressing the transgene. Neurons derived from both the roof of 
the fourth ventricle and the cerebellar primordium are involved in cerebellar 
development. 
Three sets of precursor neurons are involved in cerebellar development, reviewed by 
Hatten and Heintz, 1995; Hatten et al., 1997. The cerebellar primordium forms 
between the mesencephalon (midbrain) and the metencephalon. Between E 1 and 
E14 the cerebellar primoridium grows by proliferation of the cerebellar deep nuclei 
precursors within its ventricular zone. From El 3 onwards precusors for Purkinje 
cells, Golgi cells astroglia and the interneurons of the molecular layer (basket and 
stellate cells) begin to proliferate in this ventricular zone. These exit the cell cycle 
and migrate into the centre of the cerebellar primordium forming a zone of immature 
neurons. Both these populations of neurons are derived from the mesencephalon 
(Hallonet et al., 1990). Cells derived from the metencephallic roof of the fourth 
ventricle of the embryonic brain begin to migrate into the cerebellar primorium over 
the rhombic lip of the metecephalon at E13. These cells give rise to a germinal zone 
known as the external granular layer (EGL). The EGL overlies the ventricular zone 
giving rise to all other neurons of the cerebellum. After birth a rapid proliferation of 
the EGL increases its size from one to eight cell layers thick. At postnatal day 15 
EGL proliferation stops and the cells of the EGL migrate through the molecular and 
Purkinje cell layers into the cerebellar primordium to form the internal granular cell 
layer (IGL)of the adult cerebellum. 
The adult cerebellum consists of four main layers. An outer molecular layer 
containing the basket and stellate interneurons. Immediately proximal to the 
molecular layer is a single cell layer of Purkinje cells. Proximal to the Purkinje cell 
layer is the inner granular layer (IGL) containing very high numbers of granular 
neurons outnumbering the Purkinje cells around 250:1 (Hatten and Heintz, 1995). 
Two other cell type are present within the granular layer, Golgi and unipolar brush 
cells (Mugnaini and Floris, 1994). The inner layer of the cerebellum consists of the 
dense cerebellar deep nuclei. 
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WT470LZ is weakly expressed in the adult cerebellum. This domain of expression 
consists of a layer of transgene expressing cells on the distal border of the IGL at the 
level of the Purkinje cell layer. Proximal to this layer further scattered cells are 
expressing the transgene. WT470LZ is possibly marking the Purkinje cells. In the 
IGL it is possible that the transgene is marking only a subset of the granular neurons; 
however all granular cells of the IGL are believed to be genetically homogenous 
(Hatten et al., 1997). Whichever cells of the granular layer WT47OLZ is marking they 
may be the direct descendants of cells expressing WTJIWT47OLZ in the roof of the 
fourth ventricle at E13.5. Further analysis of WT47OLZ during cerebellar 
development is required. 
4.3.8.3 Transgene expression in the spinal cord. 
A further domain of WT470LZ expression spans the most rostral part of the 
myelencephalon and the cervical part of the spinal cord. It is switched on in a 
medially placed domain of the dorsal myelencephalon and cord at E12.5. By E13.5 
the most rostral neurons of this zone have sent out axons. These axons have 13-
galactosidase activity hence it is possible to trace their route through the cord (Fig. 
32d). At E15.5 there also appears to be some expression of 13-galactosidase in the 
roof plate of the cord. No expression of Wtl has previously reported in the dorsal 
cord so this is a potentially novel site of activity. However even if Wt] is not 
expressed in this dorsal cord domain the expression pattern is still very interesting. 
Whilst columns of motor neurons in the ventral half of the cord have discrete 
boundaries of expression along the rostro-caudal axis of tube similar rostro-caudal 
boundaries of expression have not been reported for neurons in the dorsal cord 
(Lumsden and Krumlauf, 1996). WT470LZ is marking a domain of in the dorsal cord 
which has a caudal boundary in the cervical region. 
Wt] activity has been described in the ventral spinal cord. Wt] comes on at El 1.5 in a 
small domain adjacent to the ventricular zone immediately ventral to the sulcus 
limitans. The position of Wz'1 activity changes moving ventrally as the cord matures 
(Armstrong et al., 1992). WT47OLZ is expressed in a pattern mirroring that of MI. 
WT470LZ is expressed in the ventral part of the cord at E12 (Fig. 32a). The 
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transgene expression runs the length of the spinal cord from cervical regions to 
beyond the hindlimbs. It is particularly strong in the lumbar region of the embryo. By 
E13.5 the domain of transgene expression encompasses a large area of the 
ventromedial part cord (Fig. 32b). At E15.5 the domain of transgene activity lies at 
the most ventromedial part of the cord and the level of expression has become much 
weaker (Fig. 32c). 
The expression pattern of WT470LZ in the ventral spinal cord appears to be very 
similar to the interneuron subset of the Lim3 gene expression pattern (T. Jessel pers. 
comm.). In the chick Lim3 is expressed along the whole length of the ventral spinal 
cord. It is expressed the motor neurons of the median motor column (MMC) 
(Tsuchidaet al., 1994; Tanabe and Jessell, 1996). By analogy to the timing of Lim3 
expression in the chick, expression of Lim3 in the mouse would be expected to begin 
at around E10.5. WT470LZ is not seen as early as E10.5. El1.5 embryos have not 
been properly examined for WT470LZ activity in the spinal chord. However Wt] 
expression has been described in El 1.5 spinal cord. It remains to be determined 
whether Wtl is marking the same neurons which also express Lim3 or whether it 
marks a population of neurons generated half a day to a day later. 
4.3.8.4 Transgene expression in the eye. 
A further ectodermally derived tissue in which Wtl expression has been detected (by 
RT-PCR) is the eye (Armstrong et al., 1992). WT470LZ expression is switched on in 
individual cells scattered throughout the outer germinal layer of the neuroretina at 
E13.5 (Fig. 33a). At E15.5 expression is much stronger and is localized to the inner 
(non germinal) layer of the proximal neuroretina immediately adjacent to the optic 
nerve (Fig. 33b). Light X-gal staining of the hyaloid tissue and back of the lens is 
seen which is due to endogenous 3-galactosidase activity. As with the eye the 
neuroepithelium of the nose is derived from an ectodermal placode. At El 5.5 a 



















Fig. 30 WT470LZ expression in the forebrain and midbrain. 
(a) Transverse section E12.5 mouse embryo (x25) (line A). WT470LZ is expressed 
in the ventricular layer if the corpus striatum medial. (b) Saggital section E13.5 
mouse embryo (x 10) (line A). WT470 is expressed in the corpus striatum , cerebellar 
primordium, neural tube as well as pericardium, pleura, peritoneum and tongue. (c) 
E13 mouse embryo - dorsal view (line A). WT470LZ expression is seen in the 
midbrain (putative trigeminal mesencephalic nuclei), roof of the fourth ventricle, 
neural tube and limb. (* plane of section for plate d). (d) Transverse section of the 
midbrain at the level of the third ventricle (E12.5) (x400) (line A). Large round cells 
expressing the WT470LZ transgene are potential trigeminal mesencephalic nuclei. 
Abbreviations : (CSL) lateral corpus striatum, (CSM) medial corpus striatum, (NT) 
neural tube, (D) dorsal, (V) ventral, (CN) caudal neural tube, (LN) lumbar neural 
tube, (CP) cerebellar primordium, (CS) corpus striatum, (T) tongue, (Viv) fourth 
ventricle, (Viii) third ventricle, (Lb) limb, (MB) midbrain, (VL) ventricular layer, 









Fig. 31 Expression of WT47OLZ at the metencephalic/mesencephlic junction. 
(a) Lateral sagittal section form E13.5 embryo (xSO). (b) Medial sagittal section from 
E 13.5 embryo (00). Abbreviations: (T( VZ)) ventricular zone of the tectum, (CP) choroid 
plexus, (CB) cerebellar primordium. (RViv) roof of the fourth ventricle. 






















Fig. 32 Expression of WT470LZ in the spinal cord. 
(a) Transverse section through the lumbar region of the spinal cord in E12.5 mouse 
embryo (x 100) (Line A). WT470LZ is expressed adjacent to the ependymal layer 
adjacent to the suculus limitans. (b) Transverse section lumbar region of the spinal 
cord in E13.5 mouse embryo (x50) (Line H). The domain of transgene expression has 
moved ventrally. (c) Transverse section lumbar region of the spinal cord in E15.5 
mouse embryo (x50) (Line H). (d) Transverse section cervical region of the spinal 
cord in E13.5 mouse embryo (x50) (Line H). The transgene is expressed in the dorsal 
part of the cord and axons extend from this region through the white matter and 
express b-galactosidase. 
Abbreviations: (D) dorsal, (V) ventral, (CC) central canal, (EL) ependymal layer, 
(SL) suculus limitans, (DRG) dorsal root ganglion, (WM) white matter, (GM) grey 
















Fig. 33 Expression of WT47OLZ in the developing eye. 
(a) E13.5 mouse eye (x 100). WT47OLZ expression is switched on in individual cells 
scattered throughout the outer germinal layer of the neuroretina. (b) E15.5 mouse eye 
(x50). WT470LZ expression is localized to the inner layer of the proximal neuroretina 
adjacent to the optic nerve. Abbreviations: (P) pigmented epithelium. (N) neuroretina, 
(Ls) lens, (OD) optic disc, (IN) inner layer of neuroretina, (ON) outer layer of neuroretina. 
Embryo sections are from line A. 
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4.4 Transgene expression in line E. 
Transgene expression in line E occurs at a much lower level than A and H (Fig. 34a). 
It first appears in the mesonephros (E9.5). By E 12.5 expression encompasses the 
whole urogenital ridge and in the adult it is expressed in the metanephric glomerula 
podocytes. As in lines A and H, WT470LZ expression occurs in the pleura, 
peritoneum and pericardium at a much reduced level. The transgene is expressed in 
the developing limb/body wall musculature but no activity occurs interdigitally. 
There is no transgene activity in the nervous system equating with that occurring in 
line A and H. However ectopic expression is seen in the ciliary body of the eye and in 
a stripe along the midline of the midbrain roof. 
4.5 Expression of WT280LZ in line C. 
The 3-ga1actosidase expression pattern in line C throughout embryonic development 
is very similar to that of lines A and H (Fig. 34b). Between E9.5 and El 1.5 line C, A 
and H embryos, have transgene expression in the pericardium, pleura, peritoneum, 
mesonephric ridge, base of the limbs and the corpus striatum. However at El 1.5 
ectopic domains of expression peculiar to line C become apparent. There is transgene 
expression in the dorsal root ganglia running the length of the body, the branchial 
arches and in a bar running above the eye. 
The similarity between the transgene expression pattern in line C and lines A and H 
continues throughout foetal development. At E13.5 in lines C, A and H there is 
transgene activity in the pericardium, pleura and peritoneum, interdigital regions and 
muscle along the dorsal and ventral sides of the developing limb. The transgene is 
expressed within both the mesonephros and the gonad; but the level of 3-
galactosidase expression in the gonad is greatly reduced compared to that of the 
mesonephric ridge. This does not occur in lines A and H. Furthermore line C, in 
contrast to in lines A, E and H, shows no transgene expression in the developing 
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metanephros, or adult metanephros. At E13.5 line C transgenic embryos also show 
very similar transgene expression in the head to those of line A and H. There is 
strong expression in the developing head muscles, tongue, lower jaw and in the 
mesenchyme adjacent to the oral and nasal cavities. Interestingly in line C there is 
also low transgene expression within the developing submandibular glands. 
In line C WT280LZ expression in ectodermally derived tissues comes on at ElO.5 in 
the corpus striatum. Later it is expressed in the corpus striatum, the roof of the fourth 
ventricle and the eye, as occurs in lines A and H. In addition, ectopic expression of 
the transgene is seen in the optic nerve, dorsal root ganglia and peripheral nervous 
system. No transgene expression occurs in the myelencephalon or spinal cord. 
4.6 Expression of WT280LZ in line D. 
In line D WT280LZ is expressed weakly in the pericardium and adjacent to the 
cardinal veins (Fig. 34c). It is expressed more strongly in the mesonephros. The 
foetal and adult gonad express WT280LZ. As in line C the expression level of the 
transgene in the developing gonad is greatly reduced compared to the level in the 
mesonephros. Additionally, as in line C, there is no expression of WT280LZ in the 
foetal or adult metanephros. 
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Fig. 34 Expression of WT28OLZ/WT47OLZ in lines C, D and E. 
(a) Sagittal section of line E embryo Eli .5 (xi 2.5). WT470LZ is expressed in the 
rnesonephric ridge and pleura and at low levels in the pericardium. There is ectopic 
expression of the transgene in a stripe across the roof of the midbrain. (b) El 1 .5 line 
C embryo. WT28OLZ is expressed in the same domains as endogenous WtJ as well 
showing ectopic expression in the dorsal root ganglia. branchial arches and around 
the eye. (C) Dissection of a line D embryo El 0.5. There is only WT28OLZ expression 
in the mesonephros (where is localised to the glomeruli) and the mesenchyme 
surrounding the cardinal vein. Abbreviations: (Pt) pleura, (MsR) mesonephric ridge, 
(MB) midbrain, (P) pericardium, (BA) branchial arch, (CS) corpus striatum, (E) eye, 
(DRG) dorsal root ganglion, (CVM) mesenchyme surrounding common cardinal 













4.7 The WT280 YAC can partially rescue the WTI 
knockout phenotype. 
Dr Andreas Schedi has used the WT280 YAC to generate three transgenic lines. 
These lines were crossed onto the Wt] knockout background. The WT280 transgene 
was able to rescue those defects in the Wt] knockout which lead to embryonic death. 
Neonates homozygous for the Wt] null allele and carrying the WT280 transgene were 
recovered at the expected frequency. They had no edema or disruption of the thoracic 
organs. These neonates however died within 48 hrs of birth. A post-mortem indicated 
defects in kidney development to be the probable cause of death. 
In the majority of partially rescued mice no branching of the ureteric bud occurs and 
consequently no subsequent development of the metanephros. This metanephric 
phenotype is the same as is seen in Wtl knockout animals (Kriedberg et al., 1993). In 
a subset of partially rescued mice however metanephric development begins but does 
not proceed to completion. In these animals in the initial stages of nephrogenesis 
occur normally; branching of the ureteric bud occurs and comma and S-shaped 
bodies are formed. Mature glomeruli are not observed in the partially rescued kidneys 
at E18.5. Detailed analysis of the S-shaped bodies present in these partially rescued 
kidneys (E18.5) indicates that the flattening of the proximal part of the S-shaped 
bodies which gives rise to mature podocytes does not occur. Throughout the 
epithelial structures of the partially rescued kidney apoptosis is significantly 
increased to a level four times that of wildtype. The partially rescued phenotype 
demonstrates a second role for WT  in nephrogenesis. As well as being required for 
the initial stages of kidney induction WTI is also necessary at a later stage in the 
epithelial maturation of the glomerular podocyte cells. 
In partially rescued animals in addition to the failure of metanephric development, 
gonad formation is also blocked. At E15.5 a small region of adrenal cortex is present 
however neonates have no evidence of adrenal glands. No Wt] expression in the 
developing adrenal has been detected in Wt] in situ hybridization studies or with the 
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WT470LZ transgene. However in addition to a requirement for Wtl in gonad and 
metanephric formation, the gene is also required for adrenal formation. 
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5. Analysis of Wt] expression and the 
phenotype of the Wtl knockout mouse. 
Study of the expression patterns of the WT470LZ and WT280LZ transgenes reveals 
expression in tissues and organs where Wt] activity has not been previously reported. 
In particular expression of the transgene in the limb and dorsal spinal cord represents 
potentially newly discovered sites of Wtl activity. We carried out Wtl whole mount 
mRNA in situ analysis on E12.5 and E13.5 embryos and further radiaoactive niRNA 
in situ analysis on sections from E12.5 embryos to attempt to confirm some of these 
potentially new expression patterns. 
Using the data provided by the analysis of the WT470LZ and WT280LZ as a guide 
the Wt] knockout mouse was rexamined. This was done to attempt to detect any 
subtle defects not picked up in the original analysis of the animal. 
5.1 Wtl is expressed in the limb. 
In lines transgenic for either WT28OLZ or WT47OLZ -galactosidase is expressed in 
the anterior, posterior and interdigital apoptotic zones. Whilst Wtl expression has not 
previously been reported in the mouse limb, it has in alligator. This study reported 
WD expression at the base of the limb, in the developing musculature and anterior 
and posterior marginal zones (Kent, 1994; Kent et al., 1995). These regions in the 
alligator are apparently homologous to those expressing the transgene in the mouse, 
with the exception of the interdigital apoptotic zones (Fig. 35f). 
Whole mount Wt] mRNA in situ analysis carried out on E12.5 embryos highlighted a 
clear domain of Wtl expression at the base of the webbed mesenchyme between 
digits 3 and 4 (Fig. 35a and b). At E13.5 expression of Wt], whilst less strong, runs 
in a stripe either side of the developing digits (Fig.35d). Wtl expression in the 
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musculature at the base of the limb was confirmed by radioactive Wtl in situ analysis 
on sections of an E13.5 mouse embryo (data not shown). The domain is continuous 
with that already described in the body wall (Armstrong et al., 1992). 
5.2 Wtl is not expressed in the dorsal part of the spinal 
cord. 
WT470LZ is expressed in the dorsal part of the spinal cord at cervical levels. Wtl 
whole mount in situ on E13.5 decapitated embryos shows expression of the gene in 
ventral parts of the spinal cord at this level (Fig. 35e). This ventral domain of 
expression is the same as that already described in the cord at lumbar levels 
(Armstrong et al., 1992): No expression was seen in the dorsal part of the cord. 
Transgene expression in this domain may be due to ectopic expression of 13-
galactosidase caused by cryptic elements in the transgene. Similar ectopic expression 
in the dorsal part of the cord at caudal regions has been seen in embryos carrying 
other transgenic constructs, e.g. the Trpl promoter linked to lacZ (I. Jackson pers. 
comm.) 
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Fig. 35 Whole mount WtJ mRNA in situ analysis. 
(a) WtJ whole mount in situ analysis on a E12.5 mouse embryo. Wt/ expression can 
be seen interdigitally, in the musculature at the base of the limb and in the flanks. (b) 
Section (x50) through hand plate of the El 2.5 embryo (plate a) demonstrating WtJ 
expression interdigitally at the base of the digits. (c) E12.5 mouse embryo in situ 
'sense' control demonstrating that signal within the head in due to trapping of the 
probe in the cerebral ventricles. (d) WtI whole mount in situ analysis on a limb from 
E13.5 mouse embryo demonstrating weak Wz'I expression in the interdigital region. 
(e) Cervical region of a decapitated Wi'] whole mount in situ El 3.5 mouse embryo. 
There is Wtl expression in the ventral but not in the dorsal neural tube. (I) Stage 12- 
13 alligator whole mount WTI mRNA in situ analysis demonstrating WTI expression 
in the developing handplate, limb musculature, body wall and hindbrain (from Kent 
et al. 1995). (i) front view, (ii) rear view. 
Abbreviations: (NT) neural tube, (P1) pleura, (ID) interdigital mesenchyme, (D) digit, 
(Rs) rostra], (C) caudal, (P) pericardium, (L) limb, (Mu) musculature, (HP) hand 
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5.3 Wtl is not expressed in the somite. 
In WT470LZ transgenic embryos the transgene is expressed in myotome derived 
body wall, limb and intercostal muscles. Kent et al. suggested that WTI expression 
may be expressed in part of the sclerotome in stage 21 chick embryos (Kent et al., 
1995). This finding seems surprising. -galactosidase expression is not seen in 
scierotome derived tissues in WT470LZ transgenics and Wtl expression has not been 
reported in these tissues. We re-examined WTI and Myogenin in situs carried out by 
Kent et al. on stage 21 chick. These show chick WTI expression abutting the 
somitocoel, in what appears to be the ventral part of the somite (data not shown). 
We examined the expression of the WT470LZ transgene in embryos of El 0.5-E 11.5 
to ascertain whether the transgene is being expressed within the somite. 3-
galactosidase expression envelops the ventral end of the somitic myotome but is not 
clearly within the somite derived tissue (Fig. 29a). To further investigate the nature of 
somitic V/ti expression radioactive in situ analysis of this region on sections of an 
10.5 mouse embryo were undertaken using Pax], Pax3 and Wri molecular probes. 
Paxi is a marker of scierotome derived cells and Pax3 a marker for myotome derived 
cells. In the axial region of the E10.5 embryo domains of cells expressing either Wti, 
Pax] or Pax3 abut, but are mutually exclusive (Fig. 36). WtI is not being expressed 
within any somite derived cell populations. This analysis was carried out in mouse 
and not chick. However the stages of somitic development between those in situs 
carried out by Kent et al. and myself are comparable. It is possible that in some 
anterior somites, at one stage of development, WTI is expressed in the cells of the 
chick somite. This however seems unlikely. A more likely explanation is that the 
expression of WTI observed by Kent et al. is in cells of the intermediate mesoderm 
which have invaded a region originally occupied by somitic cells. This could occur 
whilst the somite undergoes morphogenetic changes during the formation of the 
scierotome and dermomyotome. This invasion may be possible because although the 
somite lays down a basement membrane as it forms, the membrane is not continuous 
and is broken in vicinity of the intermediate mesoderm (Christ and Ordahi, 1995). 
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There may be no functional relationship between the Wt] expressing tissue of the 
intermediate mesoderm and the somite. Alternatively invasion of Wt] expressing 
cells may limit the process of myogenesis. Intermediate mesoderm co-cultured with 
somitic mesoderm prevents myogenic differentiation within this tissue (Gamel et al., 
1995). Loss of WTI expression in Wilms' tumours appear to be correlated with a 
large amount muscle formation within them, furthermore WT1 protein can repress 
myotube formation in myoblast cell culture (Hastie, 1994). Could a role of WTI in 
the suppression of myogenesis explain the expression of the gene in the epaxial 
myogenic regions of the embryo? 
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Fig. 36 In situ hybridization analysis of the junction between the intermediate 
mesoderm and the somite. 
(A) - MI. (B) - Pax3. (C) - Pax]. (all xl 00). WtJ abuts the edge of the ventral 
myotome and wraps around it but the two domains of expression remain distinct. 
Abbreviations: (nt) neural tube, (mt) mesonephric tubule, (md) mesonephric duct, 
(my) myotome, (Sc) scierotome, (a) aorta, (ug) urogenital ridge, (g) gut, (mth) 
mesothelium/coelomic epithelium, (lb) limb bud. Image enhanced using the X-
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5.4 Analysis of Wtl-I- embryos. 
With knowledge of the expression pattern of the WT470LZ and WT280LZ 
transgenes the phenotype of homozygous null Wt] embryo was re-examined (gift of 
J. Kreidberg Harvard Medical School, Boston, USA and R. Jaenisch, Whitehead 
Institute for Biomedical Research, Cambridge, USA) (Kreidberg et al., 1993). E12.5 
and El 3.5 Wt] knockout embryos were isolated, sectioned and haematoxylinleosin 
(H&E) stained. No obvious morphological effects of the loss of WtI were seen in any 
ectodermally derived tissues. Similarly no effects were apparent in those in areas of 
transgene expressing head mesenchyme. 
5.5 A Wt] null phenotype in the pleura, pericardia and 
diaphragm. 
The phenotype in the developing urogenital system of homozygous WtI null mice has 
already been reported (Kreidberg et al., 1993). The same investigation notes that 
these embryos have a small malformed heart, lungs and discontinuities of the 
diaphragm. Pericardial bleeding and edema also occur which are postulated to be due 
to cardiac malfunction. There is no expression of the transgene within the 
myocardium. These abnormalities are however, consistent with the transgene/WtJ 
expression in the visceral and parietal pericardia, pleura and diaphragm. 
Wt] knockout embryos were isolated, sectioned and examined at E12.5 and El3.5. In 
these embryos there was an apparent reduction in the volume of the outer 
pericardium and the pleura. The reduction of the pericardium is consistent with loss 
of part of the WT470LZ/Wtl positive parietal pericardial layer (Fig. 27d). The Wt] 
negative fibrous pericardia which lies distal to this layer may not be affected. E12.5 
and E13.5 knockout embryos show edema. Therefore it is difficult to tell whether the 
pericardial and pleural tissues are simply present and displaced by the swelling of the 
embryo or reduced in cell number. A large number of apoptotic bodies and 
phagocytes are present within the pericardium and pleura of the E12.5 and E13.5 
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knockout embryos. This implies that a high level of cell death is taking place in these 
tissues. Even if the cell death occurring in these tissues is above than that in wildtype 
embryos however, it may be as a consequence of embryonic edema and death rather 
than loss of local Wt] expression. 
5.6 No obvious Wt] null phenotype in the limb. 
Both WT470LZ and \VT280LZ are strongly expressed in the apoptotic interdigital 
mesenchyme of the developing limb (Fig. 29). Cell death in these regions is essential 
for correct limb digit patterning to occur (Konig etal., 1993). Expression of Wt  
within these domains was confirmed by whole mount in situ analysis (Fig. 35). We 
therefore undertook a study of any potential differences in Wt] knockout and wild 
type limb patterning. Fore and hind limbs were removed from knockout mice and 
wild type litter mates at E12.5 and E13.5. The pattern of apoptosis within these limbs 
was examined by TUNEL analysis and H&E staining (Fig. 37). No differences in the 
patterns of apoptosis between wild type and knockout embryos could be identified. 
Similarly there was no apparent difference in limb musculature between wild type 
and knockout embryos. 
The lack of Wt] expression in the forming limb may not give rise to any phenotype. 
Alternatively the Wt] knockout mice limb phenotype may be very subtle and not 
obvious at the early stage of development (E13.5) when homozygous null embryos 
die. Wt] has a very transient expression pattern during limb development and it 
would be unsurprising if the gene had only a very subtle function in limb patterning. 
The regulatory element responsible for driving Wri expression in the developing limb 
is carried on the 5kb region of promoter present in pUSWT 1. If this element could be 
further defined and then disrupted in WT280, neonate mice partially rescued with 
this YAC would not have expressed Wtl in the limb during development. In these 
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Fi2. 37 Coninarison of forelimb patterning in wild type versus homozygous Wt/ null 
E13.5 mouse embryos. 
(a) Wild type E13.5 forelimb (00). (b) Homozygous null E13.5 forelimb (x50). (c) 
Close-up of region from plate b (x200). There is no obvious difference in patterning of 
the digits or regions of apoptosis between the wildtype and WtI knockout limbs. 
Abbreviations: (D) digit. (ID) interdigital mesenchyme, (ApC) apoptotic cells. 
In plate c apoptotic cells are not TUNEL labelled but H&E staining of the section 
strongly labels apoptotic cell bodies. 
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5.7 Crossing Wt] knockout mice with WT470LZ (line A) 
transgenic mice. 
To better determine the effect of the loss of Wtl activity tissues which normally 
express the endogenous gene, we attempted to cross the WT47OLZ transgene onto a 
Wt] homozygous null background. Line A transgenic mice were mated with Wt] 
heterozygous null (+1-) mice. As line A is male sterile only female offspring from this 
cross were used for further matings. These were mated to Wt] +1- males in order to 
generate Wtl-/- mice carrying the WT470LZ transgene. 
Thirty four E12.5 embryos were isolated from this cross. 6 were homozygous null for 
Wtl and 16 expressed the WT47OLZ transgene. Surprisingly no embryos which were 
Wtl null expressed the transgene although half would be expected to do so. Given 
this surprising result it seemed possible that the transgene had integrated onto the 
same chromosome, (chromosome 2), as the endogenous Wt] locus. FISH analysis 
(Fantes et al., 1992) was carried out with a cosmid probe specific for the human WTI 
locus (B2.1(Fantes et al., 1995)) to detemine if this was indeed the case. WT470LZ 
in line A is integrated on chromosome 4 (Fig. 21a). Hence it should be possible to 
isolate Wt] homozygous null embryos which carry the transgene. Besides the 
possibility of simply being unlucky there seemed two other likely explanations for 
the inability to do so. 
The WT470LZ transgene may not be able to be expressed on the Wtl knockout 
background. Rupprecht et al. 1994 have footprinted several Wt  binding sites in the 
Wt] promoter and propose that Wtl negatively autoregulates itself. However as 
WT470LZ potentially fails to be expressed on the Wt] null background it may be that 
WO protein is actually required for Wt] expression. If this is the case positive 
autoregulation of the Wtl locus is occurring. Alternatively tissues which normally 
express the transgene may be lost from E12.5 and E13.5 Wt] knockout embryos. 
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We postulated that, if transgene activity is lost because of the loss of transgene 
expressing tissues at E12.5, it may be possible to detect activity at earlier stages of 
embryonic development. E9.5 and E10.5 embryos were isolated and decapitated. The 
heads were washed 4 times in PBS before being genotyped by PCR analysis 
(Grindley et al., 1995 and materials and methods). The bodies of these embryos were 
stained for 3-galactosidase activity. Of 20 embryos isolated 6 were knockout but only 
one of these (which was an E9.5 embryo) carried the W7470LZ transgene. In this 
embryo the transgene was expressed. Another 6 embryos were not Wt] homozygous 
null but carried and expressed the transgene. Again there were fewer embryos which 
were Wt] knockout and carried the transgene than expected. One embryo did 
however, indicating that the transgene can be expressed on a knockout background, 
at least at this early stage of development. It is still not possible to explain why so 
few Wtl knockout embryos express the transgene. Possibly tissue expressing 
WT470LZ in Wt] knockout embryos does undergoes apoptosis as development 
proceeds. An E9.5 day embryo expresses WT470LZ in the mesonephric mesenchyme 
which is largely unaffected in a Wt] homozygous null embryo. Organs developing 
later such as the metanephros, gonad and pericardia are affected by loss WTI activity. 
The more recently characterized line H also contains the WT47OLZ transgene. FISH 
analysis of this line also localized the transgene integration site to chromosome 4 
(Fig. 21b). Furthermore this line does not have problems of male sterility. In order to 
further analyze the expression of WT470LZ on the Wtl null background a cross is 
presently being undertaken between line H and the Wtl knockout line. 
141 
6. Discussion. 
6.1 Tissue specific regulation of the WTI gene. 
The WTI gene is expressed in a complex tissue-specific manner during development. 
Attempts to study how the gene is regulated have met with some difficulty. Hence, to 
date, all information on WTI gene regulation has been generated in cell lines (Fraizer 
et al., 1994; Cohen et al., 1997; Hofmann et al., 1993; Rupprecht et al., 1994; Wu et 
al., 1995; Hewitt et al., 1995a). We have attempted to study WTI promoter activity in 
vivo in transgenic animals. The results of similar transgenic studies have recently 
been reported by other groups (Cohen et al., 1997; Hewitt et al., 1996). We have been 
able to go much further than the these groups towards elucidating WTI promoter 
activity. Firstly, we have been able to use YAC based transgenic constructs to mimic 
the endogenous expression pattern of the Wtl gene. Secondly, we have compared the 
expression pattern of a lacZ reporter gene driven by three different WTI 
promoter/reporter constructs in lines where the constructs have either integrated 
intact or are rearranged. By carrying out this comparative analysis we have been able 
to begin to localize tissue specific regulatory elements within the WTI promoter. 
(Table 5 summarizes reporter gene expression patterns driven by WT470LZ, 
WT280LZ and USWT1 and compares this to the previously reported endogenous 
Wtl pattern.). 
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Table 5 -galactosidase expression in WT470LZ, WT280LZ and NOR!NLS 
transgenic embryos. 
1 - Expression level is reduced compared to other transgenic lines. 
2 - Wtl expression detected by RT-PCR. 
3 - Expression domain different to that of endogenous WT1 or other lines. 
4 - Expression of WT28OLZ has been seen in 3/3 transient trangenic lines analysed. 
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6.1.1 Plasmid (USWT1) transgenic analysis. 
The putative 5' proximal WTI promoter encompassed by USWT1 is very weak and 
subject to position effects in transgenic animals. However analysis using this 
construct has demonstrated that tissue-specific enhancer elements responsible for 
driving WTI expression in the spinal cord, handplate, epaxial musculature and 
pericardium, pleura and peritoneum may all localize to the WTI promoter sequence 
in USWT1. No reporter gene expression driven by USWT1 has been detected in the 
urogenital system of 10/10 NORINLS transgenic embryos examined. 
It is to a degree surprising that no expression of lacZ in the NORINLS transgenic 
embryos was seen in the urogenital system, whilst weak expression was identified in 
the pericardium, pleura and peritoneum. All of these tissues consist of mesenchyme 
produced originally by the proliferating coelomic epithelium. One explanation is that 
there may be low levels of reporter gene expression in the mesonephros and the 
gonad in some of the NORJNLS transgenic embryos. This low level of expression 
however, is masked by endogenous -galactosidase activity. Alternatively, the 
regulatory elements required for the expression of WTI during the development of 
the metanephric and gonadal mesenchyme may be different from those required for 
generalized mesenchymal expression. This second hypothesis seems more likely as 
line C and D embryos also show differential transgene activity between the urogenital 
system and the pleura, pericardia and peritoneum. 
The WTI promoter region contained on USWT1 is reported to have promiscuous 
promoter activity in all cell lines in which it has been tested ((Fraizer et al., 1994; 
Cohen et al., 1997) and Table 2). This same promoter has potential tissue specific 
activity when assayed in vivo. This difference between promoter activity in cell lines 
and transgenics illustrates the importance of carrying out the analysis of any putative 
promoter elements in an in vivo transgenic assay. Cohen et al. 1997 and Hewitt et al. 
1996 made a total of 10 transgenic animals with a construct a similar to USWTI 
(Fig. 9). They found no transgene expression at all. The Cohen and Hewitt constructs 
seem to have integrated in an 'inactive' chromatin configuration whilst those in 
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NORJNLS transgenics have not. The NOR or NLS transgenes themselves are very 
susceptible to position effects. One of the implications of these results is that the 
chromatin structure of the WTJ promoter region may be regulated during 
development. USWT1 may contain specific sequences, which serve to open up the 
promoter into a more active configuration, sequences which may be missing from the 
Cohen and Hewitt constructs. 
6.1.2 Expression of -galactosidase in lines A and H driven by 
WT470LZ mimics that of the endogenous Wt] locus. 
The expression pattern of the lacZ reporter gene in WT470LZ transgenic animals is 
very similar to that of the endogenous Wtl gene. It is expressed in the same spatio-
temporal pattern during embryonic development as endogenous Wtl, except for the 
Sertoli cells of the testes and potentially the granulosa cells of the ovary. It appears 
that nearly all the correct regulatory sequences are present on this YAC construct to 
get proper expression of the WTI locus in vivo. 
6.1.3 Localization of potential tissue specific regulatory elements. 
WT280LZ in lines C and D is truncated somewhere 5' of the WTI gene. These lines 
show no transgene expression in the developing metanephros or mature podocyte 
cells. Transient transgenic analysis with WT280LZ shows that this construct can 
drive -galactosidase in the same cells as endogenous WTI during nephrogenesis. 
Elements required to drive WTI expression in the developing metanephros appear to 
have been deleted in lines C and D and are likely to lie 5' of the WTI locus. Lines A, 
H and E which do not show any disruption of the YAC transgene 5' of WTI have a 
normal 3-ga1actosidase expression pattern during nephrogenesis. The USWT 1 
construct is unable to drive f-galactosidase expression during metanephric 
nephrogenesis hence elements controlling this expression may be located some 
distance further 5' of WTI than the area covered by USWT1. Long distance, tissue 
specific, regulatory elements are quite common. A number of human genetic diseases 
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are proposed to be caused in some patients, by the displacement of such elements by 
chromosomal translocation. Examples of diseases where this has been reported are 
aniridia (PAXO), X-linked deafness (POU3F4) and Campomelic dysplasia (SOX9) 
(Bedell et al., 1995). Similarly, several mouse mutants can be ascribed to DNA 
rearrangments far from the gene locus. For example tissue specific defects in the 
expression of steel factor (SCF) from the Si locus are caused by DNA rearrangments 
over 100 kb 5' of the SI gene (Bedell et al., 1996). 
Expression from USWT1 is very weak and susceptible to position effects. In the 
WT280LZ/WT47OLZ YAC transgenics a much larger region of the promoter is 
integrated. These show strong, tissue specific expression of the transgenic construct. 
The WT470LZ transgenes in line A (1 copy integrated into euchromatin) and line H 
(12 copies integrated into a heterochromatic telomere) show position independent, 
copy number dependant expression. These YAC transgenes may simply set up the 
correct chromatin domain for transcription because they contain all correct tissue 
specific WTI enhancer elements. Alternatively, encoded somewhere on the YACs 
may be an LCR. 
The proximal promoter sequences of genes such as tyrosinase (Montoliu et al., 1996), 
CD2 (Festenstein et al., 1996) and those of the globin locus (Martin et al., 1996; 
Townes and Behringer, 1990) have only weak, but tissue specific activity in 
transgenic animals. A locus control region (LCR) spatially separate from these 
proximal elements acts to activate strong, position independent, copy number 
dependant expression from these promoters when also included on transgenic 
constructs. The LCR of the 0 globin locus was identified because deletions upstream 
of the P globin complex, leaving the 3 globin genes intact, cause 
haemoglobinopathies associated with loss of globin function (Townes and Behringer, 
1990). No mutations have been identified in Wilms' tumour patients (Grubb et al., 
1995; Campbell et al., 1993) which directly point to the WTI locus having an LCR. 
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Whilst no naturally occurring mutations indicate the presence of a WD LCR, lines D 
and E and to some extent in line I retain the 'normal' Wtl expression pattern but 
show a very large reduction in transgene activity. Line E expresses lacZ in the 
pericardium, pleura and peritoneum, however this expression level is greatly reduced 
compared expression in lines A and H. The elements required to drive tissue specific 
transgene expression in the pericardium, pleura and peritoneum probably lie 
immediately 5' of the WTI locus as lacZ expression can be driven by USWT1 in 
these tissues. The level of this USWT1 mediated expression however is low and 
susceptible to position effects. Other elements which are present on the YAC 
constructs may be needed to stabilize the transcription it mediates. Such elements 
may be missing from the integrated transgene in line E. A closer analysis of the state 
of the transgene integration within this line is required. 
6.2 Future work on WTI regulation. 
WT470LZ, and possibly WT28OLZ, express a 3-galactosidase reporter gene in the 
same spatio-temporal pattern as Wtl during embryonic development. Transgenic 
lines containing WT280LZ and WT470LZ in which potential tissue specific 
enhancers elements have been manipulated can be made. Such lines could provide a 
powerful method of assessing element function. Some of the putative tissue specific 
elements identified in cell culture experiments provide possible candidate sequences 
for analysis in this fashion, e.g. the CR element (Dehbi et al., 1996; Dehbi and 
Pelletier, 1996) and the CTC repeat (Cohen et al., 1997). 
The CR element lies around 400 bp upstream of the main WTI transcription initiation 
start site. It contains two paired box binding sites and has been implicated in the 
repression of the WTI promoter by co-transfected Pax2 and Pax8. These molecules 
are strong candidates for interaction with WTJ. They are co-expressed with WTI 
during the early stages of nephrogenesis and later adopt a mutually exclusive 
expression pattern to it (Eccles et al., 1995). The CR element lies within the putative 
proximal WTI promoter element contained in USWT 1. However NOR/NLS 
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transgenics show no expression of 3-galactosidase during nephrogenesis. This does 
not mean that the CR element definitely has no role to play in the nephrogenic 
expression of WTI. Elements lying outside USWT 1 may be required to stabilize or 
synergize its activity. 
Sequence comparison of WT1 promoters from different species may highlight 
elements involved in gene regulation. 400bp of the proximal chick WTJ promoter has 
been cloned (Kent, 1994). It does not show extensive homology to the mouse (47% 
identity) or human (45% identity) WTI promoter. A few regions are more highly 
conserved. None of these regions of conservation match with regions so far proposed 
to have a function in WTJ regulation. They may serve as pointers for future promoter 
dissection. The Spi binding CTC repeat is not in a highly conserved domain. It could 
none-the-less be functional in the chick, as the equivalent sequence in the analogous 
area of the chick promoter is 5' GTC CAC CCC CTC 3'. Recently a cosmid 
including the puffer fish (Fugu rubripes) WTI locus has been isolated (Dr. C. Miles 
pers. comm.). Fugu rubripes provides a useful system to dissect gene and promoter 
function. It has on average only 12% the amount of DNA at any one locus compared 
to mouse, human and many other higher vertebrates (Elgar et al., 1996). Sequences 
which are conserved between Fugu and other species are likely to be functional. The 
Fugu WTI cosmid will be sequenced, and used in transgenic assays to analyse both 
gene and promoter function. 
6.3 Why is WT280 unable to rescue Wtl homozygous null 
mice? 
Andreas Schedl crossed the WT280 transgene onto the Wtl knockout background. 
WTI expression from three different WT280 transgenic lines, when crossed onto the 
Wt] knockout background, was able to rescue the defects of the thoracic organs 
which cause embryonic death. It was however, unable to rescue adrenal glands, 
gonads or full nephrogenesis. In these partially rescued animals nephrogenesis was 
never able to proceed from the S-shaped body stage to form a mature glomerulus. 
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The failure of a full rescue implies that WT280 does not express WTI in way that can 
fully compensate for the loss of endogenous Wtl. 
Both WT280LZ and WT470LZ transgenic animals show reporter gene expression 
during urogenital development which mirrors that of endogenous Wi']. Although it 
must be pointed out that WT280LZ expression in the urogenital system has only been 
seen in transient transgenic embryos. It is likely therefore that only a subtle difference 
between the activity of the WT280 transgene and the endogenous locus leads to 
failure of urogenital development in the partially rescued mice. Functional 
differences between the YAC and the endogenous locus seem more likely to be in 
gene regulation rather than protein function. The amino acid sequence of the mouse 
and human is very highly conserved (>96% identical) (Buckler et al., 1991), on the 
other hand, species specific differences in WT] regulation exist. The WT470LZ (and 
probably the WT280LZ) transgene, for example, is not expressed in the testicular 
Sertoli cells (Fig. 25 a and c). The WT280LZ transgene does not however seem to be 
expressed in a pattern obviously different to that of Wtl in the rest of urogenital 
development. Perhaps therefore, it is subtle differences in a process, such as the 
control of the ratio of alternative WTI splice forms, which cause the partially rescued 
phenotype. Alternatively the level of WT 1 protein in different tissues may be critical. 
Podocyte formation, in particular, is associated with an upregulation of the level of 
Wt] expression (Armstrong et al., 1992; Pritchard Jones et al., 1990) (Fig. 3). In the 
WT280 transgenic kidney this upregulation may not occur. 
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6.4 Developmental role of the WTI gene. 
The expression of WT470LZ in transgenic mice mirrors that of the endogenous Wtl 
gene. Hence, investigation of the expression pattern of WT470LZ throws new light 
on potential developmental roles of the Wtl gene. 
6.4.1 Wtl is expressed in mesenchymal, but not direct epithelial, 
derivatives of the proliferating coelomic epithelium. 
At E8.5 WT470LZ is expressed in the intermediate mesoderm. This tissue gives rise 
to the organs of the urogenital system and the adrenal glands (Saxen, 1987; Bannister 
et al., 1995). At the same time WT47OLZ expression is also detected in the septum 
transversum (Fig. 22). This structure will give rise to parts of the diaphragm, 
pericardium and gut mesentery (Bannister et al., 1995). The intermediate mesoderm 
is formed by proliferation of the coelomic epithelium at the junction of the 
splanchnopleuric and somatopleuric mesoderm. The septum transversum also 
represents a localized mesenchymal cell population derived from the proliferating 
coelomic epithelium. The splenic capsule which forms later in development (E15.5), 
is another structure formed in this way. This tissue also expresses WTI (Armstrong et 
al., 1992). 
By ElO expression of the WT470LZ transgene has spread throughout the coelomic 
epithelium. The coelomic epithelium is beginning to proliferate and gives rise to 
mesenchymal cells sandwiched between the coelomic epithelium and the underlying 
mesoderm (Fig. 27). WT470LZ is expressed in this tissue. This tissue will form 
different serosal structures, e.g. pleura, pericardia, peritoneum or diaphragm, 
dependent upon the location. The cells of this newly formed mesenchyme are 
histologically distinct from those which constitute the splanchnopleuric and 
somatopleuric mesoderm. Although WT470LZ/Wtl is expressed in the coelomic 
epithelium as it undergoes proliferation, it is not a prerequisite for this proliferation. 
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WT470LZ is expressed in the intermediate mesoderm before it is expressed in the 
overlying coelomic epithelium. 
In addition to giving rise to mesenchymal cells, the coelomic epithelium also 
invaginates to form epithelial structures, e.g. the mesonephric duct and the 
paramesonephric duct. These tissues do not express Wt] or WT47OLZ (Figs. 22 and 
23). The coelomic epithelium itself however does express Wtl/WT470LZ implying 
that Wt] expression must be lost during the process of invagination to form these 
tissues. In short, WT470LZ/Wtl is expressed in the mesenchymal cells, but not in the 
epithelial cells, which derive directly from the coelomic epithelium. This relationship 
is schematized in Fig. .38. 
Occasionally extra-renal Wilms' tumours are found in the retroperitoneal space and 
gonads (Aterman, 1989). These tumours may be formed by misplaced metanephric 
tissue. Alternatively, all the mesenchymal tissue derived from the coelomic 
epithelium may have the same original developmental potentiality. This tissue would 
include the mesonephric cord, gonads and peritoneum. Mutation of WT1 or other 
Wilms' tumour genes in these tissues, before their developmental potentiality is 
restricted, could potentially give rise to a tumour histologically similar to Wilms' 
tumour. Similarly metanephric blastemal cells have a greater developmental 
potentiality than just the formation of nephrons and stroma. Mutation of WTI or 
other Wilms' tumor genes in the metanephric blastema can give rise to foci of 
ectopic bone, muscle and adipose tissue. 
Desmoplastic small round cell tumour (DSRCT) is associated with the fusion of the 
N terminus of the EWS gene to the C terminus of WTI. This tumour also occurs in 
tissues derived from the proliferating coelomic epithelium such as the gonad, 
peritonea and pleura (Gerald et al., 1995; Ladanyi and Gerald, 1994). One 
explanation for sites of DSRCT generation by the chimeric protein is that the tumour 
is generated where WTI is normally active. The EWS/WT1 protein may interact with 
the members of the same cellular pathway as WTI. One case of DSRCT has been 
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reported in the brain; perhaps this tumour was generated from a region which is 
expressing WT470LZ and hence potentially Wtl (Tison et al., 1996). 
Fig. 38 WTI is expressed in the mesenchymal, but not the epithelial cells which 
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6.4.2 Wtl in metanephric organogenesis. 
The WT470LZ and WT280LZ transgenes show the same pattern of expression as the 
Wtl gene during metanephric nephrogenesis. During the process of nephrogenesis the 
proximal part of the S-shaped body matures into the podocyte cells of the 
glomerulus. This process is associated with upregulation of 
Wtl/WT470LZIWT28OLZ expression. It is this stage which is blocked during 
metanephros formation in WT280 partially rescued mice. As metanephros formation 
occurs normally until this stage, the partially rescued kidney demonstrates a role for 
the Wtl gene in nephrogenesis which differs from that demonstrated in Wt] knockout 
mice. Wtl is required for the final maturation of the glomerular podocytes epithelium 
during nephrogenesis. Although epithelial structures form in Wilms' tumours which 
represent different stages of nephrogenesis no structures corresponding to mature 
glomerulus form (Pritchard Jones and Fleming, 1991). Perhaps the glomeruloid 
bodies seen in some Wilms' tumours are equivalent to the furthest stages of 
nephrogenesis seen in the WT280 partially rescued kidneys. 
6.4.3 Wtl function in the adrenogenital primordium. 
The adrenogenital primordium lies within the mesonephric ridge (Hatano et al., 
1996). WT470LZ, and by implication Wtl, is expressed in the adrenogenital 
primordium from its origin at E9.5. As the primordium splits, WT470LZ expression 
is lost in the adrenal part remaining only in the gonadal part (Fig. 23). Loss of Wt  
expression in the developing foetal adrenal cortex may be involved in specifying the 
differences between adrenal and gonadal developmental pathways. 
In Wtl knockout mice, partially rescued with the WT280 transgene, formation of the 
gonad or adrenal gland does not take place. Wt] is expressed in the adrenogenital 
primordium but is no longer expressed at later stages of adrenal formation. Wtl 
function in the adrenogenital primordium is therefore required for later adrenal gland 
formation. It is not clear what happens to the adrenogenital primordium in Wt] 
homozygous null mice. It may undergo apoptosis or simply fail to proliferate and 
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remain as a rudimentary structure. By analogy to the phenotype seen in the 
metanephric blastema of a Wt] homozygous null embryo, expression of Wt] may be 
required to allow the primordium to transduce and respond to a proliferative signal. 
Alternatively Wt] may simply be required for primordium proliferation itself. 
Given the requirement for Wtl in the adrenogenital primordium to allow adrenal 
formation, the loss of Wt] expression from this primordium would also be expected 
to prevent gonadal development. However this may not be the case. Reinterpretation 
of the Wtl knockout mouse data provided by Kreidberg etal., 1993 indicates that the 
gonad starts to extend into the coelomic epithelium, and may begin to form some 
internal structure, before it is lost. If the gonadal mesenchyme does begin to form 
before receding, there may be parallels between the effects of Wt] loss on the 
development of the gonad, and on the metanephros. Perhaps the gonad begins to 
develop but undergoes apoptosis in the absence of an inductive signal. Such a signal 
may come from the development of the rete testis/ovarii or alternatively the primary 
sex cords. On the other hand it may not be the lack of a signal which causes the 
apoptosis but the failure of the gonadal mesenchyme to respond to it. 
6.4.4 The role of the Wt] gene in sex determination. 
Severe genital and gonadal abnormalities are associated with (both XY and XX) 
patients suffering from Denys-Drash syndrome. In addition to malformed or 
ambiguous external genitalia patients may have streak gonads or ovo-testes. In these 
patients the process of primary sex determination i.e. Sertoli cell formation has been 
disturbed. Circumstantial evidence that WT 1 may play a role in the formation of 
Sertoli cells comes from a study of WT 1 gene expression in the urodele amphibian 
testis (Del Rio-Tsonis et al., 1996). In urodeles, in regions termed regenerating cysts, 
testicular duct cells appear to engulf germ cells and differentiate into Sertoli cells. 
WTJ is expressed in these duct cells during this process. 
WT470LZ is not expressed in the Sertoli cells (and possibly the granulosa cells) 
whereas endogenous Wt] is (Fig. 25). The sequences required to drive P - 
154 
galactosidase expression in these cells must be missing from the transgene. 
WT470LZ contains the human WT1 gene and promoter. The species specific 
differences between the WTI promoter of humans and mice may be responsible for 
the inability of the WT470 promoter to drive lacZ in Sertoli cells. Support for this 
hypothesis comes from the study of pUSWT1 activity in cell lines. This human 
promoter was able to drive reporter gene expression in human granulosa cells but not 
in murine Sertoli cells. 
The mammalian SRY gene (Ramkissoon and Goodfellow, 1996) provides a good 
example of a gene in which the rapid evolution of species specific differences is 
occurring. It is evolving very rapidly outside its DNA binding domain, and appears to 
undergoing species specific divergence which is faster that the rate of natural drift at 
that locus (Whitfield et al., 1993). SRY is involved in sex determination. It is the 
switch required to force precursor cells to form Sertoli cells and hence trigger all 
subsequent secondary male sexual differentiation. In the absence of SRY a default 
female pathway is taken. A murine Sry transgene introduced into XX mice causes 
gonadal sex reversal by driving the differentiation of Sertoli cells in the XX gonad 
(Koopman et al., 1991). However a human SRYtransgene is unable to do the same 
although it is expressed at the right place and time. Rapid species specific evolution 
of genes involved in sex determination may aid the process of speciation by causing 
intraspecific hybrid sterility. 
Wtl is expressed in the gonadal ridge before the onset of Sry expression. However 
perhaps Sry binding on the Wtl promoter and its association with other species 
specific factors may be responsible for the Wtl expression in Sertoli cells. The 
murine Wtl promoter contains a putative Sry/SRY binding site AACAAT (Harley et 
al., 1994) (Fig. 8) although no such sequence is present in the human promoter. 
The Sox9 gene is co-expressed with both Wtl and Sry in the gonadal ridge and is 
involved in sex reversal and Campomelic dysplasia (Ramkissoon and Goodfellow, 
1996). Following male gonadal sex determination Sox9 expression becomes localized 
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to Sertoli cells. A human derived YAC covering the SOX9 locus, as with WT470LZ, 
was unable to drive expression of a lacZ reporter in Sertoli cells (V. Wunderle pers. 
comm.). This raises the possibility that Sry, Wtl, and Sox9 could all be part of a 
species specific co-evolving group of genes. 
6.4.5 Wtl in limb development. 
Wtl is expressed in the limb musculature and throughout developing epaxial 
musculature of the embryo (Fig. 29). WT470LZ is expressed in these domains 
although it is unclear in which cell type. The transgene does not mark all myogenic 
cells. Perhaps Wtl expressing tissue is repressing the myogenic pathway, as has been 
discussed by Hastie, 1994. The anterior, posterior and interdigital apoptotic zones of 
the developing limb also express Wtl (Fig. 35). They represent sites where apoptotic 
cell death occurs during the process of limb morphogenesis (Zakeri and Ahuja, 
1994). Expression of Wtl in these domains suggests that the gene may be involved in 
patterning the developing limb. WT470LZ does not appear to be expressed in the 
interdigital undergoing apoptosis. Its expression appears to be in cells adjacent to 
those which are apoptotic. It is first expressed in the proximal part of the interdigital 
mesenchyme whilst the distal part undergoes apoptosis. WT470LZ then becomes 
localized alongside the developing digits as the apoptosis of the interdigital 
mesenchyme spreads proximally. Wt] may be involved in limiting the region of 
death. Its expression comes on first in the proximal interdigital mesenchyme which is 
last to die. Furthermore, in Wtl knockout and partially rescued mice, apoptosis 
appears to be the default pathway taken by some tissues which would normally 
express the gene. Interestingly when cell death in the interdigital regions of chick 
embryos is blocked the default pathway for these cells is chondrogenesis (Zou and 
Niswander, 1996). In correlation with this finding tumours loss of WTI expression in 
some Wilms' can lead to the aberrant differentiation of metanephric blastemal stem 
cells into muscle and cartilage. 
156 
6.4.5.1 Are any limb defects related to WTI mutation in humans? 
The observed interdigital expression of Wtl described in this thesis may be of clinical 
relevance. A strong correlation between sporadic Wilms' tumours and exostoses in 
patients has been noted (Hartley et al., 1994). Exostoses are benign enchondromata 
which consist of cartilage capped osseous projections especially from the long bones 
of a patient. They are rarely present at birth but develop within the first decade of life. 
The expression pattern of WT470LZ laying alongside the developing bones of the 
limb and thorax raises the interesting possibility that WTI may be involved in the 
suppression of exostoses development. 
Recently a gene (EXT2) involved in hereditary multiple exostoses was isolated from 
11p12 (Wuyts et al., 1996). In at least one case of a Wilms' tumour patient with 
exostoses the individual had a deletion of llpll.2-pl4..2 (Bartsch et al., 1996). 
Hence in this case ETX2 lies within a contiguous deletion including other loci 
involved in the WAGR syndrome. However disruption of EXT2 is unlikely to 
explain exostoses formation coincident with a number of sporadic Wilms' tumour 
cases. 
6.4.6 Potential developmental roles for Wt] in mesodermally 
derived organs. 
6.4.6.1 Wt] may be involved in the mesenchymal to epithelial cell type 
transition. 
The expression of Wt] in a number of tissues which undergo a mesenchymal to 
epithelial cell type transition lead to the suggestion that it plays a role in this process 
(Armstrong et al., 1992). In support of this theory, data from A. Schedl (this thesis) 
demonstrates that Wtl is required for the final stages of epithelial maturation in the 
glomerular podocyte cells. 
A general role for Wtl in the mesenchymal to epithelial cell type transition process 
seems unlikely given the expression pattern of the WT47OLZ transgene. The 
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glomerular podocytes and the rete testis/ovarii represent the only structures which 
express WT470LZ when undergoing this process. Interestingly both the glomerular 
podocytes and the rete testis/ovarii are derived from tissue which is already 
expressing Wt]; the level of Wt] expression is upregulated during their formation. 
Other epithelial tissues derived from mesenchymal cells e.g. the cornea or coelomic 
epithelium (mesothelium) do not express Wtl whilst forming and form in the Wt] 
knockout mouse (Kreidberg et al., 1993). WT1 cannot be involved in the 
mesenchymal to epithelial cell type transition in these tissues. The idea that WTI 
does not play a role in this transition in the mesothelium is supported by Langerak et 
al. They found no correlation between WTI expression levels and epithelial 
characteristics in mesothelial cell lines (Langerak et al., 1995). 
The role of WT1 in controlling a mesenchymal to epithelial cell type transition during 
nephrogenesis is also not clear. Epithelial structures are found within Wilms' 
tumours which have lost both copies of the WTI gene. Although in these cases it 
does remain unclear as to whether such structures have undergone the full epithelial 
maturation programme. No structures representing mature glomeruli are found in 
Wilms' tumours (Pritchard Jones and Fleming, 1991), supporting a role for WTI in 
the final podocyte maturation step. 
If WTJ does not have a general role in mesenchymal to epithelial transitions what 
else might it be doing? Perhaps WTI may play a role in mediating the processes of 
proliferation and apoptosis. The WT470LZ transgene is expressed in all the 
mesenchymal derivatives of the proliferating coelomic epithelium (Fig. 38). It is also 
expressed in the proliferating coelomic epithelium itself. Potentially, the gene could 
be promoting the proliferation of these tissues, although these tissues do form in the 
Wtl homozygous null mice. Expression of Wtl in the interdigital regions of the 
embryo suggests that WTI has a role in mediating the process of apoptosis. In 
support of this hypothesis, the developing metanephros undergoes apoptosis in the 
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Wt] knockout mice. In these animals furthermore, the lack of Wt] expression in the 
pericardium, pleura and septum transversum may also lead to increased apoptosis. 
6.4.6.2 WTI may interact with the Bone Morphogenetic Proteins. 
Bone morphogenetic proteins, (BMP5), are presently the molecules most favoured to 
play a major role in controlling apoptosis and patterning in the developing vertebrate 
limb. BMPs are secreted signalling molecules which are members of the TGFI3 
superfamily. Bmp2, Bmp4 and Bmp7 are all expressed in the developing mouse limb. 
Bmp7 and Bmp2 in particular become localized alongside the developing digits in a 
very similar expression domain to that of Wtl (Hogan, 1996). Studies of BMP 
signalling in the chick limb also imply that this process has an important role in 
control of both interdigital cell death and chondrogenesis (Yokouchi et al., 1996; 
Macias et al., 1997; Zou and Niswander, 1996; Kawakami et al., 1996). Bmp7 and 
Wt] potentially interact in mediating metanephric nephrogenesis (see introduction). 
Perhaps Wtl and Bmp7 also interact in controlling apoptosis in the interdigital 
regions. 
In addition to Wtl interaction with BMP molecules during nephrogenesis and limb 
patterning, BMP molecules could potentially induce WTI expression in mesodermal 
patterning. BMP4 plays a major role in mesoderm formation and patterning in 
Xenopus embryos (Hogan, 1996) where xWTJ may mark the site of intermediate 
mesoderm formation (Carroll and Vize, 1996). In chick BMP4 may also play a role 
in patterning the mesoderm (Takahashi and Tonegawa, 1997), and WTI again marks 
the site in intermediate mesoderm development (Kent et al., 1995). In mice, the 
majority of homozygous null Bmp4 embryos die around the time of gastrulation 
without making any embryonic mesoderm (Winnier et al., 1995). A few Bmp4 
knockout embryos survive to the forelimb bud stage. In these embryos, the mesoderm 
is highly disorganized and it is not clear if an intermediate mesoderm forms. As the 
WT470LZ transgene is a marker of the intermediate mesoderm, crossing it onto 
Bmp4 knockout mice would give an indication of whether intermediate mesoderm 
formation is occurring. 
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Examination of transgenic embryos expressing the WT470LZ and WT280LZ 
transgenes has identified Wt] activity in several lineages. It is expressed in the 
mesenchymal derivatives of the coelomic epithelium, the somatopleuric mesenchyme 
of the limbs, in developing epaxial muscles of the embryo and in the ectodermal 
tissue of the CNS. Evolutionarily all of these expression domains are conserved at 
least as far as alligator and chick (Kent et al., 1995). Is there any way of rationalising 
why the gene may be expressed in such a diverse range of cell types? If Wtl is part of 
a BMP mediated signalling pathway, then acquisition of elements responsive to BMP 
may help to explain the expression pattern of the gene in the higher vertebrates. The 
acquisition of responsiveness to BMP signalling has previously been suggested to be 
responsible for the recruitment of the Msx genes to limb pattern formation (Davidson, 
1995) and perhaps the same may be true for Wtl. In addition BMP signalling could 
drive gene expression during the formation of the intermediate mesoderm and in 
parts of the nervous system (for example the neural crest (trigeminal mesencephalic 
cells) and the eye). 
6.4.7 A potential role for Wt] in patterning. 
Expression of Wtl during the process of nephrogenesis and in the developing nervous 
system implies that it may have a role in the process of patterning. 
Following condensation of the metanephric blastema at the tip of the branches of the 
ureteric bud, the Wt] positive renal vesicle forms. The vesicle is already patterned at 
this early stage of nephrogenesis. Cells adjacent to the ureteric bud express E-
cadherin whilst more distal cells express K-cadherin. By the S-shaped body stage, 
proximal cells express E-cadherin, distal cells Wtl, and those in the middle K-
cadherin. Mesenchymal cells which do not form epithelium lose Wtl expression and 
express the forkhead transcription factor BF2 (Lechner and Dressler, 1997). 
An interaction between Wtl and Pax2 has been proposed to occur during 
nephrogenesis. Wt] and Pax2 are co-expressed in the renal vesicle and then Pax2 is 
down regulated in the distal part of the S-shaped body concurrent with Wtl 
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upregulation in this structure (Eccles et al., 1995). An interaction between Pax2 and 
Wt] may also occur during patterning of the spinal cord. Pax2 is expressed 
throughout the neural tube from E 1 except in a small domain in the ventral part 
(Nornes et al., 1990) This ventral domain seems to be convergent with the domain of 
the cord in which Wtl is expressed. Double staining WT47OLZ with anti Pax2 
antibodies will allow this relationship to be investigated further. 
In the developing spinal cord WT470LZ/Wtl is expressed in similar fields to the lim 
domain genes (Tsuchida et al., 1994; Tanabe and Jessell, 1996). Expression in these 
domains implies that Wtl is not involved in the generation of neurons but in their 
subsequent patterning. Wtl may be co-expressed in a domain of Lim3 positive 
interneurons. Lim3 expressing neurons arise in the ventricular zone of the neural tube 
expressing Pax6. They fail to develop in homozygous Pax6 mutant embryos (Sey&5 
(Ericson et al. 1997). Given this information we are now undertaking a study to look 
at the state of Wtl expression in the neural tube of Sey d  embryos. 
Interactions between lim domain genes and Wtl may also be involved in patterning 
the embryonic mesoderm. Limi is expressed within the presumptive lateral and 
intermediate mesoderm at E7.5 of mouse development, it becomes localized to the 
intermediate mesoderm a day later (Barnes et al., 1994). At later stages Limi is 
expressed during mesonephric and metanephric nephrogenesis (Fujii et al., 1994). 
Expression of Lim] precedes that of Wtl within this structure. In the absence of Limi 
expression, no formation of the pronephros or the mesonephros occurs and the 
embryos die at about E 1 (Shawlot and Behringer, 1995). 
In the eye WT470LZ is again expressed in a Pax6 positive domain of neuron 
generation (Mugnaini and Floris, 1994). This putative Wtl eye expression domain in 
the proximal part of the neuroretina, is also adjacent to Pax2. At E14 Pax2 is 
expressed in the optic stalk and most proximal part of the neuroretina. At E18 Pax2 
expression is found on the innermost cells of the proximal neuroretina (Nornes et al., 
1990). 
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In the developing cerebellum Wtl is expressed in cells of the roof of the fourth 
ventricle at E12.5. Here again Wt] is probably co-expressed with Pax6 and in a 
domain adjacent to but exclusive from Pax2 (Stoykova and Gruss, 1994). WT470LZ 
activity is seen in the Purkinje layer of the adult cerebellum and in a few scattered 
cells of the granular layer. Pax6 continues to be expressed in the internal granular 
layer in the adult whilst the Golgi cells which come from the same precursors as the 
Purkinje cells do not express W7470LZ but do express Pax2 (Stoykova and Gruss, 
1994). Since the completion of the study for this thesis we have detected strong 
expression of Wt  within the cells of the Purkinje layer by immunohistochemistry. In 
keeping with the scattered expression of lacZ positive cells in the granular cell layer, 
Wt  is also present but to a much lesser extent in these cells. The localisation of the 
Wtl protein in both the Purkinje and granulosa cells is not nuclear but solely 
cytoplasmic. This unusual cellular localisation for the Wt  protein raises the exciting 
the possibility that Wt  may be involved in RNA metabolism in these cells. 
6.5 Future work on the developmental role of WTI. 
One of the most important future pieces of work to carry out is the evaluation of 
WT470LZ expression in the brain of both the lines A and H. The transgene 
expression seen in these lines then needs to be correlated with that of the endogenous 
Wtl locus by a mixture of mRNA in situ hybridization and immunohistochemical 
analysis. 
I also wish to further investigate the expression of Wtl in the spinal cord. This will 
require double labelling of the spinal cord with either Wtl or P galactosidase 
antibodies and markers of a number of neuronal populations within the cord (e.g. 
Lim I, Lim3 and Pax2) (Tanabe and Jessell, 1996). The target of any axonal 
projections which come from the population of Wtl positive neurons in the spinal 
cord and other neurons in the brain can be investigated by the use of a tau-lacZ 
cassette targeted in the WT470 WTI locus. The protein encoded by this tau-lacZ 
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construct binds microtubules and is transported down the axons of labelled neuronal 
cells (Mombaerts et al., 1996). 
The WT470LZ transgene is a good marker of cells in an embryo either expressing 
WTI or which are able to express the gene. Hence the WT47OLZ transgenic animal 
provides a useful tool to analyze the fate of these cells on different genetic 
backgrounds. I am crossing the WT470LZ transgene onto the Wt] knockout 
background. Preliminary results (Chapter 5) indicate that the transgene may not be 
expressed on this background at midgestational stages. If this is the case WTI may be 
positively autoregulated at these stages of development. If the WT470LZ transgene is 
expressed on the WTI knockout background then it will be a useful marker to follow 
the fate of the cells which normally express the gene. This may be particularly useful 
in determining what happens to the pleura and pericardial tissues in the Wt] knockout 
animal. It is defects in these tissues which may be responsible for the Wtl 
homozygous null embryonic lethality (Kreidberg et al., 1993). Furthermore it will be 
interesting to investigate any alterations which occur in the development of the spinal 
cord and brain in the Wt] homozygous null embryo. Any such alterations are not 
apparent by normal morphological analysis. Subtle alterations may be difficult to 
detect even using the WT470LZ marker. For example En  interneurons do not 
require En 1 function for their early survival or differentiation (Matise and Joyner, 
1997). In the same way Wt] expression in neurons may not be required for their 
generation or maintenance but instead for a later stage of development such as correct 
axonal targeting. In this eventuality a tau-lacZ transgene will be required to ascertain 
any neural defects in the Wtl knockout animal. 
Neurons which express Wt] are generated in the Pax6 positive domain of the spinal 
cord. The patterning of the spinal cord is altered in Sey (Pax6 null) animals. In 
particular Lim3 positive neurons which arise in the Pax6 positive domain in wildtype 
animals have an altered fate in Pax6 null animals (Ericson et al. 1997). Hence I am 
presently crossing the WT470LZ transgene onto the Seyed  mutant background. 
However, as with the cross of the transgene onto the Wt] knockout background, any 
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alterations in neuronal patterning may be easier to ascertain using a tau-lacZ 
containing YAC transgene. 
A reporter gene driven by WT470 mimics the endogenous expression pattern of WTI. 
Hence WT470 may be used as a promoter to investigate the lineage of cells in organs 
in which Wtl is expressed. A lacZ cassette in which the first 289 bp of the lacZ gene 
is duplicated (LaacZ) has been inserted into 800/4 (C. Miles pers. comm.). 
Duplication of the first 289 bp of lacZ creates a stop codon and the LaacZ gene is 
unable produce an active product. With a very low frequency in mammalian cells (1-
2 x 106)  intragenic recombination between the direct repeat in this cassette occurs. 
Recombination within the LaacZ gene produces reconstitutes an active lacZ locus 
and hence an active 3 galactosidase enzyme (Bonnerot and Nicolas, 1997; Nicolas et 
al., 1996). This WT470LaacZ transgene will be useful for investigating the 
distribution of cells produced by the proliferating coelomic epithelium in the 
pericardium, pleura and peritoneum. It may also help investigate whether cells and at 
different point in kidney and gonad development become restricted in the set of 
tissue types which they can form. Such a restriction has been proposed to operate in 
the kidney (Qiao et al., 1995). This transgene will also be to address the level of 
contribution of mesonephric tissues to the developing gonad. A question which has 
proved intransigent to study (Buehr et al., 1993; Satoh, 1985; Satoh, 1991). 
WT470LZ is not expressed in the Sertoli cells of the gonad. Similarly a SOX9 YAC 
transgene driving a lacZ reporter is not expressed in these cells. This raises the 
possibility that there has been a species specific evolution of regulatory sequences 
which drive expression of these genes in the Sertoli cells. The Sry/SRY gene, 
responsible for male sex determination in mammals is expressed in the Sertoli cells. 
Sry contains an HMG (High Mobility Group) box capable of sequence specific 
binding. Introduction of mouse Sry gene can cause sex reversal in female mice. The 
human SRY gene however is unable to cause the same effect (Koopman et al., 1991). 
Recent evidence implies that this difference between the mouse and human Sry genes 
in this assay is inherent to a region of the protein in the C terminal domain outwith 
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the HMG box (Bowles et al., 1997). We intend to cross mice expressing the human 
SRY gene onto lines carrying WT470LZ or the SOX9 transgene. If 0 galactosidase is 
then expressed in the Sertoli cells of the resultant offspring of these crosses it would 
demonstrate that the regulatory framework of the WD and SOX9 gene is co-evolving 
with the SRY protein. 
YACs are very useful for transgenic experiments because of their large insert size 
and the ease with which inserts can be altered by homologous recombination. 
However they have a number of drawbacks including a tendency to re-arrange and be 
chimeric. The reason that a human YAC covering the WTI locus was used in this 
study was because a YAC of the homologous mouse locus was unstable. Bacterial 
artificial chromosomes (BAC5) have a large insert size up to 350 kb (Peterson et al., 
1997). They are however, very stable. A recent technological advance means that it is 
now possible to carry out accurate homologous recombination in BACs at a high 
frequency (N. Heintz pers. comm.). Therefore it may be easier in the future to use a 
BAC construct for the type of transgenic analysis detailed in this thesis. To this end 
we shall screen a mouse BAC library to attempt to get BACs spanning the WTI 
locus. 
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7. Materials and methods. 
7.1 Bacterial Cell Culture and Plasmid DNA Preparation. 
7.1.1 Media and solutions. 
All chemical were supplied by BDH unless otherwise stated. All media were 
sterilised by autoclaving. Solution and media are made up as described in Sambrook 
et. al., 1989 unless otherwise stated. 
L-broth (LB) :In 1 litre water dissolve lOg tryptone, 5g yeast extract, lOg NaCl, 2.46g 
MgSO4 . 
L-agar: In 1 litre water dissolve lOg tryptone, 5g yeast extract, lOg NaCl, 2.46g 
MgSO4, 15g agar (Oxoid Ltd). 
Ampicillin (Sigma) :Make stock at 50mg/ml in dH20, filter sterilise. Store at -20°C. 
Use at final concentration 50pg/ml. 
X-Gal (Sigma): Make stock at 20mg/ml in DMF (Sigma). Store protected from light 
at -20'C. Use at final concentration of 40p.g/ml. 
IPTG (Sigma): Make stock at 100mM. Store protected from light at -20°C. Use at 
final concentration of 0.5mM. 
7.1.2 Growing bacterial cells on agar plates. 
The desired volume (up to -200111) of bacterial cells is pipetted onto the surface of 
the L-agar, and is then spread by a sterile bent glass rod until the liquid has 
thoroughly soaked into the agar. (If more cells than are contained in 200p.l are 
required, the cells may be concentrated by 1 min centrifugation in a microfuge 
followed by resuspension of the pellet in a smaller volume). The plates are then 
inverted and incubated for 12-16 hours at 37°C. Cells were viable from plates stored 
at 4°C for several weeks. 
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7.1.3 Preparation of plasmid DNA. 
Small scale - The desired colony on an agar plate was used to inoculate 6m1 of LB 
plus ampicillin and was grown at 37°C overnight with continuous shaking at 250rpm. 
These cells were then harvested and purified with a QlAprep Spin Plasmid Kit 
(Qiagen) as per manufacturers instructions. 
Large scale - The selected bacterial colony was grown overnight at 37°C in a 400ml 
for a further overnight culture. The culture was then centrifuged in 50m1 volumes at 
4000rpm for 20mins at 4°C. These cells were then harvested and purified with a 
Qiagen Plasmid Kit (Qiagen) as per manufacturers instructions. 
7.2 Enzymatic Manipulation of DNA. 
7.2.1 Solutions. 
TE: 10mM Tris, 1mM EDTA. 
7.2.2 Restriction enzyme digestion of genomic DNA. 
Digestions of DNA with restriction endonucleases were carried out in the appropriate 
buffer at the recommended temperature. Restriction enzymes were supplied by 
Boehringer Mannheim, NEB and Gibco BRL. lp.g of DNA was digested in 10-20jtl 
using 1-2 units of enzyme for 1 1/2 hours. Genomic DNA was digested overnight with 
the addition of 1/20 volume 0. 1M spermidine (Sigma). If two different enzymes were 
used, both of which required the same buffer, the digests were carried out 
simultaneously. Otherwise, after digestion with one enzyme, the sample was ethanol 
precipitated and then resuspended. The appropriate buffer was then added and the 
second digestion carried out. When necessary, reactions were terminated by heating 
to 68°C or 80°C for 15 minutes, according to the heat sensitivity of the enzyme. 
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7.2.3 Dephosphorylation of 5' termini. 
Calf intestinal phosphatase (CIP) was used to dephosphorylate the 5' ends of the 
vector molecules before cloning. This prevents recircularisation of vector molecules 
during the ligation step. 
7.tg DNA was dephosphorylated with 0.1 unit CIP (Boehringer Mannheim) in 50jil 
lx CIP buffer (10mM Tris.HC1, pH 8.3, 1 m ZnC12, 1mM MgC12) at 37°C for 30 
mins. The reaction was stopped by the addition of 1.t1 of 0.5M EDTA. The 
dephoshorylated DNA was then extracted with 1:1 phenol:chloroform and ethanol 
precipitated. The pellet was resuspended in lOj.tl TE. 
7.2.4 Ligation of cohesive termini. 
On ice, the insert DNA and the vector DNA were mixed, typically in a ratio of 5:1 
vector to insert. lO-lOOng of vector DNA was normally used. The reaction was 
carried out in 10-50iil using 0.1 unit of bacteriophage T4 DNA ligase (Boehringer 
Mannheim). in lx ligase buffer (66mM Tris.HC1, pH 7.5, 5mM M902, 1mM DTT, 
1mM ATP). The ligation mixture was then incubated at 16°C overnight, or at RT for 
2 hours. 
7.3 DNA electrophoresis. 
7.3.1 Electrophoresis solutions. 
20x TBE: 1M Tris.HC1, pH8.0; 20mM EDTA; 1M boric acid, pH8.3. 
20x TAE: 0.8M Tris.HC1, pH 8.0; 20mM EDTA; 0.4M acetic acid. 
lOx DNA Loading Buffer: 20% Ficoll (Pharmacia), 100mM EDTA, orange G 
(Sigma). 
7.3.2 Agarose gel electrophoresis. 
DNA molecules were separated according to their size on horizontal agarose medium 
gels (SeaKem LE, FMC Bioproducts). The percentage of agarose used to make the 
gel depended on the size range of the DNA molecules to be resolved. Digested 
genomic DNA or plasmid DNA was commonly run on 0.8% agarose gels, whereas 
smaller fragments, such as most PCR products, were run on 1-2% agarose gels. All 
agarose gels were made with and run in lx TAE. 1/10 of the sample volume of lOx 
loading buffer was added to the DNA prior to loading the sample on the gel. Either 
mini gels (30m1 agarose) or midi gels (120m1 agarose) were used depending on 
requirements. Gels were run at 25-80V, in Hybaid gel tanks, depending on resolution 
and run-time required. 250ng of the appropriate size marker was used per gel. Size 
markers used were: ?. DNA digested with Hind ifi (Boehringer Mannheim) or OX174 
digested with Hae ifi (Boehringer Mannheim). 
After electrophoresis, DNA was stained by gently agitating the gel in running buffer 
containing 250pg/m1 ethidium bromide for 20 minutes. DNA fragments were 
visualised on a mid range UV transilluminator and photographed using a video copy 
processor (Mitsubishi). 
7.3.3 Purification of DNA from agarose. 
Following a run, gels were viewed on a mid range UV transilluminator and the 
required fragment was excised using a sterile scalpel blade. This was done as quickly 
as possible to minimise UV nicking of the DNA. Care was taken to ensure that a 
minimum of agarose was excised with the required DNA band. DNA was isolated 
from the gel slice using the QIAEX Gel Extraction Kit (Qiagen) as per manufacturers 
instructions. 
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7.3.4 Pulsed field gel electrophoresis. 
Agarose plugs were washed once in TE and equilibrated to the running buffer (0.25x 
TBE) over three hours. A 1% agarose (MP agarose, Boehringer Mannheim) gel was 
made up in 0.25x TBE and the plugs inserted into the wells. The wells were sealed 
with 1% LMP agarose and the gel run in pre-cooled sterile 0.25x TBE at 12°C. Gels 
were run using the Chef-DR II pulse field tank and control module (Biorad). PFGE 
conditions used for WT470, WT470LZ, WT280 and WT280LZ: Initial time 22, end 
time 30, voltage 200V. 
7.4 Cloning of DNA Molecules into Plasmid Vectors. 
7.4.1 Strain of bacteria used. 
The competent cells were made from E.coli, strain XL1-Blue (Stratagene). The 
genotype of XL1-Blue cells is: recAl endAl gyrA96 thi-1 hsdR17 supE4 relAl lac 
[F' proAB lacr ZM15 TnlO (Tet')] 
7.4.2 Preparation of competent cells. 
Using a sterile loop, XL 1-Blue bacterial cells from a frozen stock were streaked out 
onto a fresh L-agar plate and grown at 37°C overnight with continuous shaking at 
250rpm. One of the resulting colonies was then used to inoculate lOmls of LB plus 
tetracyclin, which was left at 37°C in a shaking incubator overnight. This whole 
culture was then used to inoculate 11 of LB plus tetracyclin, and this was grown 
shaking at 37°C. The absorbance at 600nm of the culture was continually checked on 
a spectrophotometer. 
The cells were harvested when the Abs 600 was between 0.5 and 1.0, which is still in 
the log phase of growth. The flask containing the culture was then chilled on ice for 
15-30 mins then the contents were centrifuged in ice cold SOml Falcon tubes for 15 
mins at 4000rpm at 4°C. The supernatant was discarded and the pellets resuspended 
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in a total of 11 of sterile water before centrifugation as before. The pellets were 
resuspended in a total of 500m1 sterile water and re-centrifuged. Pellets were then 
resuspended in 20m1 of sterile distilled water and centrifuged again. The final 
resuspension was in 2-3m1 of sterile distilled water or 10% glycerol. This cell 
suspension was then aliquoted into 40il volumes in 1 .5m1 eppendorf tubes. Cells 
resuspended in water were used immediately. Cells in glycerol were snap frozen on 
dry ice plus methanol (Fisons) and stored at -70°C. 
7.4.3 Plasmid vectors. 
The plasmids vector used were pBluescribe (pBS; Stratagene) and pUC18. 
pBluescribe is a 2746bp plasmid derived from (Yanisch-Perron et al., 1985). pUC18 
is the same as pUC19 but with the multiple cloning site inverted. 
7.4.4 Electro-transformation of competent cells. 
An aliquot of competent cells was thawed on ice, and then the transforming DNA 
(usually 1tl of the ligation reaction) was added, mixed with the cells and left on ice 
for 1mm. This was then transferred to an ice-cold cuvette (Flowgen) and subjected to 
a pulse of 2.47kV in a BioRad Gene Pulser. The cells were swiftly mixed with lml of 
LB, transferred to an eppendorf tube and left at 37°C for lhr to enable the cells to 
begin to express the ampicillin resistance gene conferred by the transformed plasmid. 
Aliquots of several different volumes were then spread onto L-agar plus ampicillin 
plates and incubated overnight at 37°C. 
7.4.5 Selection for colonies that contain recombinant plasmids. 
Selection was by a simple process of blue/white selection. The polylinker of the 
vector pBS interrupts the 3-galactosidase producing gene, lacZ. However the 
disruption is in-frame and results in a harmless insertion of a few amino acids into 
the f3-galactosidase gene. Expression of this gene within bacterial cells can result in 
the production of a blue colour if the medium on which the cells are grown contains 
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the chromogenic substance X-Gal and the derepressor of the lac operon, IPTG. If 
however the polylinker site in the plasmid is interrupted by an insert of foreign DNA, 
a functional -galactosidase enzyme cannot be transcribed and hence the resultant 
colonies are white. 
7.4.6 Ethanol precipitation. 
To concentrate DNA and remove salts, a 1/10 volume of 2M NaAc, pH 5.5 was 
added to the DNA solution, followed by 2-2 1/2 volumes of 100% ethanol at -20°C 
(alternatively 0.7 vols of isopropanaol can be used). The contents of the tube were 
mixed and then chilled at -20°C for ihour to overnight. The tube was then 
centrifuged at 11,000rpm for 15 mins at 4°C. The supernatant was poured off, and 
the pellet dried under vacuum. The pellet was then resuspended in the desired 
volume of dH20 or TE. 
7.5 Manipulation of Yeast. 
All protocols in this section are adapted from Schedl et. al. 1996a. 
7.5.1 Media and solutions. 
SE: 1M Sorbitol, 20mM EDTA pH8 
TENPA: 10mM Tris pH7.5, 1mM EDTA pH8.0, 1000mM NaCl, 30p.m spermine, 
70p.m spermidine. 
Microinjection buffer (IB): 10mM Tris pH7.5, 0.1EDTA pH8, 100mM NaCl, 30j.tM 
spermine, 70p.M spermidine 
For 11 of medium: 20g glucose, 6.7g D.O.B. 2% raffinose (BlO 101 Inc)-Yeast 
nitrogen base for use with drop out media, amino acids (Sigma) added minus those 
required for selection as described in Markie, 1996. Autoclave the resulting mixture. 
If plates are required instead of liquid media add 1% Bacto-agar (Oxoid) before 
autoclaving and pour plates whilst the agar is still molten. 
172 
7.5.2 Lithium Acetate yeast transformation. 
Yeast was grown to approx. 2x10 7 cells/ml, lOmis of cells are required for each 
transformation. The cells were span for 2000rpm 5n -tins then washed in 1/2 vol. of 
0.1MLiOAcin TEpH7.5. They were the resuspended in 1/100 volume of 0.1M LiOAc 
in TE pH7.5 and gently agitated for lhr. Following this the cells were aliquoted and 
ltg of transforming plasmid DNA added per 0.1ml of cells, lOjil of sheared 
deproteinized carrier DNA was also included in the reaction. These cell were then 
incubated for 30mins at 300C. Next 0.7m1 of 40% PEG 3300, 0.1MLiOAc in TE 
pH7.5 and was added and mixed well. (40% PEG is made by autoclaving a stock of 
44% PEF and adding 1/10 volume of 1MLiOAc inTE pH7.5 when the solution is 
cool). The cells were then incubated lhr at 30 0C followed by heat shock of 42 0C in a 
water bath for 5 mins. The cells were then harvested by spinning 2000rpm for 5mins 
(or microfuge 5s) and washed in TE. The cells were then resuspended in 0.2-0.4ml of 
TE or sterile water and 0.2m1 plated on a selective plate. The plates were incubated at 
300C for 2-3 days whilst transformants grew up. 
7.5.3 Preparation of yeast plugs. 
5m1 of SD medium was inoculated with yeast and grown until late log phase (2-3 
days, 300C, 250rpm agitation). A solution of 1% Seaplaque GTG LMP agarose 
(FMC) in SE buffer containing 14mM 3 mercaptoethanol was made up and kept at 
420C until use. Cells were harvested at 4000rpm for 5mm (Sorvall RT6000) and the 
pellet resuspended in 50m1 of SE buffer. The cell suspension was transferred into a 
50ml Falcon tube and washed 2x in SE (4000rpm 5mm). Meanwhile the bottom of 
insert moulds (Pharmacia) were sealed with strips of autoclave tape, they were then 
placed on ice. Following the final wash of the yeast cells the supernatant was 
decanted off. All traces of liquid were removed by cleaning the inside of the tube 
with a paper towel. 200p.l of SE buffer was added to the cells which were then 
resuspended with a cut off yellow tip. 0.5 aliquots were transferred to an eppendorf 
tube and kept at 370C. Just before use 10mg Zymoiyase-100T (ICN Biomedical) was 
dissolved in 2.5ml of the LMP agarose and 0.5m1 of this solution was transferred to 
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the yeast cell suspension. This was mixed thoroughly by pipetting up and down with 
a cut off blue tip, this suspension was kept at 42 0C. Using a cut off yellow tip pipette 
lOOp.l aliquots of the mixture into were transferred to the plug formers on ice and left 
to set for lOmins. Once set the plugs were transferred to SE buffer + 14mM 13 
mercaptoethanol and 1mg/mi Zymolase and incubated 4-6hrs 37 0C. After this period 
the buffer was replaced with 0.2M EDTA, 0.1M Tris pH8, 0.5M NaCl, l%SDS, 
0.5M 13 mercaptoethanol and 1mg/mi proteinase K (BCL Biochemical) using at least 
0.5mlIplug. The plugs were then incubated at 37 0C overnight. Following this 
incubation the plugs were washed for 600mins in TE pH8 until no bubbles from 
SDS solution were left. Plugs were stored in 0.5M EDTA at 4 0C. 
7.5.4 Restriction enzyme digestion of plugs. 
Around 1/3 of a plug (20-40p.l) was melted at 650C with 4p.l of restriction enzyme 
buffer in an eppendorf tube. This tube was then transferred to 37 0C (or temperature 
required for enzyme of choice) and allowed to cool. Then restriction enzyme was 
added and the solution left to incubate overnight. For loading on an agarose gel the 
mixture was heated up to 65 0C and then loaded. 
7.5.5 Isolation of YAC DNA for microinjection. 
The process of the isolation of YAC DNA for microinjection is schematized in Fig. 
39. Stages from the purification of W7280LZ YAC DNA for microinjection are 
demonstrated in Fig. 40. 
PFGE was carried out on yeast plugs loaded in tandem next to one another in the 
preparative lane. After the gel had run the marker lanes on either side of the 
preparative lane including about 0.5cm of the preparative lane were cut off and 
stained in Ethidium Bromide. The position of the YAC was marked under UV with a 
sterile scalpel blade (Fig. 39a, Fig. 40a). The gel was reassembled an the position of 
this mark used as a guide to excise the part of the preparative lane containing the 
YAC. A slice from above the YAC and another below it were also excised to serve as 
marker lanes for the second gel run. The gel slices were positioned on a minigel tray 
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with the YAC slice in the middle and a 4% Nusieve GTG LMP agarose (FMC) gel 
(0.25xTAE) cast around them (Fig. 39b). This is done so that this second gel runs at 
900 to the original PFGE run. The gel was run for 6-8hrs at 4V/cm in 0.25xTAE, 
circulating the buffer. The two marker lanes were cut off and stained to enable the 
localization of the required YAC DNA (Fig. 39c). The concentrated DNA from the 
corresponding position of the YAC DNA lane was then excised. This slice was 
equilibrated on a rocking platform in 20m1 of TENPA buffer for >1.5hrs. All traces 
of buffer were then removed and the agarose melted for 3min at 68 °C. This was the 
centrifuged for lOs, incubated for an additional 5min at 68 °C and then transferred to 
42°C for 5mm. 2U agarase (New England BioLabs) per 0. 1 m of molten gel slice was 
then added and a further incubation of Mrs at 42 °C undertaken. The DNA solution 
was dialysed for lhr on floating dialysis membrane (Millipore, pore size 0.05Eim) 
against microinjection buffer (IB). DNA concentration was determined by checking 
1-2il on a thin 0.8% agarose gel with small slots using ?. DNA of known 

















Fig. 39 Schematic drawing of the two step gel isolation procedure for YAC DNA to use 
for microinjection. 
After Schedi et. al. 1996. (A) After preparative PFGE both sides of the gel are cut off, 
stained in ethidium bromide (hatched areas), and the position of the YAC DNA is marked 
under UV light using a scalpel blade. The gel is reassembled and the region of the gel 
containing the YAC in the preparative lane (hatched box), as well as two marker slices 
containing yeast chromosomes (black boxes) are excised. (B) Gel slices are positioned on 
a gel chamber, embedded in 4% agarose, and standard gel electrophoresis is performed 
at a 900 angle to the PFGE run. (C) Marker lanes are stained to localize the concentrated 
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- 245 
Fig. 40 Steps in the purification of WT280LZ for microinjection. 
(a) Following preparative PFGE marker lanes are cut off and stained and the position 
of WT280LZ marked but cutting out a small piece of gel with a scalpel. (b) Following 
final purification the integrity of the WT280LZ DNA for microinjection is checked by 
PFGE. 
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7.6 DNA isolation from murine tissues. 
7.6.1 DNA extraction from tail tips. 
Once tail tip had been obtained it was immediately placed into 0.5m1 of tail tip buffer 
(1%SDS, 03M NaAc, 10mM Tris pH7.9, 1mM EDTA, 200 jig/ml proteinase K (BCL 
Biochemical). Samples were incubated overnight at 550C. DNA was then extracted 
from the tail tips by ethanol precipitation (section 7.4.6). Alternatively for PCR 
analysis the tips were frozen at -20 0C and then spun 10min at 4 0C in a 
n-iicrocentrifuge. 0.2.tl of the supernatant from this spin could then be used as a DNA 
template in a PCR reaction. 
7.6.2 DNA extraction from adult tissues. 
A kidney was homogenized in buffer (100mM EDTA, 50mM Tris pH8, 1%SDS, 
0.5mg/mi) and further buffer then added up to 25m1. The homogenate was digested 
overnight at 500C. The DNA was extracted once with an equal volume of phenol, 
once with 1:1 phenol:chloroform and once with chloroform. The DNA was them 
ethanol preciptated, spooled and washed in 70% EtOH. After air drying for 15mins 
the DNA was resuspend overnight in -1m1 TE. 
7.7 Transfer of DNA and RNA to membranes. 
7.7.1 Southern transfer. 
DNA was transferred from gels to nylon membranes by capillary blotting. This 
method was adapted from Southern, 1975. 
Gels were photographed next to a ruler to allow for future sizing of DNA fragments. 
The DNA was depurinated by gently shaking the gel in 0.25M HCl for 20 mm. The 
acid was then neutralised by gently shaking the gel in 0.4M NaOH 3x 15mins. A 
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large strip of 3MM filter paper (Whatman) was soaked in 20 X SSC (3M NaCl, 0.3M 
Na3C6H5( 7 .2H20, pH7.0) and placed on a board. The ends of the paper were placed 
in a reservoir of 20x SSC, forming a wick. The gel was placed inverted on top of the 
wet filter paper, then a correctly sized piece of nylon membrane (Biodyne B, Pall), 
was placed directly onto the gel. Four pieces of 3MM blotting paper, pre-soaked in 
20x SSC, were placed on top of the membrane. Air bubbles were removed carefully. 
Any exposed wick was screened off with Saran wrap (Dow Chemical Company), 
then a weighted stack of paper towels was placed on top. Gels were blotted for 
overnight. After blotting, the membranes washed with 2xSSC and then DNA was 
bound to the filter by baking the membranes at 80°C for 1-2 hours. Membranes were 
stored in Saran wrap at 4 °C. 
7.7.2 Transfer of bacterial colonies to filters. 
Nylon (Hybond-N, Amersham) circular filters were laid carefully on the surface of 
the agar plate, so as to avoid air bubbles. The filter was left on the surface for 
approximately lOs. At this point the orientation of the filter on the dish was marked 
by stabbing a needle containing waterproof ink through the filter into the agar in an 
asymmetric pattern. 
One sheet of 3MM paper was soaked in each of the following solutions: 
10% SDS 
denature - 1.5M NaCl, 0.5M NaOH 
neutraliser - 1.5M NaCl, 0.5M Tris.HC1 (pH 7.5) 
2x SSC 
The excess was then poured off and the sheets of 3MM placed in trays. The filters 
were placed face up on the sheets of 3MM and left for 1 min in SDS, then 3min in 
denature, 3min in neutraliser and 30s in SSC. The filters were left to air dry and were 
then baked at 80°C for 1 hour. 
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7.8 Radiolabelling of DNA. 
7.8.1 Random Priming of DNA probes. 
This method is adapted from Feinberg and Vogeistein, 1984. A labelling reaction 
with [a-32P]-dCTP involves random priming from hexanucleotides and then 
polymerization along the DNA strand catalysed by the Klenow fragment of E. Coli 
polymerase 1. A radiolabelled base is incorporated at every C nucleotide. 
DNA to be used as a probe was either in solution or contained within a gel slice. 25-
50ng was labelled for a single hybridization. Before use in a labelling reaction, the 
slice was remelted at 70°C. For oligonucleotide probes, 25-50ng of the precipitated 
oligonucleotide was used. 
The DNA strands were firstly denatured by heating to 100 °C for 10mm. DNA in 
solution was then kept on ice to prevent reannealing of the strands, DNA in a gel 
slice was cooled to 37 0C. The labelling reaction was carried out using a Random 
Prime kit (Boehringer Mannheim). 1 1tl total of DNA plus water was mixed with 3jil 
10pCi/pJ [c- 32P]-dCTP (Amersham), 1il (2 units) Klenow enzyme, 1tl each of 
dATP, dTTP and dGTP and 2p1 reaction buffer. The reactions were then incubated at 
370C for 30-40mm. 
The percentage incorporation of the radiolabelled nucleotide was checked by TCA 
precipitation of —0.5jil of the reaction mix on a GF/B circular filter (Whatman). If the 
incorporation was 50% or above, the unincorporated nucleotides were removed by 
running the probe through a Sephadex G-50 Nick column (Pharmacia Biotech). The 
storage buffer was removed and then the column was washed by running through imi 
TB. The probe was then added to the top of the column, followed by 4001.11 TE. The 
probe was then eluted with a further 400pi TE. The probe was denatured by heating 
to 100°C for 10mm, and was kept on ice until adding it to the prehybridization 
solution in the bottle. 
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7.8.2 End-labelling of DNA oligonucleotides. 
This labelling reaction involves the transfer of the radiolabelled terminal phosphate 
group of [7-32P]ATP to the terminal 5'-OH group of the oligonucleotide. 
lOpmoles oligonucleotide DNA was mixed with Sjil (30tCi) [y- 32P]ATP 
(Amersham) and 2p1 (20 units) PNK (Boehringer Mannheim), in a total of 20j.tl lx 
PNK buffer (5mm Tris.HC1, pH 8, 1 M M902, 0.5mM DTT). The reaction was 
incubated at 37 0C for 30mm, then the probe was added to the hybridization bottle. 
7.8.3 Hybridization of filters. 
Hybidization buffer: 0.25M Na 2HPO4 pH7.2, 0.175% SDS, 1mM EDTA 
Wash buffer (DNA probes): 20mM Na 2HPO4 pH7.2, 1% SDS, 1 m EDTA 
Wash buffer (Oligo probes): 2xSSC, 1% SDS, 1mMEDTA 
Under a solution of 50mM Na2HPO4 pH7.2, the filter was placed between two 
slightly larger sheets of gauze. For hybridization to multiple filters with a single 
probe, up to 3 layers of filters could be placed in the same bottle, with layers of gauze 
separating them. Sheets of gauze were not always used. Air bubbles trapped between 
the filter and the gauze were removed. The filter and gauzes were then rolled up 
together, transferred to a glass hybridization bottle (Hybaid) and unrolled onto the 
surface of the bottle. Around 12m1 of prehybridization solution was added to a small 
bottle and about 18m1 to a large bottle, and the bottle rotated in an hybridisation oven 
(Hybaid) at 68 0C for a minimum of 1 hour before adding the probe. 
For oligonucleotide probes, prehybridization (and hybridization) was performed at a 
temperature —10 0C lower than the Tm of the oligonucleotide, commonly 48 0C. 
For random-primed probes, hybridization was carried out at 68 0C overnight. For 
oligonucleotide probes, the hybridization was overnight at a temperature 10 0C lower 
than the Tm of the oligonucleotide (commonly 48 0C). 
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7.8.4 Washing conditions. 
Following hybridization, the filters were removed from the bottle and separated from 
the layers of gauze. Filters were washed on a rotating platform in a waterbath. For 
random primed probes the filters were washed with 300min changes of --500m1 
washing solution. The temperature of the wash (-65°C) depended on the washing 
stringency required. Filters hybridized with oligos were washed 2x5min RT, 
ixiOmin 450C. The filters were then wrapped in Saran wrap (Dow Chemical 
Company), avoiding creases. 
7.8.5 Detection of hybridization signal. 
Autoradiography The filters were placed in a light-tight cassette with a signal 
enhancing screen. They were then exposed to X-OMAT x-ray film (Kodak) for a 
length of time dependent on the amount of radiolabelled probe left bound to the filter 
(several minutes to several days). Filters hybridised to 32P-labelled probes were 
exposed at -700C, those labelled with 35  were exposed at RT. Stratagene Glogos II 
luminescent markers were used for alignment. The film was developed on an 
automatic x-ray film processor RGII (Fuji). 
Phosphorimaging Alternatively, the filters were exposed to a phosphor screen 
(Molecular Dynamics) for hours to several days. The screen was then scanned on a 
Phosphorlmager (Molecular Dynamics), where a laser beam converts the radioactive 
signal into a digital image, with variations in the pixel value proportional to the 
amount of radioactive signal present. The grey-scale image was adjusted as desired 
and was then printed on a laser printer. 
7.8.6 Removal of radioactive probe from filters. 
Filters may be used several times with different hybridisation probes, so it was 
sometimes necessary to remove radioactive probes from filters. The filters were 
washed in 0.2M NaOH at RT for 30mm, to denature the probe DNA strand from the 
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surface of the filter. The neutral pH was then restored by a 2x 1 5min wash in 25mM 
Na2HPO4 also at RT. The filters were then exposed to x-ray film overnight to check 
that all the probe had been removed. 
7.9 Polymerase Chain Reaction (PCR) protocols. 
7.9.1 Oligonucleotide Synthesis. 
Oligonucleotides were synthesised (by Agnes Gallagher) as ammonium stocks on an 
Applied Biosystems 381A oligonucleotide synthesiser. Oligonucleotides were 
precipitated from ammonium stocks by ethanol precipitation of 350 p1 of the stock. 
The precipitated DNA was resuspended in 500p.l water and the concentration (C) 
(.tmole/ml) assessed by measuring the Abs260. Abs 260= cxC. The extinction 
coefficient e of the oligonucleotide is calculated by adding up individual extinction 
coefficient for each base in the molecule. The extinction coefficient for each base is 
dGTP 1 1.7mlJp,mole, dCTP 7.3mlJj.tmole, dATP 15.4m1JpmoIe and dTTP 
8. 8mL/xmole. 
7.9.2 Standard PCR reaction mix. 
dNTPs (2mM each)(Advanced Biotechnologies) 2.5p1, 1% triton X (Sigma) 2.5 p.1 
(optional), PCR buffer ( Perkin Elmer Cetus) 2.5 91, M902  1.5mM (Perkin Elmer 
Cetus) 1.5p.l, Amplitaq ( Perkin Elmer Cetus) 0.1 p1, primers 10pM of each 
atlopmoles/ p.1, ddH20 up to 25 p.1. Template DNA added (30-50ng). Reaction 
overlaid with a drop of mineral oil (Sigma). 
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7.9.3 Oligonucleotide sequences. 
Table. 6 Oligonucleotide sequences and descriptions. 
Name Sequence 5' - 3' Description 
C91 1 ACT TCA CTC GGG CCT TGA TAG WTI, intron 9, sense 
C912 GTG GAG AGT CAG ACT TGA AAG WTI, exon 10, antisense 
J420 TG CAT OTT GTG ATG GCG GAC WTI, exon 10, antisense 
J422 TGA AAA GCC CTT CAG CTG TC WTI, exon 10, sense 
J423 GGA OTT TGG TCA TGT TFC TCT WTI, exon 10, antisense 
PT65-2 GGA OAT AAG CCC CAA AGT TA Wt], 5' proximal promoter, 
sense 
PT65-6 CCT AGC CTA GCT CAG CAA A Wtl, 5' proximal promoter, 
antisense 
443 AGC TCT GGC ACA CGT GTC AG bacterial lacZ 
444 GAA TOG ACG CTG ATA GAT GAA TTG bacterial lacZ 
E489 GCG ATG CCT OCT TGC CGA bacterial neoR 
E490 GAA GGC GAT AGA AGO CGA bacterial neoR 
H213 TAT CGA AGA CAC ACT CTA CC Pax6, 3' UTR, antisense 
H214 TAG TTT ATG GAC TGA TOT TCC Pax6, 3' UTR, sense 
7.10 Protocols for genotyping mice. 
7.10.1 PCR based genotyping. 
Genotyping NORJNLS transgenics and line E. 
Primers: 443 and 444 detect the lacZ gene 
Protocol: 940C 3mm + 30 cycles of (920C 30s, 55°C 45s, 720C 1mm) + 72°C 10mm 
For genotyping Line A,C,D,H mice. 
Primers: C911 and C912 detect human WTI genomic sequences. It is possible to 
include an internal control in this react by adding additional primers H213 and H214 
for Pax6 and removing an equivalent amount of water from the reaction mix. 
Protocol: 940C 2n-tin 30s + 35 cycles of (940C 1mm, 58°C 1mm, 720C 1mm) + 720C 
9mm 
For detection of null alleles in Wtl knockout mice. 
Primers: E489 and E490 detect the neoR  cassette in the targetted Wtl null allele 
(fig4la). 
Protocol: 93 0C 2mm + 9 cycles of (60 0C 1mm, 720C 30s, 930C lOs) + 9 cycles of 
(600C 1mm, 720C 1mm, 930C lOs) + 12 cycles of (60 0C 1mm, 720C I min 30s, 930C 
lOs) + 720C 10mm. 
7.10.2 Genotyping of Wtl homozygous null transgenic mice. 
The presence of a Wtl null allele can be detected by using a PCR reaction which 
amplifies the neoR  cassette which has been introduced into the Wtl gene during 
targeting (Fig. 41a). This method is however, unable to distinguish between a 
heterozygous and homozygous null animal. 
7.10.2.1 Southern hybridization method. 
Extra embryonic tissue was taken from isolated embryos and digested overnight at 
550C in lOOpi tail tip buffer. DNA was prepared from this by ethanol precipitation 
and resuspended in 20 .il TE. All of this DNA was then digested overnight with 
Bglll. The digestion product was run overnight on a 1% agarose gel in 1xTAE (Fig. 
41b) and then blotted overnight onto filter. The blotted filter was then probed with 
the WT300 molecular probe. WT300 hybridizes to sequences in Wtl exon 1; hence a 
lane where WT300 hybridizes toa 5kb band represents a mouse in which at least one 
copy of the wildtype Wtl locus is present, e.g. Fig40c B 1-3. A lane where 
hybridization does not occur represents an animal with no copies of Wtl exon 1 and 
which is therefore Wtl homozygous null, e.g Fig. 41c lane B6. 
This technique is very labour intensive. Furthermore it is problematical in that the 
amounts of DNA used are very small and can be lost e.g. Fig. 41b lane B4 and B8. A 
lack of signal in lanes B4 and B8 on the hybridized filter (Fig. 41c) does not mean 
that these embryos are homozygous null but rather that the DNA from these animals 
IRR 
is not present on the filter. In order to overcome these problems a PCR based method 
was designed to detect Wtl null animals. 
7.10.2.2 PCR based method 
Primers were designed to amplify part of the mouse 5' UTR which would not cross 
react with the human 5' UTR. This allows embryos carrying a human derived WTI 
transgene, e.g. WT470LZ, to be typed for the lack of endogenous Wtl mouse alleles. 
Due to the high GC content of the Wtl 5' region standard Perkin Elmer Cetus PCR 
buffer was unable to amplify sequences correctly. Therefore AM buffer (gift of Dr. 
G. Bates, Guy's Hospital, London) was used instead. AM buffer: 670mM Tris, 
166mM NH4SO4, 20mM MgC12, 1.7mg/ml BSA. Solution in TEpH8.0 
Primers: PT65-2, PT65-6 amplify mouse 5' sequences (370bp band); H213, H214 
amplify Pax6 as an internal control (150bp band). 
Protocol: 940C 5mins + 30 cycles of (94 0C 30s, 560C 30s, 72°C 45s) + 72 °C 10mm. 
Fig4ld shows an example of the result of a PT65-2fPt65-61H2131H214 PCR based 
analysis of potential Wtl knockout embryos. Lanes Al and B6 have an internal 
control band but no Wtl band and hence represent homozygous null embryos. Lanes 
B5 and B7 have the same band but also a Wtl specific band (370bp). These lanes 
represent animals which have at least one copy of the wildtype Wtl locus. 
Fig. 41 Genotyping of Wi'] homozygous null mice. 
Knockout of the endogenous Wi'] locus is carried out by replacing Wt/ exon I and 
part of intron I with a PGK-neo cassette (Kreidberg et al., 1993). (b) BglII digested 
DNA from the extra embryonic membranes of potential homozygous Wi'] null 
embryos. (c) Hybridization of a blot of DNA from b with WT300 a probe which 
hybridizes to Wi'] exoni. No band is present in lane B6 indicating that the DNA in 
this lane came from a Wi'] homozygous null embryo. The lack of bands in lanes B4 
and B8 are due to the lack of blotted DNA in these lanes. (d) An example of a result 
from a PCR based method of genotyping homozygous Wi'] null animals. Lanes Al 
and B6 have an internal control band (l5Obp) but no Wi'] band and hence represent 
homozygous null embryos. Lanes B5 and B7 have the same band but also a Wi'] 
specific band (370bp). These lanes represent animals which have at least one copy of 





Wild type allele 
W7'J Exoni 
/ 	 1kb 
0 
- 
















7.11 Transgenic methodology. 
YAC and plasmid constructs were introduced into fertilized mouse oocytes by 
pronuclear microinjection. Mice were superovulated either by myself or by members 
of the BRF/transgenic facility support staff. Oocytes were collected by myself. 
Following microinjection oocytes were cultured overnight and those which reached 
the two cell stage were then transferred into foster mothers. New born pups were 
typed to see if they were transgenic by either PCR or Southern analysis. The 
methodology was essentially the same as that detailed extensively elsewhere (Hogan 
et al., 1986). 
7.11.1 Microinjection of mouse oocytes. 
Plasmid DNA was linearized by restriction enzyme digestion and purified by Qiaex 
extraction. A concentration of plasmid DNA of 1 ng/pi diluted in TO. 1 (10mM Tris 
pH7.5, 0.1mM EDTA pH8) was used for microinjection. YAC DNA was purified 
and concentrated as described in section 7.5 and injected in microinjection buffer 
(IB) at 5ng/p.l. Injection were carried out using a IM3000 microinjector (Narashige). 
Injection was done using constant 'balance' pressure slightly higher than that 
required to counteract capillary action. In this way a constant flow of DNA solution 
is coming from the end of the microinjection needle. 
7.12 Analysis of mouse embryos. 
X-fix solution: Made up in 0.1M phosphate buffer, (made by adding 126m1 0.1M 
NaH2PO4.2H2O to 400m1 0.1M Na2HPO4), 2% formaldehyde (added as Millory's 
10% neutral buffered formalin - 10% formaldehyde in 0.1M NaH2PO 4), 0.2% 
gluteraldehyde, 2mM M902, 5mM EGTA pH8. 
Detergent wash: Made up in 0.1M phosphate buffer, 2mM M902, 0.1% sodium 
deoxycholate, 0.02% Nonidet P40 (Boehringer Mannheim), 0.05% bovine serum 
albumen (BSA). 
X-gal stain solution: Made up in detergent wash, 0.085% NaCl, 5mM K3Fe(CN) 6 , 
5mM K4Fe(CN)6, 0.1% X-gal in DMF. 
BSA/gelatin - lOOm! PBS add 0.5g gelatin heat in water bath (500C) to dissolve. 
Cool to room temp then dissolve in 15.5g BSA when this has dissolved add and 
dissolve 20g sucrose. Sodium azide 0.1% can be used as a preservative for this mix. 
Aqueous mountant - 1 O gelatin, 60m1 dH20, 70m1 glycerine, 250u1 phenol. 
Dissolve gelatin in water in a conical flask 500C and mix well. Add glycerine and 
phenol and mix well again. Aliquot into lOml amounts and store at 40C. Heat to 500C 
before use. When making up the mountant heat this in a water bath/oven not in a 
microwave. 
7.12.1 Isolation of mouse embryos. 
The day of the vaginal plug following mating was designated E0.5. Pregnant females 
were killed by cervical dislocation and the embryo dissected from the uterus into ice 
cold PBS (Oxoid). Any further embryo dissection was also carried out in ice cold 
PBS. If tissue was to be cryosectioned it was then washed in a drop OCT compound 
(Miles Inc.) and then transferred into a drop of OCT on a piece of 3MM paper 
(Whatman) and snapfrozen in liquid nitrogen. If tissues was to be whole mount X-
Gal stained it was transferred to X-fix. If tissue was for mRNA in situ hybridization 
embryos were transferred to 4% PFA in PBS overnight at 4 0C. 
7.12.2 Whole mount X-gal staining of mouse embryos and tissues. 
Embryos/tissues were placed in excess X-fix (at least lml per embryo) for lhr-
overnight at 40C. The fix was drained off and then the embryos were washed 
3x20min in detergent wash, RT. The final wash was replaced by X-gal stain and the 
embryos incubated at 300C for a few hours to overnight depending on the level of 
signal. Incubation at this temperature as opposed to 37 0C takes longer but 
significantly reduces the level of background endogenous 0 galactosidase activity in 
mouse tissues. Following staining the embryos were wash 3x20min in PBS and then 
fixed in 4% PFA in PBS overnight at 4 0C. Staining must be carried out in glass and 
not plastic containers. 
190 
7.12.3 X-gal staining of cryosections. 
lOj.tm Cryosections were cut on a JUNG CM3000 cryostat (Leica) and mounted onto 
TESPA'd slides. The sections were then allowed to warm up to RT, this takes around 
20mins. The slides were placed in a coplin jar in X-fix for 20mins then washed 
3x5min in detergent wash. The wash was decanted off and replaced with X-gal stain 
and the coplin jar sealed with nescofilm (Brandon Chemical Ind. Ltd.). The slides 
were incubated at 30 0C for a few hours to overnight depending on the level of signal. 
Following staining the slides were then washed 3x20min in PBS and fixed in 4% 
PFA for 1 hour at 40C. These slides then could be counterstained and mounted as 
required. 
7.12.4 Vibratome sectioning of embryos. 
Embryos were washed in PBS. They were then equilibrated in 4%sucroselPBS 
overnight, equilibrated in 20%sucrosefPBS overnight and then equilibrated in BSA-
gelatin mix overnight. Embryos were then removed from the BSA/gelatin mixture 
and any excess mix sticking to them blotted off. The embryos were then fixed in 25% 
gluteraldehyde for 1mm. Meanwhile 3m1 BSA/gelatin mix was added to a bijoux and 
300u1 25% gluteraldehyde added to it. This was mixed quickly by inversion a few 
times. Embryos were added to this mix and orientated with fine forceps until the 
mixture began to set. After leaving the mixture to set for a few mins the block was 
removed from the bijoux. This block was then cut to size and blotted on tissue. For 
sectioning the block was stuck to a cutting dish with superglue (Super Attak, Loctite) 
and covered with another dish to prevent drying whilst the superglue was setting 
(-5nins). The dish was placed in the vibratome (Vibratome series 1000, Technical 
Products International) which was filled with luke warm water to above the level of 
the block. The settings used were: speed 2, amplitude 8, taking 150um sections. The 
sections were floated onto a normal slide and the excess water blotted from around 
the edges of the sections. They were then mounted with aqueous mountant and left 
on a hotplate for a hour or so to prevent bubbles forming in the aqueous mountant as 
it dried. 
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7.12.5 Wax embedding and sectioning of embryos. 
Embryos were fixed overnight in 4% PFA at 4 0C and Then washed in PBS 3x20min. 
They were then transfered to a Tissue-Tek VIP (Miles Inc.) for processing. 
Programme: PBS lxlhr, 30% EtOH lxlhr 40 0C, 50% EtOH lxlhr 400C, 70% EtOH 
lxlhr 400C, 85% EtOH lxlhr 400C, 95% EtOH lxlhr 400C, 100% EtOH 2x1hr 
400C, 100% xylene 2xlhr 40 0C, paraffin wax 4xlhr 600C. The embryos were then 
embedded in further melted paraffin wax contained in a mould. The wax was set by 
holding the mould on the surface of a bath a water at RT. For in situ hybridization 
protocols all solutions need to be sterile to ensure no RNAse activity. 
Embryos of E9.5 or younger and small pieces of tissue were processed by hand. The 
process was similar to that above with the incubations done at RT instead of 40 0C 
and the length of incubation cut to 2x15-20min. 
7tm sections were cut on a standard microtome e.g. Riechert-Jung 2030. A new 
sterile blade was used for sections required for in situ hybridization. Sections were 
floated out into (sterile) distilled water at 40 0C. Section required for in situ 
hybridization were floated onto TESPA'd slides and those for standard histological 
analysis onto untreated slides. Slides were baked overnight at 60 0C to seal the 
sections onto the slide. Those slides required for in situ hybridization were stored in 
clean sealed boxes with silica gel desiccant. 
TESPA protocol - New clean slides were used straight out of the box from the 
manufacturer. The slides were washed 10%HC1 in 70% EtOH for 20s, then washed 
in sterile distilled water for 20s. The slides were then washed in 100% acetone for 
20s and air dried. When dry the slides were placed in 2% TESPA in acetone for 20s 
(TESPA: 3-aminopropyl-triethoxy silane, C 9H23NO3Si (Sigma)). After this treatment 
they were air dried and stored in clean sealed boxes with desiccant. 
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7.12.6 Histological staining of sections. 
Dewaxing: Wax sections need to be dewaxed before staining. The slides were 
washed in the following solutions: 2x5min xylene, 2x5min 100% EtOH, lx 5mm 
90% EtOH, lx 5mm 70% EtOH, lx 5mm 50% EtOH, lx 5mm 30% EtOH, few mm 
in water. 
TUNEL analysis: Detection of apoptotic cells was carried out using an In Situ Cell 
Death Detection Kit, AP (Boehringer Mannheim) in accordance with the 
manufacturers instructions. Substrate for Alkaline Phosphatase was provided using 
SIGMA FAST Fast Red TRlNaphthol AS-MX Phosphate tablets (Sigma) in 
accordance with the manufactures instructions. 
Haematoxylin and eosin (H&E) staining: Slides were placed in haematoxylin 
(Surgipath) for 4-5mm. They were then wash well in running tap water. The washed 
slides were then transferred to 1%HC1 in 70% EtOH a few seconds and washed in 
running tap water. Following this wash the slides were transferred to saturated 
lithium carbonate solution for 10-15 seconds and then washed in running tap water 
for at least 3mm. The slides were then placed in eosin solution (3 parts of 1% 
aqueous eosin (Eosin, Yellowish (TAAB)): 1 part 1% EtOH, 0.05% acetic acid) for 
2-5min depending on the tissue type. The slides were then rinsed quickly in water 
and processed as follows: 100% EtOH lxlSs then 2xlmin, xylene lx5min. Slides 
were transferred to fresh xylene whilst mounting. To mount the slides the xylene was 
drained off, a line of DPX (BDH) added over the section and a coverslip and placed 
over it. 
In many cases sections with X-gal staining were only counterstained with eosin to 
increase contrast between the X-gal and counter stain. This practice however reduces 
histological resolution in the sections. 
Sections were analyzed and photographed with either a Ziess Axioplan 2 with a 
Yashica 108 multiprogram camera or a Wild Heerbrugg Photomakroskop M400 with 
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a Wild Leitz WPS Photoautomat. The photographic film used was 64 ASA colour 
film (Fuji) 
7.12.7 Immunohistochemical staining of cryosections. 
Cryosection were left to dry at RT lhr and then fixed in 1:1 methanol: acetone at - 
200C for 10mm. They were then dried at RT for 10-20mins followed by rehydration 
in PBS for 5mm. Next the sections were incubated in blocking solution (BS) for 
15mm (BS: 2% BSA (Sigma), 2% sheep serum, 7% glycerol, 0.2% Tween 20 (ICN 
Biochemicals)). Following this the sections were incubated sections with primary 
antibody diluted in BS lhr. The primary antibodies used were a 1/100 dilution of C19 
anti Wtl (Santa Cruz Biotechnology) or 1/100 cc-Tubulin (Sigma). Following 
incubation the sections were washed 3x3min in PBS in a coplin jar. The rest of the 
procedure was carried out in a dark chamber. The sections were incubated with a 
secondary antibody diluted in PBS for 45mm (secondary antibody Donkey anti-
Rabbit- FITC (Jackson Immunolabs)). They were then washed 3x3mins in PBST 
(PBS + 0.1% Tween20 (ICN Biochemicals). The slides were mounted in 
VectaMount (Vector Labs) containing 1/1000 propidium idodide and the coverslip 
sealed with TipTop Vulkanisierfluessigkeit. Slide were analyzed using a Ziess 
Axioplan microscope with a Photometrics CCD camera and Digital Scientific 
software. 
7.12.8 mRNA radioactive in situ hybridsation. 
Some of the in situ analyses presented in - this thesis were done entirely by myself 
other with the help of E. Graham and L. McInnes. 
Probe labelling - A 355  labelled ssRNA probe was transcribed from a dsDNA 
template via the following method. 
Add to a sterile eppendorf in this order: 3p.1 5x transcription buffer (Boehringer 
Mannheim - for either T3 or T7 polymerase), 1t1 10mM rATP, 1.tl 10mM rCTP, Ipi 
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10mM rGTP, 1111  1M DTF (Dithiothreitol), 6pi water, 12.tl 35SrUTP 
(>lmCiJlOOml)(Amersham), 5p1 template DNA template linearized with the 
appropriate restriction enzyme (0.5-lmg/5m1), 1.2pi RNAse inhibitor (Boehringer 
Mannheim), 0.8p.l T7 or T3 polymerase (Boehringer Mannheim) as appropriate. 
Incubate 37 0C 25mm. Add a further 0.8111 of polymerase. Incubate a further 25 mm. 
Add 2pi tRNA (10mg/mI), 1 p.1 RNAse free DNAse (Boehringer Mannheim). 
Incubate 370C lOmins. To stop reaction add: 2p.l 100mM EDTA, 167 p.1 TE (see X) 
with 50mM DU. 
The mixture was then stuck on ice, transferred to a Microcon column (Amicon) and 
spun in a bench centrifuge for lOmins. The reaction tube was rinsed with a further 
200p.l of TE which was then spun in the column 5mm. 25p.l of TE/DDT was added to 
the column which was incubated on ice for 15mins The column was the inverted in a 
new tube and spun 5mm. The ice incubation step and spin were repeated. The 
solution spun off the column was taken as the probe. A lj.xl aliquot was taken for 
scintillation counting. 
Scintillation counting - 1p.l of probe was added to 19jil TEJDDT and mixed. lOpl 
was added to each of two Whatmann GFIB filters. One filter was washed 3x TCA 
(trichioroacetic acid solution - (Sigma)) then once in ethanol. The TCA was allowed 
to stand on the filter for a few seconds to allow precipitation of the RNA before 
being drawn through under vacuum. The filters were left to dry. Unwashed and 
washed filters were counted separately in scintillation vials with 10p.l Ecolite+ 
scintillation fluid (ICN) assuming 50% counting efficiency. Counting was done in a 
Packard Tri-Carb 1500 Liquid Scintillation Analyser. 
(precipitate count)/(total count) x 100 = % incorporation which should be at least 
10%. The probe was then diluted with TE/DTF so that when hybidization mix was 
added in a 1:9 ratio, the final count is 1.1x10 5 dpm/ml (dpm = disintergrations per 
mm). 
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50x Denhardt's solution: 5g Ficoll, 5g Polyvinyl pyrolidine, 5g BSA. Made up tp 
500m1 with distilled water, filter sterilized and stored at -20 0C 
Hybridization mix: In lx Denhardt's solution :50% formamide, 10% dextran 
sulphate, 20mM Tris pH8, 0.3M NaCl, 5mM EDTA, 10mM sodium phosphate, 
0.5mg/ml RNA. Immediately before use add 50mM DTT. 
Prehybridization treatment of slides - Slides were taken through the following 
solutions in batches of 20: Xylene 2x5min, 100% EtOH 2x2min, (90%, 70%, 50%, 
30% EtOH) 2mins each, PBS 2mins with agitation and finally 4% PFA in PBS pH 
7.2 10mm. At this point slides were split into two racks to ensure no PFA remains 
trapped between them. PBS 2x2min, 20mg/mi Proteinase K (BCL Biochemicals) in 
50mM tris, 5mM EDTA 7.5mins, PBS 1mm, 4% PFA 2mm, distilled water lOs, 
0. 1M TEA (triethanol amine) pH8 30s, 0. 1M TEA + 0.3125 % acetic anhydride 
2x5min with stirring, PBS 2mm, 0.85% NaCl 2mm, (30%, 50%, 70%,90% EtOH) 
Imin each, 100% EtOH 3x5min. Finally the slides were dried in a dust free box. 
Hybridization - Probe/hybridization mix was heated to 80 0C, rapidly cooled on ice 
and then -.50pl added per slide. Clean coverslips were put over the slides. The slides 
were then placed horizontally in a sealed box including a tissue soaked in Smls of 
50% formamide 5XSSC. The box was heat sealed inside two plastic bags and 
submerged in a water bath at 55 0C overnight. 
Post hybridization washes. These were carried out in a Hybaid Omnislide Wash 
Module. The washing protocol was: 5xSSC 55 0C a few seconds, 5xSSC 10mM DTT 
550C 15-30mm (until the coverslips fall off), high stringency wash 65-680C 30mm 
(high stringency wash 50% formamide, 2xSSC, 0. 1M DTT (add DTT just before 
use)), NTE (0.5M NaCl 10mM Tris 5mM EDTA pH7.5) 37 0C 2x5min, NTE + 
2p.m/ml RNAse A 370C 30mm, NTE 370C 30mm, high stringency wash 65-68 0C 
30mm, 2xSSC RT 4xl0min, 0.1xSSC RT 4x5min, 30% 50% 70% 90%EtOH 1mm 
each, 100%EtOH 2x5min and finally allow the slides to air dry. 
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In the dark, slides were then dipped in 1:1 sterile distilled water:Ilford K5 emulsion 
at 400C. They were then left to air dry for 3 hours. Following this they were 
transferred to a sealable box with desiccant, covered with foil (light tight) and left 
40C for 2-3 weeks before developing. Slides were developed by immersing in Kodak 
D19 developing solution for 4mm, washed in sterile distilled water lOs, fixed in a 1:2 
solution of AIMFIX:water for 5min and then finally washed in water 2xlOmin. The 
slides were then counterstained by dipping in 1% methyl green (Sigma), air dried and 
mounted with DPX. 
7.12.9 Whole mount in situ analysis. 
Preparation of probe: 1.Lg of template DNA was taken. Added to this was: 4tl of 
polymerase buffer (T7 or T3), 4j.tl of DIG mix (10mM dATP, dCTP, dGTP 6.5mM 
dUTP, 3.4mM DIG-UTP (Boehringer Mannheim)), ipi 1M DTT, 2.tl RNAse 
inhibitor, 2 p1 polymerase (T3 or T7) and sterile water to 40 p1. the reaction mix was 
incubated for lhr at 37 0C. After this step a further 2 1.tl polymerase was added and the 
incubation repeated. After this incubation 20U of DNAseI (Boehringer Mannheim) 
and ipi tRNA (lOj.tg/ml) were added. A further incubation for 15min at 37 0C was 
carried out. The reaction was stopped with 0.2mM EDTA pH8.0. The RNA was then 
precipitated by adding 5 p1 4M LiCl, 150 p1 EtOH and incubating for -20 0C for at 
least 2hrs. The tube was the spun in microcentrifuge a 15mins and the pellet washed 
2x with 70% EtOH. The pellet was then resuspended in lOOul DEPC treated water 
with ipi RNAse inhibitor added. This probe was then stored at -20 0C until use. 10111 
of the probe used for in situ. 
Hybridization: The whole mount in situ hybridization was carried out by Jacob 
Hecksher-Sorenson as detailed in In situ hybridisation a practical approach ed. 
Wilkinson, 1992. 
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7.13 Eukaryotic cell culture. 
7.13.1 Culture conditions. 
Table. 7 Cell culture conditions. 
Cell line Media Temperature and CO2 
concentration 
AC29 RPMI (GIBCO BRL), 10% FCS 370C, 5% CO2 
- foetal calf serum (GIBCO 
BRL)  
COV434 1:1 FlO (GIBCO BRL):DMEM - 37°C, 5% CO2 
Dulbecco modified Eagle's 
medium (Flow Labs)  
M15 DMEM, 10%FCS 320C, 7.5% CO2 
PyT45 DMEM, 10%FCS 370C, 5% CO2 
1OT1/2 DMEM, 10%FCS 370C, 5% CO2 
C2 DMEM, 10%FCS 37°C, 5% CO2 
Cells were cultured in 80ml tissue culture (Nunc) flasks. They were split when they 
reached confluence. All manipulation were performed in a laminar flow air cabinet. 
Splitting protocol: The medium was aspirated from the cells, 6m1 of Trypsin versene 
1:10 (0.2% trypsin, 0.04% EDTA in Dulbecco 'A') was added for Smins. 4mls of 
growth medium was then added and the cell spun at 2000rpm 4 0C. The supernatant 
was aspirated and the cell resuspended in lOmi of fresh medium, about 2mls was 
used to seed a new flask. 
7.13.2 Transfection of eukaryotic cells. 
Cells were grown in 25cm 2 round culture dishes (Nunc). Transfection was carried out 
on cells of about 70% confluency. 50j.tl of plasmid (lOng/pi), 15p.l Lipofectamin 
(GIBCO BRL) (2p.g/pi) and 35p1 medium without FCS were taken and mixed in a 
sterile tube. This mixture was incubated at room temperature for 45mins. Meanwhile 
the growth medium was aspirated and the dish quickly washed 3 times in medium 
without serum. 2m1 of medium without serum was carefully added to the 
DNA/lipofectamin mix and this was added to the culture dish. The cell were then 
incubated as normal for that cell type for 12hrs. After this period of incubation the 
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medium was aspirated and replaced with normal medium containing serum. The cells 
were grown a further 24hrs or so. Then the medium was decanted and cells washed 
once in PBS. 2.5mls of X-fix was added to the dish which was incubated on ice for 
5mins. It was then washed with PBS and 2.5m1 of X-gal staining solution added. The 
dish was now incubated at 370C for lhr or for as long as it took for the blue X-gal 
seaming to appear. 
7.14 Molecular probes. 
WT33 - WTI cDNA as first isolated by Call et al., 1990 
WTX - EcoRIJXhoI genomic fragment spanning WTI exon 1. 
WT300 - 300bp fragment of Wtl exon 1 isolated by EcoRIINcoI digestion of PKS2. 
PKS2 - 610bp fragment of Wtl 3' UTR described in Mundlos et al, 1993 
SVA - YAC short vector arm probe, 1.4 kb SalJJStuI fragment isolated from pYAC4 
LVA - YAC long vector arm probe, 1.1 kb EcoRTfPstl fragment ioslated from 
pBR322. 
L800 - -An 800bp single copy clone isolated from WT470 DNA. This clone was 
isolated from the region of the EagI site lying around 100kb downstream of WTI 
(Fantes et al., 1995) via a linking library approach (A. Schedl pers. comm.). 
TRPLZ - -6kb XbaIJBamHI fragment of plasmid UY1 (gift of H. Smith MRC HGU 
Edinburgh). UY1 consists of the 1.4 kb of the TRP1 promoter (-1335 to +107), TRPJ 
exon 1 and a lacZ reporter gene (Lowings et al., 1992). 
ILZ - 3.6kb HindfflfBamHl fragment of UY1 containing the lacZ cassette. 
Paxi - Plasmid name - 'pmprd Hind-Sad'. 313bp genomic HindllJSacI fragment 
from containing pair box region of Paxi. (gift of J.Moss MRC HGU Edinburgh) 
Pax3 - Plasmid name - 'pc pax3 PstlfHindffi'. 519bp PstllHindffl fragment from 3' 
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